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ABSTRACT
Measurements of nicotine and cotinine in human body fluids have 
become accepted as means of assessing nicotine uptake and inferring smoke 
uptake. In two long-term studies of human smoking behaviour the usefulness 
and reliability of body fluid measurements is questioned.
An alternative approach for measuring nicotine uptake is suggested 
and investigated where the retention of nicotine is measured, thus eliminating 
variability due to inter-individual differences in nicotine metabolism and 
subsequent errors due to timing of sampling.
This method is used to investigate the paradox that exists in cigarette 
smoking where effects occur which are more rapid in onset than was thought 
possible due to the absorption of nicotine from the particulate phase of 
cigarette smoke with which nicotine is associated.
From the experimental evidence and associated discussion a three- 
phase mechanism for uptake of nicotine during the smoking process is 
proposed.
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CHAPTER ONE
INTRODUCTION 
TOBACCO, CIGARETTES AND NICOTINE
A cigarette is the perfect type of perfect 
pleasure. It Is exquisite, and It leaves one 
unsatisfied. What more can one want ?
Oscar Wilde 
Picture of Dorian Grey
1.1 A BRIEF HISTORY OF TOBACCO AND CIGARETTES
A new chapter in world history opened 500 years ago. It was on the 
3rd August 1492 that Christopher Columbus sailed from the port of Palos in 
southern Spain to find a new sea route to India by sailing west across the 
Atlantic Ocean. Instead, he discovered a continent inhabited by human 
beings, animals and plants of which the rest of the world had, until then, been 
ignorant. One of the plants he discovered was tobacco.
An entry in Columbus's logbook for 6th November 1492 reads : "The 
two messengers who had been put ashore (on Juana or Cuba) to scout the 
land told that on their way they had met many aboriginals carrying burning 
torches and who held special herbs in their hands to incense themselves as 
is the custom among them."
It is not known how the Indians came to use tobacco; it may have been 
in cooking, as a vegetable, or the leaves may have been burnt to drive away 
insects or the plants simply burnt as fuel. It is certain however that by 
3500BC tobacco had become an article of established value. In Popul Vuh, 
the sacred book of the Quiche-Mayas in Guatemala, two deities are 
described, Came and Ahpu. Came is a grower of tobacco and gives Ahpu a 
large quantity of cigars which the latter must smoke in order to form clouds 
from which rain will fall so that plants may grow. Tobacco was therefore 
considered a divine gift by these and most other Indians and so featured 
heavily in their religious life; perhaps as a consequence, many medicinal 
qualities were attributed to it. With time, the use of tobacco amongst the 
various populations appears to have gradually become more for pleasure 
than for ceremonial purposes.
Although there are no records of tobacco in the rest of the world, many 
other herbs were burned in order to inhale the smoke. At Delphi the Pythian 
prophetess used to inhale the fumes of burning laurel and barley meal which 
would help her to pass into a trance. Pliny describes the inhalation of the 
smoke from burning coltsfoot through a reed as a remedy for coughing.
The use and forms of use of tobacco in Europe appears to have varied 
according to the initial form of introduction. Columbus was made a gift of 
dried leaves wrapped in another, much like a cigar, considered to be very 
valuable by the aboriginals. In 1496 Friar Ramon Pene, who accompanied 
Columbus, described the ritual of Tahitian Indians sniffing up tobacco which 
had been ground to a powder and in 1499 Amerigo Vespucci observed 
Indians on Margarita, an island near the coast of Venezuela, chewing 
tobacco. In 1513 Ponce de Leon was shown pipe-smoking by Indians in 
south-eastern North America and in 1518 Juan de Gryalva observed in 
Mexico a hollow reed filled with tobacco.
Thus when Columbus returned to Spain he took a stock of what are 
now called cigars, which, due to their supposed curative effects, became 
popular. The Portuguese obtained tobacco from their colonies in Brazil and 
the Dutch by plundering Spanish and Portuguese ships. Jean Nicot de 
Villemain (1530-1600) was the French ambassador in Lisbon, whilst there, he 
was given some imported tobacco plants. He proceeded to cultivate them 
and sent a sample of his first crop, ground up as snuff, to his queen, 
Catherine de Medici, who popularised its use in the French court as a remedy 
for headaches. Sir Walter Raleigh is credited as having introduced the pipe- 
smoking habit to the English court and took a pipe with him to the gallows. 
By the end of the 16th century the use of tobacco had spread throughout the 
known world.
In spite of the claims of the medicinal qualities of tobacco there were 
many people who were against it. The Church associated inhalation of 
tobacco smoke and other herbs with heathen worship and Pope Urbanus VII 
threatened to excommunicate every smoker. In England, Henry VIII 
threatened to whip all smokers and Elizabeth I tried to confiscate pipes and 
tobacco boxes. Her successor, James I, forbade the habit altogether and 
decreed that a six shilling fine would be levied on anyone caught smoking. 
In "Counterblaste to Tobacco" he described smoking as "a custom 
loathsome to the eye, hateful to the nose, harmful to the brain and dangerous 
to the lungs".
Before the arrival of Europeans, the two species of modern economic 
importance, Nicotiana tabacum and N. rustica, were under cultivation in parts 
of North, Central and South America and in the W. Indies. It was in the 
English colony of Virginia that commercial tobacco production began in 
earnest. John Rolfe arrived there in 1610 and started to plant tobacco. He 
achieved such very good results that other settlers followed his example and 
used every piece of cleared land to grow tobacco. The first large 
consignment was exported from Jamestown to Europe in 1612 and by 1622 
exports to England reached 60,000 pounds. Other North American colonies 
soon followed Virginia in producing tobacco for export; crops were started in 
Maryland and Kentucky and by the end of the seventeenth century tobacco 
covered land in a number of states.
While the trade between Europe and the Americas was thriving, the 
English, Spanish, Portuguese and Dutch were experimenting with tobacco 
cultivation wherever colonies were started. The Portuguese, having not had 
great success in coastal East Africa, took the plant inland and found ideal 
conditions in areas that are now Malawi and Zimbabwe. The soil and
climate in Indonesia enabled the Dutch to produce good cigar quality leaf. It 
was found that N. tabacum adapted quickly to new environments to produce 
a wide range of leaf types, for example, in Virginia the tobacco plants grew 
tall and produced large leaves, whereas, in Turkey, for example, the plants 
were shorter and produced smaller leaves.
On discovering the West Indies, Columbus saw the original type of 
cigarettes. These were shredded tobacco leaves wrapped into cylindrical 
rolls as smoked by the Indians. Paper wrapped cigarettes are not however 
a recent invention, for, according to accounts given by missionaries, by the 
16th century, Spaniards and Creoles in South America had already become 
enthusiastic smokers of paper cigarettes called "papelitos" or "little papers". 
From South America the cigarette soon found its way, via Spain, into Europe 
and the southern parts of Turkey and Russia. It appears, though, that 
cigarettes caught on rather more slowly in Northern Europe. During the 
Crimean War (1853-56), when the English and French were allies of the 
Turks against the Russians, and their troops tried cigarettes made from 
Russian and Turkish (Oriental) tobaccos. Although initially most cigarettes 
were made from Oriental tobaccos, it did not take long for them to be made 
with imported Virginia tobacco or the 'black' tobacco from southern Europe.
Cigarettes offered several advantages over the older forms of tobacco 
use. The faster pace of life brought about by the Industrial Revolution to 
factories and offices demanded more than the leisurely pipe or cigar could 
offer. The Industrial Revolution also brought higher standards of living to the 
general population, along with higher incomes which enabled greater 
spending on luxury goods like tobacco, which previously had been the 
preserve of the wealthy.
Cigarettes were initially manufactured alongside cigars and pipe 
tobacco, by hand, in factories in many countries, but even the most 
experienced cigarette maker could only make three or four a minute. In the 
second half of the 19th century the first attempts were made to manufacture 
cigarettes by machine. In 1867 a machine was demonstrated at the Paris 
Exhibition, by Luis Susini of Cuba, that could make 60 cigarettes per minute, 
but was unreliable. In 1875, Allen & Ginter, of Richmond, Virginia, 
manufacturers of hand-rolled cigarettes, offered $75,000 to anyone who 
could produce a reliable cigarette machine. In 1880, James Bonsack built 
and patented a machine capable of producing 80 cigarettes per minute. By 
the end of the 19th century the rate of production was up to 500 cigarettes 
per minute and now, towards the end of the 20th century, cigarette making 
machines in use in modern factories can produce up to 10,000 cigarettes per 
minute. ( Voges 1984)
The most significant change in cigarette construction was the 
introduction in 1952 by Brown and Williamson in the U.S.A. of cigarettes with 
a filter tip made of cellulose acetate fibre supplied by the Eastman Chemical 
Company of Kingsport, Tennessee. The filter performed two major functions, 
firstly to prevent strands of tobacco being taken into the mouth from the tip of 
the cigarette and secondly to reduce the delivery of the cigarette. This 
certainly led to an increase in the number of female smokers but took longer 
to become acceptable to male smokers.
1.2 NICOTINE
The presence of a pharmacologically active substance in tobacco has 
been assumed, judging from its medicinal use, from the earliest times. The 
first indication of its identity occurred in 1809 when Vauquelin recognised the 
presence of a basic substance in a steam distillate of tobacco sap (Pailer, 
1965). Nineteen years later, nicotine was isolated from N. tabacum by 
Posselt and Reimann and characterised as a colourless oil boiling at 246°C 
which was miscible with water, ethanol and ether. In 1893 Pinner suggested 
that nicotine, on the basis of degradation studies, had the composition 
C10H14N2 and that it possessed the structure 1-methyl-2-(3-pyridyl)pyrrdlidine
(Figure 1.1). This was confirmed by synthesis in 1895 by Pictet and 
Crepieux.
Figure 1.1 : Structure of Nicotine
Nicotine : 1-methyl-2-(3-pyridyl)pyrrolidine
1.3 OCCURRENCE OF NICOTINE
Nicotine accounts for up to 95% of the alkaloid content in commercial 
tobaccos with some variation according to species, some 0.2 - 8% dry weight, 
the remaining 5% of the alkaloid being made up of nornicotine, anabasine, 
myosmine, anatabine, nicotyrine and a variety of other compounds. 
Nicotine is found as a salt of either citric or malic acid (Darby et al, 1984). 
Nicotine is found throughout the plant but the distribution of nicotine is uneven 
with more in the upper leaves than in the lower. The distribution changes as 
the plant grows and is modified further during the curing process.
1.4 NICOTINE CHEMISTRY
Nicotine is one of the few natural liquid alkaloids. When pure it is 
colourless and volatile and has a characteristic smell. On exposure to air it 
turns brown. It is readily soluble in water, ethanol and ether and as a base, 
forms salts with almost any acid. It is dibasic and the dissociation constants 
of its conjugate acids, expressed as their negative logarithms, are pKa^ = 8.02 
and pKag= 3.32. In aqueous solution at pH 2 more than 95% of the nicotine 
molecules are present as diprotonated species, at pH 5.5 nearly 100% are 
monoprotonated and at pH 10 99% are unprotonated. The pyrrolidine ring is 
protonated first, then the pyridine ring (Figures 1.2 and 1.3). It follows 
therefore that pH is particularly important when considering the behaviour of 
nicotine. The nicotine molecule contains a single chiral, or optically active, 
carbon centre; of the two optical isomers, only (-)-S-nicotine occurs in 
Nicotlana species and is more potent than the (+)-R-enantiomer in stimulating 
nicotinic receptors (Martin et al, 1983).
Figure 1.2 : Protonation states of nicotine
Diprotonated
Nicotine
Monoprotonated
Nicotine
Unprotonated
Nicotine
Figure 1.3 ; Proportions of ionic species of nicotine at various pH's (Morie, 
1972)
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1.5 NICOTINE ABSORPTION
1.5.1 Lungs
Absorption of nicotine through the lung mucosae is the major route of 
absorption from cigarette smoke in inhaling smokers (Armitage, 1978). In 
mainstream cigarette smoke (the smoke that is drawn from the cigarette by 
the smoker when puffing) the nicotine is distributed between the smoke 
particles and the vapour phase of smoke but greater than 99% is in the 
particulate phase (B.E. Frost, personal communication). The range of particle 
size in cigarette smoke is between 0.23 and 0.44jim (Chen et al, 1986.) and 
11 to 35% of the particles of this size range will be deposited in the 
respiratory tract (Davies, 1988).
The circulation of blood in the lungs can be divided into two parts. 
The bronchi and larger airways receive blood from the systemic circulation, 
whilst the alveoli are served by the pulmonary circulation. However, the 
blood supply to the bronchi is very small (1%), compared with the blood 
supply to the alveoli (Gumming, 1981). Thus in general, any substance that 
enters the respiratory tract may reach the systemic venous or the pulmonary 
arterial, depending upon where it is absorbed. The relative importance of the 
two routes depends on the physico-chemical properties of the substance, the 
formulation (of a drug) and on the depth and duration of inhalation. 
However, it appears that depth of inhalation and breath-hold time do not 
affect nicotine absorption from cigarette smoke as measured by plasma 
nicotine boost (Zacny et al, 1987). So in general, one fraction, the more 
volatile fraction in the gas phase, is absorbed by the alveoli and transported 
to the aorta via the left heart. The other fraction, in the particulate phase, 
may be absorbed comparatively slowly, due to the poorer blood supply, via
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the trachea, bronchi and bronchioli. Thus the overall transport function from 
the respiratory tract is composed of two terms, one corresponding to the 
alveolar portion and the other to the bronchial portion. The mechanism of 
transfer of nicotine across the alveolar membrane (or buccal or nasal 
membrane) into the blood is not fully understood and may be affected by the 
pH of the membrane. At the alveolar membrane, the most likely mechanism 
is by diffusion of a nicotine salt whose overall charge is zero. When a 
molecule of nicotine in the gas phase comes into contact with the alveolar 
wall it enters the layer of fluid lining the lung. The pH of the fluid is 7.4 so the 
majority of the nicotine molecules will be in the monoprotonated form. Once 
particles impinge on the membrane they lose their particulate identity and 
their components will be taken into or passed across the membrane 
individually, with varying rates of absorption (Guerin, 1980). The transport of 
nicotine from the alveoli is rapid; an inhaled dose of nicotine reaches the 
brain as a bolus in about seven seconds, much faster than a dose injected 
into the arm, which takes about 14 seconds (Ashton and Stepney, 1982).
After inhalation of cigarette smoke into the lungs, the plasma nicotine 
concentration rises rapidly, with a peak achieved shortly after smoking 
ceases (Figure 1.4). This rapid rise in nicotine concentration confirms that 
pulmonary absorption is very rapid, but that it will depend on smoking 
technique (Darby etal, 1984; Feyerabend etal, 1975).
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Figure 1.4 : Plasma nicotine concentrations in an inhaling smoker and a non­
inhaling smoker during and after smoking one cigarette which was discarded 
at time 0. (Feyerabend etal, 1975)
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1.5.2 Mouth
The mouth is likely to be the principle site of uptake in non-inhaling 
smokers, users of chewing tobacco and nicotine chewing gum. Absorption 
can vary considerably (4 - 45%) due to its pH dependence (Wynder et al, 
1976).
Armitage and Turner (1970) showed that nicotine in buffered solutions 
was absorbed more readily by cats through the mucous membranes of the 
mouth from alkaline solutions than acid solutions. From this they suggested 
that the nicotine in cigar smoke (pH 8.5) will be absorbed more readily in the 
mouth due to the higher proportion of nicotine base than that from the smoke 
of cigarettes (pH 5.5). Gori et al (1980) suggested that nicotine in cigarette
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smoke has to pass beyond the oropharynx before absorption occurs. 
Nicotine uptake in the mouth can be studied using nicotine chewing gum, 
produced as an aid to smoking cessation. Nicotine chewing gum is available 
in two strengths, 2 and 4 mg per piece. The nicotine is bound into an ion- 
exchange resin which allows it to be released slowly over a period depending 
on the rate and vigour of chewing (Figure 1.5). The ion-exchange resin 
helps to buffer the pH to 8.5 to ensure maximum absorption in the mouth 
(Russell et a/, 1980). However, even after vigorous chewing up to 1 mg can 
remain in the gum (Benowitz et al, 1987), suggesting that complete 
absorption is unlikely.
Figure 1.5 : Plasma nicotine concentrations after chewing one piece of 4 mg 
gum (chewed 0 to 30 minutes), compared with smoking a cigarette (1.2 mg 
nicotine, smoked 0 to 8 minutes) and a large Havana cigar (smoked 0 to 60 
minutes). At least 12 hours abstinence before testing. (Russell et al, 1980)
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1.5.3 Nose
In regular snuff users plasma nicotine concentrations approach those 
seen in daily cigarette smokers (Russell et al, 1981) suggesting that 
absorption through the nasal mucosae is efficient. Russell et al, (1983) 
compared a solution of nicotine administered to the nasal mucosae (2mg 
dose) with cigarette smoking (one 1.4mg nicotine yield cigarette, with 
approximate mouth delivery of 1.9mg) and nicotine chewing gum 
(2mg/piece). They found that the nasal solution resulted in a peak plasma 
concentration (14ngmM at 7.5 minutes) less than the cigarette (26ngmM at
1.5 minutes) and greater than the gum (8.5ngmM after chewing for 30 
minutes) both in magnitude and latency, suggesting that the nasal nicotine 
solution offered a better replica of cigarette dosage than the nicotine gum 
(Figure 1.6).
Figure 1.6 : Average plasma nicotine concentrations of three subjects after 
smoking a cigarette (0 - 6 min), taking nasal nicotine solution (NNS) (0 min) 
and chewing gum (0 - 30 min) (Russell etal, 1983)
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1.5.4 Gastro-Intestinal Tract
Absorption throughout the gastro-intestinal tract is pH dependent; at 
stomach pH nicotine exists as a diprotonated ion and in the intestine as a 
monoprotonated ion. It will therefore exhibit lower systemic availability, and 
of that absorbed, only 25 - 30% will reach the systemic circulation due to 
hepatic clearance. Hence the availability of nicotine after oral administration 
(where it leaves the mouth rather than being retained in the mouth) will be 
low. Travel I (1960) found that 20 mgkg'^ nicotine at pH 8.6 caused death in 
40 minutes when introduced into the ligated stomach of anaesthetised cats, 
whereas the animals survived a higher dose, 50 m gkg'\ for more than 24 
hours when the stomach pH was 1.2.
Rectal absorption, following administration of a tobacco enema for 
constipation, may bypass the 'first-pass' effect (removal by the liver on first 
pass through it), resulting in higher systemic availability (de Boer etal, 1982).
1.5.5 Skin
Nicotine absorption through the skin can be very rapid; Faulkner 
(1933) reported the case of a florist who sat on a bench which was wet with 
40% nicotine solution used as an insecticide. Within 15 minutes symptoms 
of acute nicotine poisoning were apparent. The patient was hospitalised and 
recovered fully. On discharge he dressed in the same clothes he was 
wearing on admission and within one hour had to be readmitted suffering 
from the same symptoms, because his trousers were still damp with the 
original nicotine solution.
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An illness called green-tobacco sickness has been observed in 
workers harvesting tobacco, initially thought to be due to "... an unknown 
emetic substance in the tobacco sap ..." (Weizenecher and Deal, 1970), but 
subsequently determined to be due to absorption of nicotine through the skin 
resulting from contact with wet tobacco leaves (Gehlbach et al, 1974). As a 
result of the ease with which nicotine is absorbed through the skin, the use of 
nicotine containing patches taped to the skin has been suggested as a means 
of supplementing or replacing smoking in smoking-cessation therapy. These 
patches allow controlled release of the nicotine and more accurate control of 
the dose taken up than oral administration, such as using nicotine chewing 
gum, whilst eliminating some of the adverse effects. It has been shown to 
prevent any increase in craving for cigarettes during a short period of 
deprivation (Rose et al, 1985), but plasma nicotine reaches a peak more 
slowly (90 minutes) than nasal or buccal administration.
1.5.6 Bladder
As with absorption from the gastro-intestinal tract, absorption from the 
bladder is pH dependent. Travell, (1960), found that nicotine solutions with 
pH less than 6 instilled into the bladder of cats produced little effect, and 
inferred that there was very little absorption, but at pH greater than 8, marked 
poisoning was observed.
1.6 DISTRIBUTION
Once a compound enters the blood system the molecules circulate 
around the rest of the body, gradually being dispersed throughout the blood
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and may be absorbed by or extracted into other organs. The concentration 
of the compound at any one point can be modelled. For example, after the 
administration of a compound to the lower respiratory tract, the concentration 
of that compound at the aorta rapidly reaches a peak and then decreases 
after only a very few seconds. This is the first pass. The second and 
subsequent passes show progressive reduction due to dispersion and 
extraction on each circulation.
The observed concentration decreases due to dilution and extraction 
as fractions are removed into the rest of the body. This extraction has two 
elements, distribution into other tissues from the blood and metabolism or 
elimination. If extraction were complete there would be no recirculation, 
since the compound would be totally removed from the blood, or if there were 
no extraction the compound would recirculate continuously and reach a 
uniform concentration. The extraction rate therefore determines the number 
of recirculations and the concentration in the plasma at any one time.
Most compounds are transformed in the body into metabolites which 
may also have pharmacological activity. The concentration of the metabolite 
depends upon its dynamics i.e. :
(i) the concentration of the parent compound (the input function)
(ii) the rate of metabolism of the parent compound (the transfer function) 
the extraction rate of the metabolite (the output function)
It follows therefore that there are three types of relationship between 
the parent compound and its metabolite :
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(i) If the dynamics of the metabolite are much faster than the parent 
compound, then the metabolite concentration profile will follow the parent 
concentration profile, being dependent only on the input function.
(ii) The dynamics of the metabolite are very much the same as the parent. 
This results in the metabolite profile being more dispersed than, but similar to, 
the profile of the parent and after a period that depends upon the residence 
times of both compounds, the profiles will parallel each other.
The dynamics of the metabolite are much slower than those of the parent 
compound. In this case the parent profile can be considered to be more like 
a pulse in comparison with the wide flat profile of the metabolite.
Nicotine and one of its major primary metabolites, cotinine, fall into the 
third category. The plasma nicotine concentration rises rapidly during 
smoking to a peak just after the cigarette is finished, when it starts to drop. It 
continues to drop until the next cigarette is smoked, when it will rise rapidly 
again, resulting in a saw-tooth waveform (Figure 1.7). The plasma 
concentration of cotinine, however, exhibits a much slower rise (Figure 1.8).
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Figure 1.7 : Plasma nicotine levels while subject smoked one cigarette per 
hour (on the hour) (Russell etal, 1976)
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Figure 1.8 : Arterial blood nicotine and cotinine levels during and after 
smoking a cigarette between 0 and 10 minutes (Armitage, 1978)
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In studies of whole body autoradiography using various small and 
medium sized mammals, randomly labelled [^"^C]nicotine and [®H]nicotine 
were found to be rapidly distributed into the brain, lungs, bronchi, adrenal 
medulla,, kidneys, stomach, intestine, placenta, foetus and body fluids 
(Rotenberg, 1982). The rate of disappearance from the blood was rapid 
during the first 30 minutes of intravenous (i.v.) injection to cats. During the 
next 30 minutes the rate of disappearance slowed considerably. The 
maximum concentrations of nicotine in the brain, liver and kidneys were 
achieved within the first 5 - 1 5  minutes after injection whereas negligible 
concentrations were found in these areas after 4 - 6 hours. In rabbits a 
biexponential decline from the blood was found after i.v. injection with a 
'distribution phase' (t^ /g 6 minutes), and an 'elimination phase' (t^ /g 50
minutes.
In humans Kyerématen et al (1982) showed a similar biphasic 
disappearance, no t^ /g given for the distribution phase, with a t^ /g of 48 ±  2
minutes for the elimination phase after i.v. administration of [^"^Cjnicotine. 
They also found that non-smokers had a longer t^ /g of 78 ±  6 minutes.
In contrast, [^H]-cotinine shows an initial even distribution throughout 
the tissues when injected intravenously in the mouse. Subsequently, the 
concentration increases in the excretory organs, such as the kidneys and the 
bladder (McKennis ef a/, 1964).
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1.7 METABOLISM
The earliest description of the metabolism of nicotine was in 1876 
when Lautenberg showed that the passage of nicotine through the liver 
prevented its toxic effects in the dog. An overall view is shown in Figure 1.9 
with sections highlighted in Figures 1.10 - 1.13; {} brackets are used in the 
text where structures are shown in Figures 1.9-1.13. Metabolism of nicotine 
occurs primarily in the liver, but has also been shown in in vitro preparations 
of tissue from the kidneys and from the lungs in several species including 
man (Booth and Boy land, 1971; Hanson et ai, 1964; Boyland and de Kock, 
1966; Turner, 1969). The contributions of the various pathways involved in 
the metabolism of nicotine vary not only between species but also within a 
species according to tissue as well as numerous other factors such as age, 
sex, smoking habits, dietary habits, drug pretreatment and disease state. 
The routes of metabolism can be grouped into six general pathways : C- 
oxidation, N-oxidation, N-demethylation, conjugation, peroxidation and 
pyrrolidine ring cleavage.
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Figure 1.9 : Routes of metabolism and metabolites of nicotine; brackets 
indicate hypothetical transient intermediates; not including conjugates.
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1.7.1 C-Oxidation
Figure 1.10 : C-Oxidation pathway
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The major metabolite in most species was initially thought to be 
cotinine {2}, first shown in the dog (McKennis etal, 1957) and subsequently in 
the rabbit (Mucker et al, 1959; Papadopoulous and Kintzios, 1963), rat 
(Truhaut and de Clercq, 1959), mouse (Appelgren et al, 1962) and man 
(Bowman et al, 1959). The conversion of nicotine to cotinine is a two-step 
reaction involving two different enzyme systems (Figure 1.10). First, 5- 
hydroxynicotine {3} is formed by C-oxidation involving cytochrome P-450. 
This can be inhibited by the presence of carbon monoxide in the gaseous 
phase of an in vitro rabbit hepatic system (Murphy, 1973). Carbon 
monoxide forms a complex with cytochrome P-450 and inhibits P-450- 
dependent drug oxidation (Omura et al, 1965). 5-Hydroxynicotine is in 
equilibrium with the imminium ion {4}. The second step {3 to 2} is mediated 
by cytoplasmic aldehyde oxidase (Mucker et al, 1960; Murphy, 1973).
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Cotinine itself is also subject to C-oxidation involving hydroxylation of 
the pyrrolidine ring. Its metabolites include 3'-hydroxycotinine {18} and 5'- 
hydroxycotinine. The formation of 3'-hydroxycotinine is highly stereospecific 
with the trans-lsomer dominating (>98%). Recent studies indicate that trans- 
3'-hydroxycotinine is a major metabolite and the urinary concentration may 
exceed cotinine by a factor of 3 or 4 (Jacob et al, 1988; N eu rath et al, 1987)
1.7.2 N-Oxidation
Figure 1.11 : N-Oxidation pathways
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N-oxidation of nicotine is catalysed by a microsomal flavoprotein and 
gives the two diastereoisomers of nicotine-1'-N-oxide {5} (Figure 1.11), first 
reported by Papadopoulous in rabbits (1964), and later in cats by Turner 
(1969), with the isomers identified by Booth and Boyland (1970). After 
intravenous injection, 100% of nicotine-1'-N-oxide is excreted in the urine, 
indicating no further metabolism (Beckett etal, 1971).
Cotinine-N-oxide {6} can arise by oxidation of the pyridine nitrogen 
(Dagne and Castagnoli, 1972) but this is thought to be cytochrome P-450 
dependant (Hibberd and Gorrod, 1985). Although the isomethylnicotinium
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ion {7} is formed by N-methylation of nicotine (McKennis et al, 1963), no 
further metabolism of this ion to the cotinine methonium ion {8} has been 
demonstrated although the latter has been isolated as a metabolite.
Although the contribution of N-oxidation to the overall metabolism of 
nicotine is small it is of interest for two reasons. Firstly, nicotine-N-oxides can 
be nitrosated to form nitrosamines which have been demonstrated to be 
carcinogenic. Hecht and Hofmann (1988) have suggested that since there 
are oxides of nitrogen present in tobacco smoke and nitrites in saliva, 
tobacco-specific nitrosamines could be formed in vivo. Secondly, the 
potential exists for the N-oxides to be reduced back to nicotine, which can be 
performed in vivo by gut flora and in vitro by intestinal and hepatic 
microsomal enzymes (Sepkovic and Haley, 1987). This back-reduction might 
cause the metabolic half-life of nicotine to be extended by increasing the 
circulating levels of nicotine.
1.7.3 N-Demethylation
The third type of direct metabolism of nicotine is N-demethylation, 
which gives nornicotine {9}, the presence of which has recently been 
confirmed in the urine of cigarette smokers (Zhang et al, 1990) (Figure 1.12). 
Demethylcotinine {10} has been isolated from the urine of smokers (Bowman 
et al, 1959) and may be formed from nicotine via nornicotine. Bowman and 
McKennis, (1962) were able to isolate demethylcotinine from the urine of 
dogs when given cotinine, but not from that of humans. On administration of 
[methyl-^'^Cjnicotine to rats, they expire [^'^Cjcarbon dioxide which is thought 
to arise from cotinine via déméthylation (McKennis et al, 1962).
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Figure 1.12 : N-Demethylation pathways
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1.7.4 Conjugation
Glucuronidation is among the most frequent means by which the 
human body produces polar metabolites of foreign molecules for excretion. 
Kyerematen et al, (1990) reported that on incubation with p-glucuronidase, 
the material derived from the high performance liquid chromatographic 
(HPLC) peak of a long-lived nicotine metabolite, detected in the urine of 
cigarette smokers and non-smokers given a low intravenous dose of "^^ 0- 
nicotine, was hydrolysed almost completely (90%) to 3'-hydroxycotinine, with 
the remainder being hydrolysed to nicotine and cotinine. Recently, Curvall et 
ai, (1991) have reported that glucuronic acid conjugates of nicotine, cotinine 
and 3'-hydroxycotinine are present in human urine. Urine samples from 
cigarette smokers and snuff-users were collected and analysed for free and 
conjugated nicotine, cotinine and 3'-hydroxycotinine using a p-glucuronidase 
preparation from Helix pomatia. Caldwell et al, (1991) have synthesised a 
cotinine glucuronide conjugate and have shown that it has the same spectral 
properties as the compound excreted by humans.
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1.7.5 Peroxidation
Recently, nicotine-8'^’’®'-enamine was identified as a peroxidative 
metabolite of nicotine (Mattammal eî al, 1987) both in in vitro studies using 
lung or seminal vesicle microsome preparations and in vivo in rabbits and in a 
cigarette smoker. Nicotine-S'^'^'-enamine and the nicotine imminium ion, the 
intermediate in cotinine metabolism, are interconvertible and thus the 
enamine may be involved in that pathway (Obach and Van Vunakis, 1988).
1.7.6 Pyrrolidine Ring Cleavage
All remaining metabolites of nicotine are believed to be formed from 
cotinine or demethylcotinine via cleavage of the pyrrolidine ring (Figure 1.13). 
This can occur either by hydrolysis of the amide linkage to give y-(3-pyridyl)- 
y-methylaminobutyric acid (PMABA) {11} (Mucker and Gillette, 1959) or by 
oxidative 1,2 cleavage to give y-(3-pyridyl)-y-oxo-N-methylbutyramide {12} 
(POMB).
PMABA has been found in the urine of dogs given nicotine or cotinine 
(McKennis etal, 1957,1959,1961; Mucker and Gillette, 1959), in the urine of 
rats given cotinine (Morselli et al, 1967) and in the urine of smokers 
(Bowman et al, 1959). It can rearrange chemically to form cotinine 
(McKennis et al, 1957), but there is no evidence that it is an intermediate in 
the enzymatic formation of cotinine (Mucker et al, 1960; Mucker and 
Gillette,1960). It is possible that PMABA might be an intermediate in the
formation of demethylcotinine since it can spontaneously lactamise, (the 
amide group forms a 5 membered ring ) (McKennis, 1964), but there is no 
evidence.
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Figure 1.13 : Pyrrolidine ring cleavage pathways
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POMB has been found in the liver and kidney of mice receiving 
nicotine (Hanson and Schmiterlow, 1965) in the urine of dogs (McKennis et 
al, 1961, 1962), rats (Morselli et ai, 1967), mice and humans receiving 
nicotine or cotinine (Bowman and McKennis, 1962), and has been found in 
vitro in mouse tissue slices incubated with nicotine (Hanson et ai, 1964). 
Whereas PMABA does not appear to be metabolised further, POMB can, in 
the dog and rat, be metabolised to Y-{3-pyridyl)-y-oxobutyric acid {13}
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(POBA) by oxidative deamination (Hanson et al, 1964). This compound can 
also arise by deamination of demethylcotinine (McKennis, 1964). POBA is 
metabolised to Y-(3-pyridyl)-y-hydroxybutyric acid (PHBA) {14} by ketone 
reduction (McKennis et al, 1964,1964a; Turnbull et al, 1958). This 
compound is of interest since it can exist as a lactone, 5-(3- 
pyridyl)tetrahydrofuranone-2 {15} (McKennis 1964; Bowman, 1968) although 
the lactone has not been detected as a metabolite of nicotine. The lactone 
may participate in nicotine metabolism since on its administration to rats, 
PHBA, y-(3-pyridyl)butyric acid {16} and 3-pyridylacetic acid {17} were among
the metabolites present (Bowman,1968). These have also been found in 
rats and dogs after administration of POBA (McKennis et al, 1964; Turnbull 
etal, 1958).
3-Pyridylacetic acid appears to be the ultimate degradative product of 
nicotine metabolism, and has been isolated from the urine of dogs (McKennis 
etal, 1961), mice (Bowman ef a/,1964), humans (McKennis ef a/,1964) and 
cats (Turner, 1969) receiving nicotine or cotinine. No evidence has arisen 
yet to show that further oxidation of 3-pyridylacetic acid occurs.
1.7.7 Metabolic Differences
Benowitz et al, (1982) found up to a three-fold inter-individual 
variability in the volume of distribution and clearance of nicotine in 14 men, all 
regular cigarette smokers. Thus for the same amounts of nicotine inhaled 
there might be very variable blood concentrations. Conversely, if a smoker 
wishes to maintain a certain blood level of nicotine then his or her metabolism 
may influence their smoking behaviour. Similarly, the use of cotinine levels 
might well be misleading without prior knowledge of that individuals nicotine
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metabolism, and the above authors found no relationship between cotinine 
concentration and metabolic clearance of nicotine.
In a later paper Benowitz and Jacob (1984) showed that men appear 
to metabolise nicotine faster than women and Beckett and Triggs (1967) 
found that smokers metabolise a greater proportion of nicotine to cotinine and 
do so faster than non-smokers, suggesting induction of the enzyme systems, 
but in the routes other than to cotinine since the amounts of this remain 
comparable. They also suggest that the increased enzyme activity persists 
for two months after smoking has ceased.
Gorrod and Jenner (1975) describe the urinary recovery of nicotine 
and cotinine from four groups, male and female smokers and non-smokers, 
whose urine was acidified with ammonium chloride to prevent reabsorption of 
nicotine and/or cotinine through the kidney tubules. Nicotine was given by 
i.v. injection in controlled doses to simulate smoking. The male smokers fell 
into two groups. One showed a lower recovery of both nicotine and cotinine 
than male non-smokers, the other showed a similar recovery of nicotine but 
more cotinine than the non-smokers. Female smokers excreted less nicotine 
than female non-smokers but had a higher combined recovery. Male non- 
smokers excreted less nicotine but more cotinine than female non-smokers, 
suggesting sex-linked differences in metabolism, but this is difficult to detect 
in smokers due to the apparent changes induced by the smoking. In the low 
recovery group smoking may have induced metabolism of both compounds 
whilst in the high recovery group smoking may have either inhibited further 
metabolism of cotinine or enhanced the metabolism to cotinine at the 
expense of other routes. In the female smokers smoking led either to 
increased metabolism to cotinine or inhibited metabolism beyond cotinine.
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The relative proportions of each metabolite that is produced are likely 
to vary between individuals depending upon previous and current exposure to 
nicotine. Some 70% of nicotine is metabolised to cotinine, but of this only 
10% is excreted directly, the majority, 39%, being excreted as trans-3'- 
hydroxycotinine (Benowitz, 1987). Thus frans-3'-hydroxycotinine may form 
the most abundant metabolite of nicotine (Neurath,1987). Curvall et al 
(1991) reported a study where urine samples from cigarette smokers and 
snuff users were collected and analysed for nicotine, cotinine, trans-3'- 
hydroxycotinine and their glucuronide conjugates. Based on the data from 
this study they suggest that of the total dose of nicotine, 5% is excreted as 
nicotine-1'-N-oxides, 3% as cotinine-N-oxide, 10 - 15% as free and 
conjugated nicotine, 20 - 25% as free and conjugated cotinine and 50 - 60% 
as free and conjugated frans-3'-hydroxycotinine (Figure 1.14). While their 
data from snuff users appears to be sound the assessment of nicotine intake 
from cigarette smokers was based on machine smoking yields. A recent 
study by Mariner et al 992) where estimation of nicotine intake was made 
from actual smoking behaviour suggested that nicotine, cotinine, trans-3'- 
hydroxycotinine and their glucuronide conjugates accounted for 61% of 
nicotine intake.
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Figure 1.14 : Relative proportions of urinary metabolites (free and conjugated 
forms) (Curvall ef a/, 1991)
Nicotine-N-oxide (5%)
Cotinine-N-oxide (3%)
3-OH Cotinine 
(50-60%)
Nicotine (10-15%)
Cotinine (20-25%)
1.7.8 induction of Nicotine Metabolism
Much attention has been given to the phenomenon whereby the 
metabolism of nicotine is modified by single pre-exposure or repeated 
exposure to nicotine or tobacco smoke.
In rabbits, nicotine pre-treatment results in increased metabolic 
capacity over control treatments (Dixon and Lee, 1912) but this has not been 
shown conclusively in dogs (Edmunds and Smith, 1915), or in rats (Takeuchi 
et al, 1954). Werle and Muller (1941) showed a decrease in activity 
following pre-treatment in one study, but on using a lower dosage-regime 
over a longer period they found only slight increase in hepatic activity, but 
extra-hepatic activity (lung, kidney and brain) increased 100% over controls 
(Werle and Uschold, 1948). Other studies have demonstrated that a single
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dose of nicotine will result in induction of hepatic acetylaminofluorene 
hydroxylase and benzpyrene hydroxylase in the rat but treatment over three 
days caused a reduction in activity (Yamamoto et al, 1966); similarly, 
treatment of mice over a three day period caused a reduction in activity, 
whilst treatment for 10 or 17 days had little effect (Stalhandske and Slanina, 
1970). There is, however, conflicting work. Ruddon and Cohen (1970) 
found that the repeated injection of nicotine into rats (four times a day for 
three days) produced an increase in hepatic metabolism of ethylmorphine 
and norcodeine, and chronic administration in drinking water also produced 
an increase . However, if the dose dropped below a total of 4.4mgkg*^24hrs‘  ^
the increased activity was not maintained. It is important to note, however, 
that the dosing regimes in all these animal studies are many times greater 
than those that occur during human smoking.
The effect of nicotine on drug-metabolising activity is complex, but 
work so far suggests that dose, length of administration and stress-induced 
effects are all of importance.
1.8 TOLERANCE TO NICOTINE
A state of tolerance is said to have developed when prolonged 
exposure to a drug results in decreased response. Smokers know that 
tolerance develops to the dizziness and nausea which accompanies the first 
cigarettes. Rottenstein et al, (1969) showed that intravenous injection of 
nicotine did not cause nausea and vomiting in smokers but did in non- 
smokers. Porch et et al, (1988) have developed a model of tolerance applied 
to nicotine where tolerance results from an antagonism of the agonist effect 
by a hypothetical substance e.g. a metabolite, driven by the agonist
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concentration; thus tolerance lags behind and is approximately proportional to 
the agonist concentration. After testing the model in humans, using 
intravenous administration of nicotine and measuring heart rate, they 
estimated a half-life of development and regression of tolerance of 35 
minutes and that tolerance reduces the effect of nicotine on heart rate by 
80%. The interval at which cigarette smokers smoke cigarettes may be 
determined to a considerable degree by the kinetics of regression of 
tolerance.
1.9 EXCRETION
In man and other mammals, the kidney is the main organ for excretion 
of nicotine (Turner, 1969). Saliva is a further important route for nicotine 
excretion, however, the ratio of nicotine concentration in saliva to plasma may 
exceed 10 (Russell and Feyerabend, 1978). Other, less important, routes of 
nicotine elimination are sweat (Larson et al, 1961), breast milk (Luck and 
Nau, 1984), bile, gastric secretions and faeces (Turner, 1969).
As already indicated, pH plays a significant role in the renal excretion 
(Schachter et al, 1977; Beckett et at, 1972; Rosenberg et al, 1980). At 
urinary pH above 7, nicotine is readily reabsorbed through the renal tubule 
and only 2% of a dose is recovered unchanged in the urine. When urine is 
more acidic, pH less than 5, as much as 23% of a dose of nicotine can be 
recovered in the urine as nicotine. In this way, acidification of the urine has 
been shown to increase cigarette consumption in man by increasing the 
excretion of nicotine and reducing the circulating levels (Benowitz and Jacob, 
1985).
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1.10 PHARMACOLOGY OF NICOTINE
Some studies have suggested that systemic levels of nicotine are 
critical determinants of smoking behaviour by observations of self­
administration of intravenous nicotine by smokers (Henningfield et al, 1983) 
and by the effects on smoking behaviour of nicotine antagonists (Stolerman 
et al, 1973). Self-administration of nicotine from nicotine gum by smokers 
has been shown to reduce cigarette smoking and reduce smoking withdrawal 
symptoms (Jarvik and Henningfield, 1988). However, other studies claim that 
systemic nicotine levels are not an important determinant of smoking 
behaviour. Kumar et al, (1976) found that intravenous nicotine administered 
during smoking did not reduce smoking as had been expected. It may be that 
sensory factors such as irritation in the mouth and/or throat, or the taste or 
flavour play an important role (Sutton etal, 1982).
The existence of a specific 'receptor', mediating the effects of nicotine, 
was postulated in 1905 by Langley and since then a large number of 
pharmacological effects have been ascribed to drug actions on nicotinic 
receptors. These receptors have generally been supposed to be innervated 
by nerves utilising acetylcholine (ACh), the principal transmitter of the 
parasympathetic and preganglionic sympathetic neurons of the autonomic 
nervous system. The actions of ACh were divided into a nicotinic and a 
muscarinic component by Dale (1914). While the muscarinic effects 
dominate at the parasympathetic end-organs, the nicotinic component 
determines the response to ACh in autonomic ganglia and at the 
neuromuscular junction. Cholinergic effects in the central nervous system 
seem to involve both nicotinic and muscarinic mechanisms.
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Thus, the pharmacology of nicotine can be described by reviewing its 
effects at the three major physiological sites of nicotinic action i.e. (i) the 
neuromuscular junction, (ii) the autonomic ganglia and (iii) the central 
cholinergic synapse.
1.10.1 The Neuromuscular Junction
The sequence of events in neuromuscular (NM) transmission is 
generally conceived in the following way : a nerve impulse travels along the 
axon of a motorneuron to reach its terminal, where it stimulates release of 
ACh into the synaptic cleft (Dale et al, 1936). The ACh molecules combine 
with postsynaptic nicotinic receptors to open ion channels which carry a 
positive charge into the muscle cell (Takeuchi and Takeuchi, 1960), thereby 
producing a small depolarization, the miniature end plate potential (MEPP). 
The summation of a number of MEPPs subsequently brings about the larger 
depolarization necessary to cause contraction of the muscle fibres.
Most of the molecular studies of the nicotinic receptor have been 
performed using receptors from the electric organs of fish such as the 
Torpedo ray but it has been shown by cloning and DNA sequencing of 
receptor subunits that there is much similarity between this and bovine calf 
and human receptor (Noda et al, 1982,1983). The nicotinic receptor is 
thought to be composed of five subunits. The a  subunit is the recognition site
for ACh and other antagonists which bind irreversibly to the receptor. When 
agonist molecules bind to the recognition sites, conformational changes take 
place between the subunits with the result that the ion channel, between the 
subunits, opens.
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Administration of nicotine to a muscle fibre typically elicits a brief 
contraction followed by a prolonged paralysis of the fibre. This is illustrated 
by the often fatal respiratory paralysis in cases of nicotine poisoning, which 
may occur in association with the use of nicotine as a pesticide (Sutton 1963).
1.10.2 Autonomic Ganglia
There are several reasons for making a distinction between the 
nicotinic receptor at the neuromuscular junction and the nicotinic receptor in 
autonomic ganglia. They have different embryological origins: the former is 
of mesodermal origin and the latter comes from the neural crest. Although 
a-bungarotoxin binds to both, it inhibits transmission only at the NM junction 
(Oswald and Freeman, 1981). The two receptors are blocked by different 
methonium compounds: hexaméthonium (C6) blocks ganglionic transmission, 
while décaméthonium (CIO) blocks NM transmission (Paton and Zaimis, 
1949).
The observation of Langley and Dickinson (1889) that painting the 
superior cervical ganglion with nicotine elicits a brief stimulation followed by a 
prolonged ganglionic blockade was not only very important for the 
physiological analysis of the autonomic nervous system, but it was also the 
first description of the dual action of nicotine. Electrophysiologically, the 
nicotine effect is seen as an initial depolarization, followed by a repolarization 
with a persistent block of transmission (Lundberg and Thesleff, 1953; Paton 
and Perry, 1953)
The ganglion-stimulating action of nicotine is reflected in an increased 
rate of synthesis of postganglionic transmitter, such as noradrenaline in
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sympathetic ganglia, after systemic doses of nicotine (Hanbauer and Costa, 
1976). Adrenal medullary cells are very similar to postganglionic sympathetic 
neurons hence the fact that nicotine stimulates the release of adrenal 
catecholamines is not surprising. This action, first described by Cannon et al 
(1912), is also present in isolated adrenal medulla (Schneider, 1969). The 
action of nicotine in stimulating the adrenal glands is also reflected in 
increased levels of catecholamine synthesising enzymes and decreased 
catecholamine levels in the adrenals (Slotkin and Seidler, 1975). Nicotine 
can also cause the release of noradrenaline directly from postganglionic 
sympathetic nerve endings (Su and Bevan, 1970) and systemic 
administration of nicotine produces decreased tissue levels of noradrenaline 
(Westfall, 1965). A dose dependant increase in blood levels of adrenaline 
and noradrenaline after treatment with nicotine has been observed (Dominiak 
efa/, 1984).
When all of the above described actions of nicotine are considered, 
together with the nicotine-induced effect on chemoreceptors of the carotid 
and aortic bodies and on the cardioregulatory centres, a very complex 
picture of the effects of nicotine on cardiovascular mechanisms emerges. 
Nicotine is able both to stimulate and to block sympathetic and 
parasympathetic ganglia and also to directly affect catecholamine release 
from the adrenal glands and sympathetic nerve terminals. Yet, the most 
consistent acute effects of nicotine in man are elevated blood pressure and 
heart rate together with peripheral vasoconstriction. The question of 
tolerance has not been answered, although experiments in humans indicate 
some degree of tolerance to cardiovascular effects (Porchet etal, 1988).
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1.10.3 The Central Cholinergic Synapse
Although ACh was suggested as a central neurotransmitter several 
years before, it was the demonstration in 1954 of a rapid synaptic excitation 
of Interneurons in the spinal cord that firmly established a role for ACh in 
central nervous transmission (Ecoles et al, 1954). Cells in different parts of 
the brain display differential responsiveness to ACh and cholinergic drugs. 
Some neurons, like cells of the medial habecular nucleus respond mainly to 
nicotinic stimulation (McCormick and Prince, 1987a), while most show 
predominantly muscarinic responses e.g. neocortical neurons (Krnjevic and 
Phillis, 1963). Other brain regions, such as the thalamus (Andersen and 
Curtis, 1964), medulla oblongata (Bradley et al, 1966) and the hippocampus 
(Rovira et al, 1983), exhibit both types of cholinergic receptor mechanisms. 
Frequently, when ACh evokes both excitation and inhibition in the same 
neuronal population, the nicotinic response is rapid excitation and the 
muscarinic response is slow excitation or inhibition.
1.10.4 Nature of the Central Nicotinic Receptor
The distribution and nature of central nicotinic receptors have been 
extensively studied. Initially, a-bungarotoxin was used because of its
irreversible interaction with the neuromuscular nicotinic receptor and the 
identification of specific binding sites in the brain (Oswald and Freeman, 
1981). Later, when tritiated nicotine became available, autoradiographs 
showed that the binding sites of nicotine and a-bungarotoxin were different 
(Clarke et al, 1985b). More recently, immunological purification has shown 
that the binding sites are structurally different in rat brain (Whiting and 
Lindstrom, 1987).
40
Molecular studies suggest that although brain nicotinic receptors may 
be structurally different from ganglionic nicotinic receptors, they share the 
same pharmacological characteristics, including insensitivity to a- 
bungarotoxin and sensitivity to K-bungarotoxin. This was confirmed by 
Upton et al (1987) when they demonstrated that nicotinic responses to ACh 
from retinal cells were blocked by the ganglion blocking drugs 
hexaméthonium and mecamylamine, suggesting that the central nicotine 
receptor is a C6 receptor.
1.10.5 Regulation of Brain Nicotinic Receptors
One of the central principles of pharmacology is that treatment with a 
drug causes a decrease in the number of receptors at which it operates, while 
treatment with an antagonist causes an increase in the number of receptors. 
However, a number of studies have shown that prolonged nicotine treatment 
results in an increase in the number of receptors (Schwartz and Kellar, 1985; 
Marks and Collins, 1985). It has been suggested that either there are two 
forms of nicotine receptor, a high activity low affinity form and a low activity 
high affinity form and that it is only the second form that is recognised in most 
studies, or that the number of receptors increases as a compensatory 
response to desensitisation. In line with the above animal studies, Benwell et 
a / (1988) have reported that smokers have a higher density of brain nicotine 
receptors than non-smokers.
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1.10.6 Behavioural Pharmacological Aspects
Both nicotine and tobacco smoke produce an electroencephalographic 
(EEG) desynchronization which is associated with behavioural arousal in 
laboratory animals (Domino, 1967; Hall, 1970) which can be blocked by 
mecamylamine, supporting the C6 receptor hypothesis. In humans, 
however, tolerance develops to the activating effect of tobacco smoke, and 
the relative EEG depression of deprived smokers can be restored to normal 
by smoking (Knott and Venables, 1977).
Stimulation of brain noradrenaline function was suggested by. Vogt 
(1959) to be an important effect of tobacco smoking. Subsequent studies 
showed that the turnover of noradrenaline in the brain (Bhagat, 1970) and 
noradrenaline and adrenaline in the hypothalamus (Andersson et al, 1980) 
was increased under nicotine administration. The largest site of action of 
noradrenaline in the brain is the locus coeruleus which is thought to be 
involved in vigilance and arousal, stress reactions and in the regulation of 
psychosomatic reactions (Foote et al, 1983). Nicotine administration results 
in increased noradrenaline synthesis (Lewander et al, 1977) and neuronal 
firing (Svensson and Engberg, 1980) from this site. This stimulation by 
nicotine may help to explain apparently contradictory central effects such as 
enhanced vigilance and memory as well as sedation under adverse 
environmental conditions.
1.11 HUMAN SMOKING BEHAVIOUR
The act of smoking a cigarette, although ostensibly very simple, 
involves a number of separate actions. After placing the cigarette between
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the lips, it must be lit. This requires that an ignition source is placed close to 
the cigarette tip and a puff is taken. Firstly the glottis must be closed to 
separate the mouth from the throat; then the puff is taken by contracting the 
floor of the mouth, thereby increasing the volume of the buccal cavity, so 
reducing the pressure, and drawing air through the cigarette. The volume of 
the puff of smoke will therefore depend upon the physical size of the mouth, 
100ml being near the upper limit, and whether the smoker terminates puffing 
for any reason.
Thus smoke resides in the buccal cavity for a finite time during which 
absorption may occur, and absorption may be modified by many factors, such 
as the residence time, the extent to which the tongue is moved around within 
the mouth, and the pH of the smoke, all of which need to be investigated.
Immediately following the puff, which may be taken at any phase of 
respiration, the glottis is opened and an inspiration taken. This inspiration 
may be of any size, from a small breath (a shallow inhalation) to approaching 
vital capacity (a deep inhalation). Some smokers claim not to inhale but 
objective evidence shows them to be mistaken (Woodman et al, 1986), or to 
have aberrant ideas of what the activity constitutes. After taking the puff of 
smoke, but prior to inhalation, some smokers allow a proportion of the puff to 
drift out of the mouth or nose, this is called waste smoke.
The last component of the smoking act is the breath-hold, and 
although it may be of only short duration, it gives a further opportunity for 
absorption.
Therefore within the actions associated with a single puff the smoker 
can make many changes to the way the smoke is manipulated, any of which 
may affect the absorption of nicotine from the smoke. Within a cigarette.
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however, there is scope for even more manipulation since, in addition, the 
number of puffs and the inter-puff interval can also be altered.
1.12 OBJECTIVES
There has been some debate over the usefulness of plasma nicotine 
as a measure of nicotine intake. The problem arises because the time at 
which sampling takes place is critical. As can be seen from Figures 1.4 and 
1.7 the levels of plasma nicotine vary greatly during and after smoking. It is 
because of this variability that the time of sampling is so critical and should be 
very carefully controlled. Since most blood samples are venous samples it is 
slightly less critical than arterial samples where the levels are varying even 
more rapidly.
The dynamics of cotinine are such that the cotinine levels do not follow 
the nicotine levels, but instead tend to average out, or dampen the variabiiity 
of nicotine. It is this averaging effect and the long half-life of cotinine that 
has led to the use of plasma or saliva cotinine levels as indicators of the 
nicotine intake in smokers.
As nicotine is a basic amine its tissue distribution is dependent upon 
lipid solubility as well as upon pH differences. Small changes in physiological 
pH cause substantial changes in the ratio of unionised to ionised nicotine. 
Basic amines tend to attain higher tissue concentrations than blood 
concentrations because their lipid solubility promotes passage through 
membranes (Goldstein and Kapmann, 1974).
From the background described in the preceding sections several 
questions arose. The first question was :-
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Can body-fluid levels of nicotine and cotinine be used as reliable
measurements of nicotine uptake ?
In order to answer this question it was necessary to develop an 
analytical procedure for the analysis of nicotine and cotinine in body fluids 
and this is described in Chapter 2.
Once the analytical procedure was available it was used, along with 
procedures to measure smoking behaviour, to investigate the uptake of 
nicotine by cigarette smokers when alterations were made to the nicotine 
yield of the cigarettes smoked; firstly, by reducing the tar and nicotine yields 
simultaneously and secondly, by reducing the tar and nicotine yields 
independently. These two studies are described in Chapter 3.
The conclusion of the first study was that body fluid measurements 
gave some indication of changes in nicotine and smoke uptake on smoking 
different cigarettes but the changes observed did not account for all the 
observed changes in smoking behaviour. In the second study the 
measurements of saliva cotinine bore no relationship to the observed 
changes in smoking behaviour. It is therefore unacceptable to relate nicotine 
and cotinine in body fluids to smoking behaviour and thence nicotine uptake. 
This therefore prompted a second question
Is there an alternative means of measuring nicotine uptake ?
Cigarette smoking is an activity which uniquely administers 
pharmacologically active substances via the lungs and into the pulmonary 
circulation to produce their systemic effect. In order properly to understand 
the smoking habit a full understanding of the route of administration is 
required.
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Cigarette smoke is an aerosol with a defined particle size distribution 
with sufficient small particles to traverse the host defence mechanisms in the 
upper airways and reach the lower airways. It would be expected that 
particles would then deposit, by settling and impaction, upon the bronchial 
mucosae where they would presumably dissolve. The soluble materials from 
the particles would then diffuse through the bronchial wall to the bronchial 
veins from where the blood would be carried to the vena cava and the right 
heart. This process must take many seconds (though this has not apparently 
been measured) and it is a paradox that the pharmacological effects of the 
inhalation are felt within a few seconds.
There is a hypothesis which might explain the paradox of the rapid 
pharmacological effects obtained by inhaling nicotine and this relates to its 
ionic state. As has been described above, nicotine can exist in several ionic 
states. Nicotine is in the particulate phase of smoke on smoke generation 
(B.E. Frost, personal communication) and all ionic states may be present. 
Unionised nicotine has the highest vapour pressure, and during inhalation 
may vapourise, leave the particle and enter the alveolar space, where 
absorption is rapid, as a gas. A third question therefore arose :
Does nicotine evaporate from particies during inhaiation ?
It was realised that it might be possible to answer both these questions 
by measuring the retention of nicotine i.e. the difference between the amount 
of nicotine that is inhaled by the smoker and the amount that is exhaled. If 
successful, it would provide an alternative to body fluid measurements; also, 
by administering aerosols of nicotine at different pH's, and therefore different 
ionisation states, and measuring retention, it might be possible to elucidate 
the means by which the uptake of nicotine could be sufficiently rapid for the
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pharmacological effects of cigarette smoke to occur. The development of a 
means of measuring retention and its use for experiments with aerosols of 
nicotine and cigarette smoke are described in Chapter 4.
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CHAPTER TWO
BODY-FLUID ANALYSIS OF NICOTINE AND COTININE
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2.1 INTRODUCTION
The processes of solvent extraction with adjustment of pH, back- 
extraction and precipitation, have been used since the earliest volumetric and 
gravimetric assays of nicotine were first described. The first volumetric assay 
was developed by Keller in 1898, but suffered from poor specificity due to the 
failure to remove pyridine during the extraction. In 1904, Konig demonstrated 
the formation of coloured complexes with pyridine and 3-substituted pyridine 
molecules which were to be used by later colorimetric assays. Chapin 
(1911) developed a gravimetric method which, although sensitive to about 
2pgm l'\ still suffered from the failure to remove pyridine; by 1937, Spies had 
developed gravimetric techniques to the point where quantities of nicotine as 
low as 0.1 ng could be measured.
From its initial isolation there was much interest in the pharmacological 
effects of nicotine and in some cases the only methods of detection with 
sufficient sensitivity for nicotine were bioassays; for example, the use of the 
atropinised decerebrate cat (van Leeuwin, 1919), which had a lower limit of 
sensitivity of approximately 100pgml'\ It suffered from some of the problems 
typical of bioassays such as variability of response and long recovery time 
and it was not possible to prove, when using tobacco products, that the 
response was due to nicotine alone.
In 1942, Perlman et a/developed a bioassay involving the swimming 
behaviour of the crustacean Daphnia magna which was sensitive to quantities 
as low as 5ng of nicotine. The first estimate based on direct evidence of the 
smoking dose of nicotine was made by Johnston in 1942. He compared the 
subjective effects of intravenous injections of nicotine with the inhalation of 
puffs of cigarette smoke and found that the effects of one puff of smoke could
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be mimicked by an injection of 90 to 130pg and estimated the total nicotine 
dose from a cigarette to be approximately 1.3mg. (The nicotine yield of a 
typical middle tar cigarette is about 1.3mg.)
During the early 1950's paper chromatography was developed to the 
stage where up to 23 substances from tobacco extracts including 11 alkaloids 
could be separated (Porter et a/,1949; Tso and Jeffrey, 1953). Jeffrey and 
Eoff took this a stage further in 1955 by using randomly labelled ^"^C-nicotine 
(first produced by Geiling et al, (1948) by growing tobacco plants in an 
atmosphere of ^"^C-carbon dioxide) to identify seven metabolites of nicotine in 
the urine of cats and dogs.
Turner in 1969 developed quantitative procedures for the assay of 
(2)-nicotine and cotinine in biological material with a sensitivity of Ing nicotine 
per gram of tissue or fluid using thin layer chromatography. With this method 
Turner was able to study the distribution and metabolism of 'smoking doses' 
of nicotine in the cat, rather than the large, unrealistic doses used in previous 
work. With the development of more efficient scintillation counting it became 
possible to estimate isotope enriched nicotine at much lower levels of 
radioactivity (Turner, 1971).
Whilst it was of importance that nicotine could be determined 
accurately in the body fluids of laboratory animals, the requirement to 
measure the levels of nicotine and its metabolites in the body fluids of 
humans was steadily increasing. Whereas laboratory animals could be given 
substantial doses of nicotine or radio-labelled materials this was not possible 
with human subjects. It therefore became important that the procedures for 
the determination of nicotine and metabolites in human body fluids were 
made more sensitive in order that lower doses could be used and smaller
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samples of body fluids be required in order that multiple samples could be 
taken.
The first report of the use of gas chromatography (GC) in the analysis 
of nicotine appeared in 1958 (Quin) and in 1963 Parker et al, reported a GC 
method for nicotine determination for use in toxicological studies with a 
sensitivity of lOpg injected onto the column. During the period 1965 to 1970 
there was much effort put into improving nicotine analysis by GC. Beckett et 
al (1965) and McNiven et al (1965) both introduced internal standards in 
order to improve precision and account for losses. Over this period 
sensitivity was improved from 200ngmM of urine (Beckett and Triggs, 1966) 
to 1 - 2ngmM of plasma (Isaac and Rand, 1971). One of the reasons for the 
improvement was the use, by Isaac and Rand, of an Alkali Flame Ionisation 
Detector (AFID) (or Nitrogen Phosphorus Detector (NPD)) as their GC 
detector. This is a modification of the Flame Ionisation Detector (FID) which 
has greatly enhanced sensitivity to molecules containing nitrogen or 
phosphorus atoms. In the NPD a heated bead of rubidium sulphate is 
positioned above the tip of the jet of the FID. This enhances the response to 
nitrogen containing compounds 100- to 500-fold, whilst retaining a similar 
sensitivity to unsubstituted hydrocarbons (Aue et al, 1967). If the position of 
the collecting electrode and the hydrogen and air flows are varied, the 
detector can be made to distinguish phosphorus or halogenated compounds .
In 1973 an analysis using a completely different approach was 
published. Langone et al described a method using a radioimmunoassay 
(RIA) technique to measure nicotine and cotinine in tissue extracts and body 
fluids. The technique is based on the competition between radioactively 
labelled and unlabelled antigen for binding to a limited number of sites on a 
specific antibody. Antibodies were raised in rabbits immunized with covalent
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conjugates prepared by linking fra/7s-4'-carboxycotinine and trans-3'- 
succinylmethylnicotine to human serum albumin and keyhole limpet 
haemocyanin. This is necessary because low molecular weight molecules, 
such as nicotine and cotinine, do not always elicit an antigenic response and 
must be linked to macromolecules in order to make them do so (Landsteiner 
et al, 1945). The labelled (^H)-nicotine and (^^®l)-cotinine were prepared by 
random catalytic tritium exchange and iodination of N-(p-hydroxyphenethyl)- 
fra/7s-cotinine carboxamide with sodium ^^ i^odide respectively. A mixture of 
the sample (containing unlabelled nicotine and cotinine), labelled nicotine and 
cotinine and antibodies was incubated overnight and the precipitate of 
antibody-antigen complexes was collected by centrifugation. The 
radioactivity of the precipitate was then determined. Since a fixed amount of 
radioactive nicotine and cotinine was added to the unknown sample, the more 
radioactivity that was present in the precipitate the less unlabelled nicotine 
and cotinine there was in the original sample, because of the fixed amount of 
antibodies available to react with labelled or unlabelled antigen. The limits of 
detection were 350pg nicotine and 200pg cotinine with very low cross­
reactivity. Low cross-reactivity is important because unless the antibodies 
are specific for the compound of interest the total amount found will have a 
contribution from other compounds.
More recently, monoclonal antibodies specific for nicotine and cotinine 
have been prepared and used to develop fluid-phase RIA’s with the ^^ ®l- and 
^H-labelled tracers as well as enzyme-linked immunoabsorbant assays 
(ELISA) and a fluorescence immunoassay (FIA) in a microtitre plate format 
(Bjercke etal, 1986; 1987).
In 1975 Feyerabend et al published a method based on that of Isaac 
and Rand where an acid back-extraction step was included, followed by a
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further solvent extraction into heptane. GC was again used for analysis and 
the internal standard was quinoline. With this method Feyerabend efa/were 
able to achieve a sensitivity of 0.1 ngml'^ but they also noted the presence of 
a background or 'blank' level of nicotine of O.Sngml'^ which they suggested 
came from the atmosphere in the laboratory. They found that non-smokers 
who had avoided any exposure to cigarette smoke had plasma nicotine levels 
of 0.5ngml'\ they therefore subtracted the 'blank' level to give a 'true' value of 
zero.
From 1975 onwards a number of papers were published describing 
procedures for the determination of nicotine and/or cotinine with varying 
degrees of complexity, both in extraction procedure and means of 
detection/identification. Falkman et al (1975) used steam distillation with gas 
chromatography-mass spectrometry (GC-MS) and quinoline as an internal 
standard for nicotine; Hengen and Hengen (1978) used diethyl ether and acid 
back extraction with separate GG-NPD analyses for nicotine and cotinine and 
modaline and lidocaine as internal standards respectively; Maskarinec et al 
(1978) used Amberlite XAD-2 resin to extract nicotine and cotinine from blood 
and urine and high-performance liquid chromatography (HPLC) with 
ultraviolet detection; Dow and Hall (1978) used the extraction of Feyerabend 
et al (1975) with capillary GC-MS; Gruenke et al (1979), using GC-MS, 
achieved a lower detection limit of 25pg; Feyerabend and Russell (1979, 
1980a) described an improvement of their previous method and highlighted 
some of the problems of contamination from reagents, apparatus and the 
atmosphere; Grubner et al (1980) suggested that adsorption onto surfaces 
outside the gas chromatograph could be a source of error when working at 
low levels; in a further paper in 1980, Feyerabend and Russell published a 
modification of their nicotine method such that cotinine could be analysed
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easily with packed column GC; Jacob et al (1981) described the use of 
structural analogues of nicotine and cotinine as internal standards, N- 
ethylnornicotine and N-(2-methoxyethyl)-norcotinine respectively; Verebey et 
ai (1982), and Curvall et al (1982) reported procedures for the simultaneous 
extraction of nicotine and cotinine from plasma and simultaneous analysis 
using capillary column GC with NPD; Kyerematen et al (1982) reported a 
procedure using HPLC to monitor intravenous doses of ^"^C-nicotine in 
humans.
Since the bulk of the work on body-fluid analysis described in this 
thesis was completed there have been further advances in the analysis of 
nicotine and its metabolites. The most important advance involves the use of 
derivatising reagents, diethylthiobarbituric acid (DETBA) or 2,2-dimethyl-1,3- 
dioxane-4,6-dione (Meldrum's acid), to produce coloured derivatives of 
nicotine and its metabolites which are then separated and quantified by HPLC 
with UV detection (Barlow et al, 1987; O'Doherty et al, 1988; Smith et al, 
1989; O'Doherty et al, 1990). With this procedure 3-pyridyl acetic acid, 3'- 
hydroxycotinine, demethylcotinine, cotinine, nicotine and nicotine-1-N'-oxide 
can all be determined in the urine of smokers. If this approach is coupled 
with the glucuronidase hydrolysis of the glucuronide conjugates of the 
metabolites a comprehensive picture of the nicotine and its metabolites in 
urine can be achieved (Moore et al, 1990; Curvall et al, 1991 ).
2.2 NICOTINE AND COTININE ANALYSIS
After the above review of available methods it was decided to use the 
GC methods of Feyerabend et al (1975) for nicotine and Feyerabend and 
Russell (1980) for cotinine. An RIA method was not selected because of the
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delay that would be necessary to establish a reliable supply of suitable 
antibodies from a rabbit colony. The GC methods were the most appropriate 
because they were straightforward liquid extractions followed by packed- 
column GC. Packed column GC was chosen because without experience of 
GC it would be easier to establish than capillary column GC, and nitrogen 
specific detection was chosen in preference to mass spectrometric detection 
on the basis of cost. Although it was envisaged that with time nicotine and 
cotinine analyses in blood, saliva and urine would be required, it was decided 
to concentrate initially on the analysis of nicotine in plasma and saliva 
(section 2.2.2). Once a working method was available the analysis of cotinine 
in plasma and saliva was investigated (section 2.2.3).
The first analysis that was required on a large scale, however, was 
cotinine in saliva for a study investigating the lung function of smokers as a 
confirmation of self-reported smoke exposure. The results from this study are 
not reported because they are not relevant to this thesis. This procedure was 
then applied to plasma.
At this stage, working methods for the analysis of nicotine and cotinine 
in saliva and plasma were available. There was a disadvantage, however, in 
that to perform the analysis of one sample of saliva or plasma for nicotine and 
cotinine two extractions had to be performed and two analyses. The limiting 
factor in the process would be the analysis time since each chromatographic 
run would take about 30 minutes and each extract would be analysed in 
duplicate. This meant that, even with an autosampler to enable continuous, 
unattended analysis only 12 samples could be analysed per day. However, 
a further human volunteer study was under way in which samples of plasma 
and saliva were being collected (up to 24 samples per day). It was decided 
that it was necessary to develop the extraction and analytical procedures to a
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point where one extraction could be used for both nicotine and cotinine and 
one analysis used for both nicotine and cotinine, i.e. simultaneous extraction 
and simultaneous analysis. This procedure is described in section 2.2.4.
2.2.1 Internal Standards
The use of internal standards (IS) was considered to be very important 
since it would reduce the errors from a number of sources. It is of course 
important that the compound chosen as IS should be completely absent from 
the sample.
(i) By assuming that the IS behaves in exactly the same way as the analyte 
during the extraction procedure i.e. has similar solubilities in and partition 
coefficient between the aqueous and organic phases and is similarly acidic or 
basic, the requirement for complete recovery of the analyte is reduced.
(ii) By using a ratio of the amount of IS to the amount of the analyte, the 
requirement for the amount of material injected into the gas chromatograph to 
be exactly the same on each injection is reduced. The IS therefore 
compensates for variable amounts injected, either due to variation in the 
volume in the syringe or variation in the time the syringe needle is left in the 
injection port.
For GC analysis it is important that the internal standard has similar 
chromatographic behaviour, i.e. it has a retention time (RT) as close as 
possible to that of the analyte whilst remaining baseline resolved. Ideally it 
should be in the same homologous series, preferably only one removed from 
the analyte.
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N-ethyl nornicotine was chosen as the IS for nicotine (Figure 2.1). it 
was synthesised as the bis-oxalate salt by Maybridge Chemical Company, 
Tintagel, Cornwall using the method of Jacob et al (1981 ). The equivalent for 
cotinine, N-ethyl norcotinine, was not available and therefore lidocaine was 
chosen, according to the method of Feyerabend and Russell. It was obtained 
from Sigma Chemical Company, Poole, Dorset.
Figure 2.1 : Structures of nicotine, cotinine and internal standards
Nicotine N-ethyl nornicotine
Cotinine Lidocaine
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2.2.2 Nicotine Anaiysis : Piasma and Saiiva
2.2.2.1 Reagents
All reagents were of analytical grade. Diethyl ether, hydrochloric acid, 
n-heptane and sodium hydroxide were supplied by Fisons Scientific, 
Loughborough, Leics. Nicotine was supplied by Sigma Chemical Co., Poole 
Dorset.
2.2.2.2 Extraction procedure
To a 3ml sample (either plasma or saliva) in a 12.5ml glass stoppered, 
tapered centrifuge tube was added lOOpI IpgmM N-ethyl nor-nicotine as 
internal standard, 2ml 5M sodium hydroxide, and 3ml diethyl ether. The tube 
was vortex mixed for 2 minutes and then centrifuged for 10 minutes at 1500 g 
in a bench centrifuge. The upper, diethyl ether layer was removed to a 
second tube which was stoppered and a further 3ml diethyl ether added to 
the aqueous layer and the mixing and centrifugation repeated. The 
combined organic layers were evaporated at room temperature under a 
stream of nitrogen down to a volume of about 400pl. lOOpI 2M hydrochloric 
acid was added and the tube was vortexed for 2 minutes and recentrifuged. 
The diethyl ether layer was discarded and the aqueous layer was washed 
with 0.5ml diethyl ether which was also discarded. Any remaining ether was 
evaporated off under nitrogen. After transfer to a Dreyer tube, 400pl 5M 
sodium hydroxide and lOOpI n-heptane were added. The tube was vortexed 
mixed and centrifuged again and a 5pl aliquot of the n-heptane layer injected 
into the gas chromatograph.
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2.2.2.S Gas chromatography
Instrument : Perkin-Elmer 8310 gas chromatograph with a nitrogen-
phosphorus detector and built-in integration and data-handling
Column : 2m glass column (2.75mm i.d.) packed with 10% Apiezon L
and 10% potassium hydroxide on 80-100 mesh Chromosorb W 
(Perkin-Elmer)
Heated zones : Oven 170°C, detector 300°C, injector 250°C
Gas flow rates: Helium (carrier gas) 50mlmin'\ air 50mlmin'\ hydrogen 
5mlmin'^
Injection volume : 5pl, on-column.
The empty glass columns were purchased from Perkin-Elmer ready 
silanised. The column was marked 12cm from the injector end and 4cm from 
the detector end. A plug of silanised glass wool approximately 5mm long 
was inserted into the detector end up to the mark. A vacuum line was 
attached, with a trap, to the detector end and a small funnel was attached to 
the injector end. A small amount of column packing was added to the funnel 
and a vibrating engraving tool was held carefully against the column to 
ensure close, even packing. This was continued until the mark at the injector 
end of the column was reached, when a second glass wool plug was 
inserted.
A consistent injection technique was important, in spite of the use of an 
internal standard, to reduce damage to the septum in the GC injection port 
and therefore avoid leaks from the septum and hence variable retention times 
and to avoid damage to the syringe. The syringe was washed with the
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solution to be analysed three times, discarding the solution each time; the 
plunger was pumped up and down about a dozen times with the needle in the 
solution to expel any air from the barrel and then 5pl of sample was drawn 
into the syringe; the needle was then removed from the solution and Ip l of air 
drawn into the syringe; the needle was then wiped with a tissue to remove 
any surplus liquid on the outside of the needle. The needle was then 
smoothly inserted through the septum, the plunger smoothly and rapidly 
pushed home and the needle rapidly withdrawn from the injection port.
2.2.2.4 Calibration and validation
An initial investigation of the procedure was made by spiking plasma 
and saliva from two non-smokers who had avoided any exposure to tobacco 
smoke for at least 48 hours. Nicotine was added to aliquots of the pooled 
plasma or saliva to give concentrations of 0 to 200ngml'\ The levels of 
nicotine in non-smokers are low even if exposed to tobacco smoke, therefore 
allowing 48 hours of active avoidance of tobacco smoke should ensure that 
many half-lives of nicotine and approximately three half-lives of cotinine have 
elapsed before samples are collected and therefore the nicotine levels should 
be negligible and cotinine levels should also be very low (Benowitz et a/, 
1983b). The results are shown in Tables 2.1 and 2.2 and Figures 2.2 and 
2.3.
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Table 2.1 : Extraction of non-smokers' plasma spiked with nicotine (Four
determinations at each level)
Nicotine Coefficient of
added Nicotine found variation
(ngml-i) (nqmM) (%)
mean s.d.
0 7.3 0.6 7.6
50 34.1 1.9 5.7
100 57.6 1.6 2.8
150 89.7 1.3 1.4
200 118.6 3.0 2.6
Figure 2.2 : Extraction of non-smokers' plasma spiked with nicotine (Mean of 
four determinations at each level ±  1 s.d. )
140 -1
120 -
100 -
40  -
20 -
20018016014080  100 
Nicotine added (ng/mi)
120
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Table 2.2 : Extraction of non-smokers' saliva spiked with nicotine (Four
determinations at each level)
Nicotine Coefficient of
added Nicotine found variation
(nqmM) (nqmM) (%)
mean s.d.
0 7.1 0.4 6.3
50 34.4 1.5 4.4
100 64.8 2.0 3.2
150 91.3 2.8 3.1
200 113.9 1.8 1.5
Figure 2.3 : Extraction of non-smokers' saliva spiked with nicotine (Mean of 
four determinations at each level ±  1 s.d. )
140 1
120 -
100 -
80  -
60  -
40  -
20 -
200180160120 14080 100 
Nicotine added (ng/ml)
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Thus, although the recoveries were low, at 50 to 60%, and a positive 
intercept was present on the extracts of spiked saliva and plasma, good 
precision and a linear response were obtained. The positive intercept might 
be due either to nicotine present in the sample or there might be 
contamination of the procedure at some stage. Further work would be 
required to improve the recovery and to determine the source of the 
'background' nicotine.
2.2.3 Cotinine Analysis : Plasma and Saliva
2.2.3.1 Saiiva cotinine analysis
2.2.3.1.1 Reagents
All reagents were of analytical grade. Acetone, dichloromethane and 
sodium hydroxide were supplied by Fisons Scientific, Loughborough, Leics. 
Cotinine and lidocaine were of the highest purity available from Sigma 
Chemical Co. Poole Dorset.
2.2.3.1.2 Extraction procedure
To 1 ml of sample in a 12.5ml centrifuge tube were added 2ml 5M 
sodium hydroxide solution, 50pl lOpgmM lidocaine solution as internal 
standard solution and 3ml dichloromethane. The mixture was vortex-mixed 
for 2 minutes and then centrifuged for 5 minutes at 1500 g. The aqueous 
layer was removed and discarded, any remaining emulsion was broken by 
brief vortex-mixing and recentrifugation. The organic layer was transferred
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to a second tube and evaporated to dryness at room temperature under a 
stream of nitrogen. 100|il acetone was added and the tube vortexed for 1 
minute and centrifuged for 1 minute. A 2pl aliquot was injected onto the 
column for analysis. Two injections were made per extract.
2.2.3.1.3 Gas chromatography
Instrument : Perkin-Elmer 8310 gas chromatograph with a nitrogen-
phosphorus detector, built-in integration and data-handling and 
a Perkin-Elmer AS 8300 autosampler
Column : 2m glass column (2.75mm i.d.) packed with 2% Carbowax
20M and 5% potassium hydroxide on 80-100 mesh Chromosorb 
W-HP (Perkin-Elmer)
Heated zones : Oven 205°C, detector 300°C, injector 250°C
Gas flow rates: Helium (carrier gas) 50mlmin'\ air 50mlmin'\ hydrogen 
5mlmin'^
Injection volume : 2|il, on-column.
2.2.3.1.4 Calibration and validation
Saliva was collected from two non-smokers who had avoided any 
exposure to tobacco smoke for at least 48 hours and pooled. Standards were 
made up by adding cotinine to aliquots of this pooled saliva to give 
concentrations of 0 to lOOOngmM. These standards were then carried 
through the extraction procedure. The results of the calibration are shown in 
Table 2.3 and Figure 2.4.
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Table 2.3 : Extraction of non-smokers' saliva spiked with cotinine (Eight
determinations at each level)
Cotinine Coefficient of
added Cotinine found variation
(nqmr^) (nqmr"') (%)
mean S.d.
0 34 3 7.9
100 155 6 3.8
200 242 5 2.0
300 321 11 3.4
400 418 14 3.3
500 559 14 2.5
600 619 7 1.1
700 723 18 2.5
800 808 10 1.2
900 918 17 1.9
1000 1047 32 3.1
Figure 2.4 : Extraction of non-smokers' saliva spiked with cotinine. Mean of 
eight determinations ±  1 s.d.at each level.
1200
1000
^  800
600
400
200
1000900500 600
Cotinine added (ng/ml)
800400 700100 200 300
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The calibration graph appeared linear over the range tested and had a 
correlation coefficient of 0.998 but did not pass through the origin (intercept = 
37.6). Since the intercept is positive it suggests that some cotinine was 
present in the 'non-smokers' saliva, or that it has arisen from analytical 
contamination. Environmental contamination could only be negligible since 
the only source of cotinine is biological fluids, so it is reasonable to assume 
that the cotinine that caused the positive intercept did arise from the saliva 
especially since the intercept corresponds so closely with the results from the 
blank samples. This being the case the difference between the intercept and 
the blank is therefore used as the background when calculating the 
concentration of cotinine in the unknowns.
An example of a chromatogram is shown in Figure 2.5. As can be 
seen, the peaks of interest, lidocaine and cotinine, are eluted from the 
chromatographic column in under 10 minutes. After the period containing the 
peaks of interest, which is denoted by "BGN" and "END" on the 
chromatogram, has past, several further peaks are eluted. The largest of 
these peaks corresponds to caffeine. Both of the non-smokers from whom 
the saliva samples were collected consumed caffeine containing drinks ad 
//M um  during the collection period. Thus, although the peaks of interest were 
eluted in under 10 minutes it was necessary to wait for a further 16 minutes 
for all the material in the extract to be eluted from the column.
Although a single extraction took about 20 minutes per sample, a 
batch of six samples could be extracted in about 60 minutes. However, the 
limiting factor with the complete extraction and analysis procedure, in terms of 
total sample throughput, was the necessity for manual injections onto the gas 
chromatograph. With a run-time of about 30 minutes only about 16 analyses 
could be performed per day and as duplicate extractions were to be
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performed on each sample, only four samples could be analysed per day. 
Since this procedure was to be used for analysis of saliva samples from a 
human volunteer study involving at least 300 volunteers an autosampler was 
purchased to enable samples to be analysed continuously over 24 hours.
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Figure 2.5 : Chromatogram of extract of non-smokers' saliva spiked with
cotinine.
Lidocaine
Caffeine
Cotinine
INJECT 10 15 20 (minutes)
6 8
2.2.3.2 Plasma cotinine analysis
Following the routine analysis of the saliva samples from the human 
volunteer study a method for the analysis of plasma for cotinine was 
developed. Initially, the saliva cotinine method was applied directly to 
plasma samples (from expired transfusion supplies) spiked with cotinine and 
was found to be satisfactory. The initial experiments were confused by the 
presence of a background level of lidocaine (which is added to the sample as 
the internal standard) in the plasma. It was then discovered that this was 
due to its use as local anaesthetic during blood collection by the transfusion 
service. From that point forward bovine blood was collected from a local 
abbatoir for use in method development and was found to be free from any 
contamination with lidocaine. Once the procedure was satisfactory a 
calibration study was undertaken using blood samples collected from a 
number of non-smokers who had been asked to avoid exposure to tobacco 
smoke for 48 hours. These samples were spun down and the plasma 
pooled. Aliquots of pooled plasma were then spiked with varying amounts of 
cotinine and taken through the procedure. The results from this calibration 
study are shown in Table 2.4 and Figure 2.6.
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Table 2.4 : Extraction of cotinine from-spiked non-smokers' plasma (12
determinations at each level)
Cotinine Coefficient of
added Cotinine found variation
(nqml'"') (%)
mean s.d.
0 0
100 102.4 3.7 3.6
250 248.8 7.0 2.8
500 493.1 7.4 1.5
750 749.0 9.7 1.3
1000 1004.7 18.1 1.8
Figure 2.6 : Extraction of cotinine from spiked non-smokers' plasma. Mean 
of 12 determinations at each level + 1 s.d.
1200
1000
800
600
400
200
1000800 900500 600
Cotinine added (ng/ml)
700300 400100 200
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This calibration appeared linear with a correlation coefficient of 0.999 
and had a positive intercept (2.77), again suggesting the presence of cotinine 
in the plasma, but at a lower level than was present in the saliva. The 
extraction procedure was simpler with plasma since, after vortex mixing and 
centrifugation, a hard plug, presumably of denatured protein, was formed 
between the aqueous and organic layers. This made it easier to separate 
the two layers without having to mix and recentrifuge as was necessary with 
the saliva. This aspect may have improved the precision and accuracy of the 
procedure.
2.2.4 Simultaneous Extraction and Simultaneous Analysis of Nicotine 
and Cotinine
The first stage of this development was the simultaneous analysis. 
On reviewing the literature again it became apparent that capillary column 
gas chromatography offered considerable advantages over packed column 
gas chromatography due to its greater separating power. However, although 
several authors had published methods utilising capillary columns (Curvall et 
al, 1982; Stehlik et al, 1982; Verebey et al, 1982) only Verebey ef a / reported 
analysing nicotine and cotinine simultaneously. The g as chromatograph was 
therefore modified to permit the use of capillary columns and suitable 
instrument conditions were established where the analysis of nicotine and 
cotinine could be performed simultaneously. The problems of contamination 
during the extraction procedure, in particular by nicotine from the 
environment, leading to positive blanks, meant that the procedure should be
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as short as possible. A number of published procedures were investigated 
before a satisfactory procedure was developed. This is outlined below.
2.2.4.1 Reagents
All reagents were of analytical grade. Dichloromethane and sodium 
hydroxide were supplied by Fisons Scientific, Loughborough, Leics. 
Nicotine, cotinine and lidocaine were supplied by Sigma Chemical Co., Poole 
Dorset. N-ethyl nornicotine was synthesised as the bis-oxalate salt by 
Maybridge Chemical Co., Tintagel, Cornwall using the method of Jacob et al 
(1981)
2.2A.2 Extraction procedure
To a 1 ml aliquot of thawed plasma or saliva in a 12.5ml centrifuge tube 
(with ground glass stopper) was added lOOpI internal standard solution 
(2.5pgmM lidocaine and 1 .OOGpgmM N-ethyl nor-nicotine bis-oxalate 
dissolved in single distilled water), 1 ml 5M sodium hydroxide and SOOfil 
dichloromethane (DCM). The tube was vortex-mixed for 2 minutes and 
centrifuged for 2 minutes at 1500 g in a bench top centrifuge to break the 
emulsion of aqueous and organic layers. The aqueous layer was removed 
and discarded. The DCM layer was transferred to an autosampler vial which 
was then sealed.
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2.2.4.S Gas chromatography
Instrument : Perkin-Elmer 8310 gas chromatograph, modified to accept
capillary columns, with a nitrogen-phosphorus detector, built-in 
integration and data-handling and a Perkin-Elmer AS 8300 
autosampler
Column : 25m x 0.32mm id fused silica capillary column, with a bonded
0.3pm polyethylene glycol coating (Alltech Assocs. Ltd., 
Carnforth, Lancs.)
Heated zones : Oven 55°C for 2 minutes, to 130°C at 5°Cmin'\ to 230°C at 
15°Cmin'^ and held for 5 minutes, detector 300°C, injector 
275°C '
Gas flow rates: Helium (carrier gas) 3mlmin'\ air 170mlmin'\ hydrogen 
2mlmin*^
Injection volume : 2pl, splitless.
2.2.4.4 Calibration and validation
As before, the procedure was validated using pooled plasma and 
pooled saliva from non-smokers who had avoided tobacco smoke exposure 
for at least 48 hours. Various amounts of nicotine and cotinine were added 
and the samples taken through the procedure. The results are shown in 
Tables 2.5 and 2.6 and Figures 2.7 to 2.10.
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Table 2.5 : Extraction of nicotine and cotinine from spiked non-smokers'
plasma. 12 determinations at each level.
Nicotine Cotinine Nicotine Cotinine
added (nqml-1 ) found (nqml-1)
mean s.d. mean s.d.
0 0 1.7 0.3 8 1.1
5 50 6.2 0.7 69 5.1
10 100 10.1 0.4 112 6.9
20 200 20.0 0.9 196 7.3
30 300 28.5 1.6 294 20.9
40 400 39.2 1.1 393 22.4
50 500 50.0 2.0 490 10.8
60 600 58.5 1.4 557 23.4
70 700 68.5 2.0 683 20.5
80 800 78.6 1.4 798 23.1
90 900 91.4 1.6 930 13.9
100 1000 102.8 3.2 1031 33.0
Table 2.6 : Extraction of nicotine and cotinine from spiked non-smokers' 
saliva 12 determinations at each level.
Nicotine Cotinine Nicotine Cotinine
added ngml'^) found (nqml'^)
mean S.d. mean s.d.
0 0 2.9 0.3 5.3 1.6
100 100 99.5 8.4 81 3.8
200 200 186 11.9 185 7.4
300 300 296 19.2 315 12.9
400 400 388 22.5 407 16.7
500 500 498 17.4 498 16.4
600 600 608 29.2 615 16.0
1000 700 940 31.0 671 19.5
1500 800 1517 47.0 793 24.6
2000 900 2016 74.6 882 33.5
2500 1000 2492 44.9 984 37.4
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Figure 2.7 : Extraction of nicotine from spiked non-smokers' plasma. Mean
of 12 determinations at each level ± 1 s.d.
120  -1
100 -
20  -
10040
Nicotine added (ng/mi)
Figure 2.8 : Extraction of cotinine from spiked non-smokers' plasma. Mean 
of 12 determinations at each level + 1 s.d.
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75
Figure 2.9 : Extraction of nicotine from spiked non-smokers' saliva. Mean of
12 determinations at each level ± 1 s.d.
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.« 1000
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2500500 1500 20000 1000
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Figure 2.10 : Extraction of cotinine from spiked non-smokers' saliva. Mean 
of 12 determinations at each level + 1 s.d.
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As can be seen, the modified method worked well with both plasma 
and saliva over the ranges tested. The range tested for saliva nicotine was 
extended up to 2500ngmM because the levels can be up to 12 times higher 
than plasma nicotine (Russell and Feyerabend, 1978).
Example chromatograms for the plasma and saliva analyses are 
shown in Figures 2.11 and 2.12. The differences in peak heights between the 
chromatograms reflect not only the different levels of the analytes, but 
different attenuation settings on the plotter both between and during runs. 
The retention times of the peaks differ between the two chromatograms 
because of the differing ages of the chromatographic columns used at the 
time of analysis. The column, when initially installed, was 25m long; however, 
with use, the column performance deteriorated. This was shown by 
broadening of the peaks and loss of sensitivity. This loss in performance 
could be recovered by removing about 30cm from the injector end of the 
column. Whereas initially this was done when necessary, during the routine 
analysis of large numbers of samples a section was removed on a regular 
basis to prevent deterioration of the chromatography. Over an extended 
period this resulted in a significant shortening of the column with a 
consequent reduction in the retention times. The practise was continued until 
the peaks could no longer be resolved at the baseline of the chromatogram. 
In Figure 2.11 the lidocaine and cotinine peaks are only just resolved at the 
baseline, thus while the peak shape may be satisfactory, the column would 
have been replaced shortly afterwards.
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Figure 2.11 : Chromatogram of extract of non-smokers' plasma spiked with
90ngmM nicotine and SOOngmM cotinine
CaffeineCotinine
Lidocaine
N-ethyl nornicotine 
Nicotine
15 (minutes)INJECT
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Figure 2.12 : Chromatogram of extract of non-smokers' saliva spiked with
SOngmM nicotine and 400ngmM cotinine
N-ethyl nornicotine
Nicotine
zÜQÛ
Caffeine
Lidocaine
Cotinine
INJECT 15 20 25 (minutes)
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Figures 2.13 and 14 show chromatograms of extracts from two plasma 
samples from one of the subjects in The Long-Term Compensation Study 
(Chapter 3.1). Figure 2.13 shows a pre-smoking plasma extract and Figure 
2.14 a post-smoking plasma extract. The nicotine content of the plasma 
increases from 19.5 ngmM pre-smoking to 39.9 ngmM post-smoking and the 
cotinine content remains at 365 ngml'L The "hump" in the baseline over the 
course of the analysis is due to the use of a facility available on the Perkin- 
Elmer 8310 gas chromatograph called Automated Bleed Compensation 
(ABC). At the high temperatures in the oven in a GC a very small amount of 
the stationary phase that coats the inside of the column will vapourise and be 
carried through the column to the detector. This is called column bleed. If 
the GC oven is being used isothermally, that is, at a constant temperature (as 
in the separate analyses of nicotine and cotinine), the amount of column 
bleed will be very low and constant, resulting in a constant offset of the 
detector response. If the GC is being used with a temperature program, that 
is, the oven temperature is increased during the course of the analysis, the 
amount of column bleed increases as the temperature increases, resulting in 
a gradually rising detector response and therefore a gradually rising baseline. 
The ABC facility was used to compensate for the column bleed if it was 
severe enough to affect the chromatography or integration. During the period 
when the body-fluid analysis was undertaken several columns were used and 
the amount of column bleed varied from column to column, with the result that 
the ABC was used only intermittently.
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Figure 2.13 : Chromatogram of extract of a smoker's plasma; pre-smoking,
containing 1 S.SngmM nicotine and 365ngmi'' cotinine.
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Figure 2.14 : Chromatogram of extract of a smoker's plasma; post-smoking,
containing 39.9ngmM nicotine, 365ngmM cotinine.
Caffeine
Lidocaine
Cotinine
N-ethyl nornicotine
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2.3 CONCLUSION
The development of the method had achieved the desired objective, 
namely a reduction in the time taken to analyse a particular sample for both 
nicotine and cotinine, by reducing both the extraction time and analysis time. 
This method was therefore used for the analysis of plasma and saliva 
samples in the two studies described in Chapter 3.
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CHAPTER THREE
STUDIES OF NICOTINE UPTAKE FROM CIGARETTES OF 
DIFFERING NICOTINE YIELDS
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3.1 : LONG-TERM COMPENSATION STUDY
3.1.1 Introduction
Previous work at the Midhurst Medical Research Institute (MMRI) had 
examined the smoking behaviour of human smokers when smoking 
cigarettes of different nicotine yields (McBride et al, 1984). Nine subjects 
were studied on four occasions, twice on their own brand of cigarette, and 
once on each of two experimental cigarettes. One was a low nicotine 
cigarette (0.55mg nicotine delivery under standard smoking conditions) and 
the other was a medium nicotine cigarette (0.9mg). Both experimental 
cigarettes had tar yields of about 9mg. Smoking behaviour measurements of 
puff volume, duration and profile were measured by using an orifice plate 
cigarette holder (Creighton et al, 1978). Measurements of ventilation 
(inhalation depth and duration), nasal air flow, cigarette butt nicotine, alveolar 
carbon monoxide and saliva nicotine were also made.
It was found that while smoking behaviour varied considerably 
between subjects, only small differences in puff volume, duration and profile 
were seen in individual subjects on smoking different cigarettes. The different 
nicotine yields of the cigarettes produced marked changes in salivary nicotine 
measurements, but neither these nor the changes in alveolar carbon 
monoxide were closely related to ventilatory measurement.
The Third Report of the Independent Scientific Committee on Smoking 
and Health (ISCSH) (Froggatt, 1983) encouraged the availability of cigarettes 
with lower smoke yields and encouraged smokers to reduce their exposure to 
potential harm by changing to these cigarettes. The ISCSH acknowledged 
that this practise might lead to changes in the smoking behaviour of the
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smoker who might not only smoke more of the lower yield cigarette, but might 
take larger puffs, more puffs or inhale the smoke more deeply, a 
phenomenon known as compensation. The ISCSH felt that it was important 
that this phenomenon should be more carefully examined since it might lead 
to a greater exposure to some of the hazardous components of smoke than 
might be predicted from the yields of the cigarettes.
Whilst the study described above provided useful information on some 
aspects of smoking behaviour it was decided, in the light of the 
recommendations of the ISCSH, that further work was necessary to elucidate 
what changes might take place when a smoker switches from one cigarette .to 
another yielding less tar. In order to achieve a better understanding of these 
changes, it was decided that it would be necessary to include in further work 
the measurement of the levels in body-fluids of nicotine and cotinine.
A study was therefore designed to answer some of the questions 
posed by the ISCSH report. Habitual smokers of at least 10 manufactured 
cigarettes per day would be recruited. Their smoking behaviour on their own 
brand would be followed for an extended period (of at least six months), after 
which a study group would be asked to switch to a brand with a tar yield 4 - 
5mg less than their own brand, the control group remaining on their own 
brand. Both groups would then be examined over a further period (of at least 
six months).
There is a more detailed description of the act of smoking in Chapter 1, 
but it is important to note the separate actions i.e. : smoke generation, 
drawing smoke from the cigarette into the mouth; manipulation, moving the 
smoke around within the mouth or allowing smoke to escape from the mouth
8 6
or nose; and inhalation, drawing the smoke from the mouth into the lungs, 
followed by a volume of air.
3.1.2 Subjects
The subjects were recruited from the local population using local 
television, radio, newspapers, promotions in public libraries and public 
houses, a recruitment agency and word of mouth. The study was approved 
by the Ethical Committee of the Midhurst Medical Research Institute and all 
subjects gave informed consent in writing before beginning. The subjects 
purchased their cigarettes from retail outlets and were reimbursed only for out 
of pocket expenses. Commercially available cigarettes were used rather than 
placed or experimental products in order to give a realistic change in smoking 
habits which could be maintained over a long period.
3.1.3 Plan of Study
This is summarised in Table 3.1. The subjects were asked to visit the 
MMRI laboratories for the measurement of smoking behaviour indices and 
collection of body fluids. Each subject was asked to abstain from smoking 
before each visit for at least 30 minutes in order to minimise any effects of 
previous cigarettes. Studies were performed throughout the working day and 
early evening, but each subject always attended at the same time and on the 
same day of the week to minimise any diurnal variations or variations in 
smoking habits between weekdays and weekends. The first visit was used 
for familiarisation and comprised a screening session and a practise run 
through the experimental procedure. At this visit lung function measurements
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were made and the MRC Questionnaire on respiratory symptoms was 
administered with some supplementary questions on smoking habits.
On the next five visits at four weekly intervals, subjects smoked their 
own, original brand exclusively, or if that brand became unavailable, a closely 
similar brand (in terms of tar and nicotine yield). After the measurements 
were made on the sixth visit, subjects smoking cigarettes with a tar yield 
greater than 10mg (according to the tar yields obtained from the tables 
published by the Laboratory of the Government Chemist (LGC)) were 
encouraged to switch to a cigarette brand with a tar yield on average at least 
3mg lower than their own brand. To help them, they were given a list .of 
about 15 brands that satisfied this requirement that were available locally. 
Although the original objective had required a reduction of 4 - 5mg tar it was 
found that the choice of brands available at that tar level was small, it was 
therefore decided to accept brands that were at least 3mg lower in tar than 
their own brand since this provided a greater choice, since it was important 
that the selection be made independently by the subject and that supplies 
would be readily available. They then attended for a further six visits at six 
week intervals, smoking the lower yield cigarettes. The duration for which the 
subjects had been smoking their lower tar brand, prior to visit seven, might 
therefore have varied from a few days to several weeks. The subjects were 
contacted by telephone at regular intervals to check on the brand being 
smoked and they were encouraged to report any problems. Some subjects 
tried several brands before finding a satisfactory alternative and a few 
subjects who continued for 12 visits did not make a suitable choice and have 
been excluded.
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3.1.4 Experimental Procedure
The subjects sat in a special room within the laboratory while listening 
to music or reading. Samples of saliva, blood and alveolar gas were 
collected both before and after smoking. To obtain a saliva sample the 
subject washed the mouth three times with tap water over a 30 second 
period, then expectorated into a sample jar for three minutes (or longer if 
insufficient saliva was collected in the first three minutes) and the saliva 
sample was stored at -20°C pending analysis for nicotine and cotinine 
(Chapter 2.2.4 - simultaneous analysis). The blood sample was obtained 
from the antecubital vein and placed in a tube containing ethylenediamine 
tetra-acetate (EDTA) anticoagulant. The carboxyhaemoglobin (HbOO) 
content of the anti-coagulated blood was determined immediately by 
spectrophotometry (Radiometer 0SM2 Hemoximeter) and the rest of the 
blood was centrifuged and the plasma stored at -20°G pending analysis for 
nicotine and cotinine (Chapter 2.2.4 - simultaneous analysis). Alveolar 
carbon monoxide (FACO) was measured on an alveolar gas sample collected 
after a 20 second breath-hold (Jones etal, 1958; Kirkham etal, 1988) by infra 
red absorption (ADC Ltd., model RF1 0 - 1 0 0  ppm). After smoking, the 
cigarette was extinguished in a tube containing dry ice and the butt length 
measured as the mean of the longest and shortest distances between the 
overwrap and the line of burning.
The subject smoked the cigarette through a holder incorporating a 
2mm orifice (Creighton et al, 1978; Guyatt and Baldry, 1988). The holder was 
connected via plastic tubing to pressure transducers (Validyne MP45 with 
Hewlett Packard 8805b carrier amplifiers) to record the differential pressure 
across the orifice (indicating flow) and the pressure applied to the cigarette 
(draw pressure). The differential pressure was linearised electronically
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before analysis since it was proportional to the square root of flow. Both 
signals were digitised at 20ms intervals using a microcomputer (Kontron Psi 
80 D) programmed in Fortran IV.
For each puff, the flow signal was integrated with time to give puff 
volume (which was then averaged over the cigarette), and the maximum flow 
rate and pressure were recorded. The product of the two signals was 
integrated to give an index, "work of puffing", with units of joules (Rawbone, 
1984) and the pressure signal was integrated with time and divided by puff 
volume to give the draw resistance, being expressed as the pressure drop at 
the standard flow of 17.5mls'\ (PI 7.5). (This is derived from the standard 
smoking conditions of a 35ml puff of 2 seconds duration taken at one minute 
intervals until a predetermined butt length has been reached.) The puff 
duration was recorded with the inter-puff interval and the time taken to reach 
the maximum pressure point (referred to here as the "pressure latency"). 
This latter index was expressed as a percentage of the puff duration ("latency 
ratio") and is an expression of the shape of the puff.
The puffing data were analysed after excluding the lighting puff and 
averaging the rest. The total puff volume was also calculated as the sum of 
the individual puffs and the duration of smoking as the time interval between 
the first and last puffs.
The holder assembly was calibrated using air at room temperature and 
no measurements of smoke temperature were made. However a separate in 
vitro study (Guyatt and Baldry, 1988) suggests that the errors in the 
calibration are small, the mean puff volume being overestimated by about 
2.8%.
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3.1.5 Numerical Analysis
In this study each subject acted as their own control, using the pooled 
pre-switch data from visits 2 - 6, except where there were significant trends 
over the period. In such cases post-switch data were compared with data 
from the sixth visit alone. Non-parametric statistical methods were used 
since many of the data were not normally distributed. Changes with time 
after switching (visits 7 - 1 2 )  were examined with the Page L trend test 
(1963); variations between visits were examined with the Friedman two-way 
analysis of variance, which can detect short term changes in a measurement 
which does not show as an overall trend; differences on switching (visits 6 
and 7) were examined with the Wilcoxon matched pairs test (Seigal 1956).
Pre- and post-smoking plasma nicotine were analysed and the nicotine 
uptake per cigarette estimated from the plasma nicotine 'boost', i.e. post­
minus pre-smoking value. The pre- and post-smoking plasma and saliva 
cotinine data were averaged before statistical analysis. Preliminary analysis 
had shown that the post-smoking values were 0.35% greater than the pre­
smoking for plasma (P > 0.6) and the pre-smoking values were 6.2% higher 
for saliva (P < 0.0001) (Figures 3.1 and 3.2). The pre-smoking HbCO and 
FACO data were also analysed and the uptake per cigarette estimated from 
the HbCO "boost" as above.
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Figure 3.1 : Comparison between pre- and post-smoking plasma cotinine for 
all visits in all 28 subjects, (r = 0.918)
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Figure 3.2 : Comparison between pre- and post-smoking saliva cotinine for 
all visits in all 28 subjects, (r = 0.839)
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Compensation based on the cotinine values was calculated using the 
formula of Sutton etal, (1978).
(O - E )x100/(1-E )
where I is the initial, pre-switch value, O is the observed post-switch value 
and E is the expected post-switch value based on the reduction in machine 
yields (from LGC tables) (pooled values for all 28 subjects). The formula can 
be illustrated by considering someone with a plasma cotinine concentration of 
SOOngml'  ^ while smoking cigarettes with a machine yield of 1.2mg nicotine. 
On changing to a brand with a machine yield of 0.6mg nicotine, plasma 
cotinine will fall to ISOngmM if there is no compensation, or fall to 225ngmM 
(i.e. 50% drop) with 50% compensation or stay at SOOngmM for 100% 
compensation. Six calculations were made, using a common initial value (!) 
averaged over visits 2 - 6, but with separate observed values (O) for visits 7 - 
12, respectively. The same formula was applied to the HbCO and FACO 
data but referring them to the change in the machine yields for carbon 
monoxide (from LGC tables).
3.1.6 Results
A full set of results (including those which are considered to be not 
relevant to this thesis, but not including the plasma nicotine boost and saliva 
cotinine analysis) will be found in Appendix A which comprises a paper 
published after completion of the study (Guyatt et ai, 1989). Some of the 
figures and tables which follow are included in the paper but are repeated for 
purposes of comparison with new data presented here.
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3.1.6.1 Subjects
The study group consisted of 28 subjects, whose characteristics are 
shown in Table 1, Appendix A. This also includes details of the default group, 
a further 123 subjects who attended on at least one occasion but either did 
not complete the study or did not fulfil the study criteria. Comparisons 
included the sex distribution of the two groups, anthropometric data, lung 
function data and questions on smoking history. The only significant 
difference was for age, the study group being on average 6.8 years older 
than the default group (P < 0.05).
3.1.6.2 Analysis of data visit by visit
The statistical analyses are summarised in Table 3.2. Columns 1 - 3 
consider the changes on switching, comprising the mean value for visits 2 - 6 ,  
the value at visit 7 (the first post-switch visit) and the significance of the 
difference using the Wilcoxon matched pairs test. Columns 4 - 5 consider 
changes over visits 7 - 1 2 ,  with the significance of the Page trend analysis, 
(including the trend direction + (increase) or - (decrease) where significant) 
and the Friedman two-way analysis of variance.
There were four significant trends over the pre-switch period (falls for 
saliva cotinine, pre-smoking FACO, puff volume and P I7.5); in these 
instances the value for visit 6 is given instead, marked by * in Table 3.2.
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Table 3.2 : Effects of switching (Wilcoxon), occurrence of trends after 
switching (Page L test, direction of trend shown as + or - ) and of significant 
variation between visits after switching (Friedman two-way analysis of 
variance). NS is non-significant (P > 0.05); * after number in column 1 
indicates a single value for visit 6 only. Average machine yields fell from 1.36 
to 0.91 mg nicotine, 15.1 to 9.3mg tar and 15.2 to 9.6mg CO.
Mean Significance 
of difference
Visits 7 - 1 2  
(Post-switching)
(
Visits 2 - 6 
Pre-switching)
Visit 7 
(First post­
switching)
Page Friedman
Plasma nicotine boost 14.70 14.62 NS NS NS
(ngmP)
NSPlasma cotinine (ngmP) 378 309 P <  0.005 NS
Saliva cotinine (ngmP) 318* 319 NS NS NS
Pre-smoke HbCO (%) 5.16 . 4.24 F < 0 .0 5 NS NS
HbCO boost (%) 1.11 0.91 P <  0.005 -P < 0 .0 1 NS
Pre-smoke FACO (ppm) 27.6* 24.5 NS NS •NS
Cigarettes/day 24.9 28.5 NS NS NS
Average puff volume (ml) 47.2* 54.7 P <  0.001 NS NS
Puff duration (s) 2.10 2.21 NS NS NS
Maximum flow (mis ’) 40.9 44.9 P <  0.001 NS NS
Puffs/cigarette 13.9 15.7 P < 0 .0 5 NS P < 0 .0 5
Total puff volume (ml) 603 768 P <  0.001 NS P < 0 .0 1
Inter-puff Interval (s) 34.2 27.7 P <  0.001 NS P < 0 .0 5
Smoking duration (s) 438 399 . P < 0 .0 1 NS NS
Butt length (mm) 6.64 5.70 NS + P <  0.005 NS
Work (mJ) 126 137 NS NS NS
P I 7.5 (kPa) 1.42* 1.21 P <  0.001 NS NS
Maximum pressure (kPa) 3.33 3.21 NS NS NS
Latency ratio (%) 31.4 31.2 NS NS NS
(Wilcoxon test was a two-tail test)
The machine nicotine yield decreased by an average of 33%, from 
1.36mg to 0.91 mg, on switching but there was no significant change in 
plasma nicotine boost. Although there was a significant reduction in plasma 
cotinine of approximately 18% on switching, there was no significant change 
in saliva cotinine, with no significant trends over the remaining visits for either 
plasma or saliva cotinine. These data are shown in more detail in Figures 3.3 
- 3.5 with the median values and 95% confidence limits for visits 2 - 1 2  
(Snedecor and Cochran, 1967).
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Figure 3.3 : Plasma nicotine boost data in 28 smokers who switched brands
after six visits. Median values and 95% confidence limits for visits 2 -12 .
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Figure 3.4 : Plasma cotinine data in 28 smokers who switched brands after 
six visits. Median values and 95% confidence limits for visits 2-12.
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Figure 3.5 : Saliva cotinine data in 28 smokers who switched brands after
six visits. Median values and 95% confidence limits for visits 2 -12 .
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The machine CO yields decreased on average by 37%, from 15.2mg 
to 9.6mg, and there were significant reductions of 18% in both pre-smoking 
HbCO and HbCO boost, but the only significant trend was a fall in the HbCO 
boost between visits 7 and 12.
The compensation estimates for plasma cotinine, pre-smoking HbCO 
and pre-smoking FACO showed no trends over visits 7 - 1 2  and when 
averaged for these six visits give similar values; cotinine 61% (range 45 - 
76%); HbCO 56% (range 34 - 73%); FACO 60% (33 - 77%). These values 
correspond to the "high nicotine regulation" range of McMorrow and Foxx 
(1983). Compensation based on saliva cotinine also showed no trend over 
visits 7 -12  but when averaged gave a lower value of 45% (range 21 - 70%)
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which corresponds to the "low nicotine regulation" range of McMorrow and 
Foxx (1983).
Mean puff volume rose 15.9% on switching and showed no trends 
thereafter (Figure 3.6). The initial rise in total puff volume (Figure 3.7), was 
greater (27%) due to an associated 13% rise in the number of puffs per 
cigarette (Figure 3.8). On later visits, the number of puffs per cigarette 
returned to pre-switch levels and total puff volume decreased but did not 
return to pre-switch levels. The changes over visits 7 - 12 are also indicated 
by significant Friedman coefficients (Table 3.2) for puffs per cigarette and its 
corollary inter-puff interval and for total puff volume.
Figure 3.6 : Mean puff volume data (average of all puffs except lighting puff 
taken on a single cigarette) in 28 smokers who switched brands after six 
visits. Median values and 95% confidence limits for visits 2-12.
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Figure 3.7 : Total puff volume (per cigarette) data in 28 smokers who
switched brands after six visits. Median values and 95% confidence limits for
visits 2 -12 .
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Figure 3.8 : Puff number per cigarette data in 28 smokers who switched 
brands after six visits. Median values and 95% confidence limits for visits 2 - 
12.
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The derived value of pressure drop (PI 7.5) fell significantly on 
switching by nearly 15%, but the "work of puffing" hardly changed nor did the 
peak pressure per puff. Other significant changes included a rise in 
maximum puff flow rate of nearly 10% and falls of 9% in the total duration of 
smoking and 19% in the inter-puff interval. The only significant trend over 
visits 7 - 1 2  was an increase in butt length, but this is of limited importance 
as it was equivalent to a mean increase of just 1.7mm.
3.1.7 Discussion
The subjects showed compensatory responses of about 60% to the 
lower tar cigarettes (averaged over visits 7 -12)  based on three variables and 
45% with a fourth and maintained this for 36 weeks without any apparent 
trend in the data. This degree of compensation is similar to earlier reports 
(Benowitz etal, 1983a; Ossip-Klein etal, 1983; Wald ef a/,1984) and similar 
values were observed for plasma cotinine, carbon monoxide and alveolar 
carbon monoxide despite the contrasting mechanisms of delivery and uptake 
of nicotine and CO.
The uptake of nicotine from the cigarette smoked in the laboratory on 
each visit can be assessed from the measurements of plasma nicotine boost. 
Although highly variable, with no significant trends or variations before or 
after switching, the mean plasma nicotine boost pre-switching was 14.7ngmM 
compared with a mean post-switching value of 11.3ngmM suggesting a lower 
uptake per cigarette from the lower yielding cigarettes, although the boost at 
visit 7 was not significantly different from the mean pre-switching value.
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Cotinine has a half-life in plasma of about 18 hours (Benowitz et al, 
1983b), in contrast to nicotine which disappears very rapidly (Armitage 1978; 
Darby et al, 1984). The rate of formation of cotinine is too slow to show 
changes produced by a single cigarette but it gives a measure of the natural 
smoking over the preceeding 24 - 48 hours. In contrast to previous studies 
where saliva cotinine was 120 - 150% of that in plasma (Curvall and Enzell, 
1986; Armitage et al, 1988), the amount of cotinine found in saliva was, on 
average, 92% of that in plasma. Figure 3.9 shows the plasma and saliva 
cotinine data from the switching subjects and shows that the majority of the 
values are either around or below the line of identity. The reason for this 
difference from previous publications is difficult to establish, but could be due 
to differences in sampling procedures. Neither Curvall and Enzell (1988) nor 
Armitage et al (1988) state how the saliva samples were collected, but in 
other studies (McNeill etal, 1989) a dental roll has been used to collect saliva 
by gradual absorption in the mouth. In the study described here the subjects 
were asked to rinse their mouths out with water before collecting the saliva 
sample in order to remove any food debris. This rinsing prior to saliva 
collection may have resulted in a dilution of the saliva especially when small 
volumes (less than 2ml in some cases) were produced.
1 0 2
Figure 3.9 : Comparison of saliva cotinine data with plasma cotinine data in
28 low-to-middle and middle tar smokers who switched brands after six visits.
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The main evidence for a mechanism producing compensation was the 
increase in mean puff volume of 15.9% after brand switching. This effect has 
often been reported (Surgeon General, USA, 1984), but was shown in this 
study to persist over a 36 week period. By contrast, the number of puffs per 
cigarette rose on switching (between visits 6 and 7) but then fell back towards 
pre-switching levels, (this contributed to the changes in the total puff volume 
and inter-puff interval). This was the only evidence obtained of a modification 
in smoking after switching (over visits 7 to 12), but it was not clear if this also 
applied to natural smoking away from the laboratory.
Since the objective was to look at changes with time, it is necessary to 
consider factors which might produce trends. It is important to ensure that 
the subject should have a consistent smoking habit and care was taken to
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recruit established smokers. More information was provided by replies to the 
initial questionnaire and it was observed that only one third of the subjects 
had made any major modification to their smoking habit over the preceeding 
year, such as switching brands or changing daily consumption. The subjects 
were repeatedly asked during the study about brands being smoked and 
consumption and any subject who deviated seriously from the protocol was 
excluded from the analysis.
A detailed series of checks was made on the equipment at regular 
intervals (Kirkham et al, 1988; Guyatt et ai, 1988; Guyatt and Baldry, 1988) 
and a quality control procedure was developed to monitor the nicotine aiid 
cotinine analyses in plasma and saliva (Appendix B). The reproducibility of 
the data was tested on visits 2 - 6 and in a group of 14 non-switching low tar 
(less than lOmg) subjects who followed the same protocol. The only 
significant trends were a fall in mean puff volume and pre-smoking FACO 
over visits 2 - 6 in both subject groups. The fall in puff volume might be due 
to the subject becoming more relaxed as the study progressed and this is 
interesting in view of the consistent elevation seen after brand switching. The 
fall in FACO suggests a reduction in smoking just prior to each visit, perhaps 
due to a lessening of anxiety regarding the tests as the subjects became 
more familiar with the procedure although it is not supported by a similar 
trend in pre-smoking HbCO.
The direct measurement of the puffing pattern is compromised since 
the use of a holder may alter the smoking pattern (Tobin and Sackner, 1982) 
but without such a device much of the present data would be unobtainable. 
These measurements also ignore wastage of smoke from the mouth and 
nose after the puff but prior to inhalation and variations in depth and duration 
of inhalation (Sinclair 1984). More information can be obtained by recording
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ventilation during smoking (Tobin and Sackner, 1982; Adams et al, 1983; 
McBride at al, 1984), or by measuring the inspired smoke volume using a 
radiotracer technique (Woodman at al, 1985), but unless the chemical 
composition of the smoke is known, these methods will not provide 
quantitative data on smoke exposure. With the present objective of looking 
for long-term trends in large groups of subjects under relaxed conditions, 
these extra measurements seemed inappropriate.
The rise in puff volume appears to reflect increases in puff duration 
(5%, but not significant) and flow rate (approximately 10% rise in the 
maximum rate and significant) but not as a result of.changes in the puff profile 
since the latency ratio did not alter. This might be explained by mechanical 
factors, since most low tar cigarettes have a lower draw resistance due to 
ventilation holes in the filter and the use of higher porosity cigarette papers 
and the results of the PI 7.5 measurements confirm this. Rawbone (1984) 
found for most types of cigarettes that the "work of puffing" was independent 
of the draw resistance, implying that smokers generate a constant pressure 
profile during puffing, irrespective of the type of cigarette smoked. 
Accordingly, for a constant puff pressure profile, reductions in cigarette 
impedance will be associated with increases in puff flow rates, and provided 
puff durations were not shortened, increases in puff volume.
The present results are consistent with this : on brand switching, the 
"work of puffing" actually increased slightly despite the fall in PI 7.5, and while 
the maximum flow rate rose, the maximum pressures hardly changed. Such 
a mechanism would tend to produce larger puff volumes as long as the lower 
impedance cigarettes were smoked. Changes in smoke composition would 
also seem to be very important, since tar and nicotine yields were also 
reduced, and have been implicated in influencing the puff volume response.
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but it is impractical to resolve these factors on the present data since special
cigarettes would be needed in which draw resistance and tar and nicotine
yields were varied independently.
Finally, it is important to see how these results can be applied to the 
population at large. The major problem lies in recruiting a suitable group of 
volunteers : originally 497 people made enquiries, 214 were recruited, 151 
attended on at least one occasion but only 28 fulfilled the study protocol. The 
subjects were older on average than the defaulters but otherwise there were 
no significant differences between the groups. The main reason for 
defaulting was lack of interest or finding the experimental protocol too 
demanding, both of which tended to affect the younger rather than the older 
volunteers. Apart from this difference, the summary in Table 1 suggests that 
the study group was representative of the original population as a whole. The 
consistency of the data was striking both among the 28 subjects and in others 
who for various reasons did not meet the full criteria for analysis, although a 
formal confirmation of this result would require further large scale studies.
3.1.8 Conclusion
From this study it can be seen that smokers who switch to lower yield 
nicotine cigarettes show evidence of partial compensation by the criteria of 
McMorrow and Foxx (1983) and that this effect appears to continue for at 
least 36 weeks. However, it is difficult to determine whether the 
compensation results directly from the reduced nicotine yield or is an indirect 
consequence of the changes in the physical parameters of the cigarettes. 
From an experimental view point, this is encouraging since it implies that 
short duration studies can still supply useful information on the effects of
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brand switching. It also fills an important gap in the literature; in their review, 
McMorrow and Foxx (1985) only listed two long duration studies, of 12 weeks 
(Jaffe et al, 1978) and of 20 months (Freedman and Fletcher, 1976). 
Although this second study was longer than the present one, it is not strictly 
comparable, since it used very limited techniques with few visits. These 
observations appear to have implications for the ISCSH strategy of reducing 
the "lifetime intake of toxic substances" by lowering the yield of smoke 
constituents (Froggatt, 1983), since this improvement would seem to be 
reduced by long-term compensation.
However, from the calculations of compensation, based upon changes 
in the measured body fluid levels of nicotine and cotinine (and HbCO, 
although not of direct concern in this thesis) and the levels predicted from the 
changes in machine yields, it has been shown that it is not possible to rely 
solely upon the body fluid levels as indicators of smoking behaviour.
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3.2 : LONG-TERM EFFECTS OF SWITCHING TO LOW TAR 
CIGARETTES WITH VARIOUS NICOTINE YIELDS
3.2.1 Introduction
The strategy of reducing the health risks of smoking cigarettes by 
reducing the delivery of tar has long been part of official policy. In 
accordance with this policy the sales-weighted average tar yield dropped over 
the period 1965 to 1985 from 31.5mg to 14.4mg (Wald, 1988). Whilst tar 
deliveries can be reduced by a variety of modifications to the cigarette, either 
by tobacco blend changes or by altering filtration efficiencies, it is difficult to 
avoid a simultaneous reduction in the nicotine delivery. It has been 
suggested that people smoke to dose themselves with nicotine (Armitage, 
1978). This could take several forms : in smokers who smoke at a frequency 
of less than one cigarette per hour, pharmacokinetic considerations (such as 
half-life and volume of distribution) suggest that the predominant plasma 
profile of nicotine would be one of peaks that are high relative to the average 
level (Figure 1.7); whereas in more frequent smokers, those who smoke a 
cigarette every 30 minutes or less, provided they inhale the smoke, the peaks 
would be smaller relative to the average level. Russell and Feyerabend 
(1978) suggest these might be described as "peak-seekers" and "trough- 
maintainers" respectively. A further possibility is that the boli of nicotine that 
reach the brain after each puff on the cigarette produce higher brain nicotine 
levels than are seen in the plasma and that these frequent "reinforcements" 
may strengthen the cigarette smoking habit (Russell and Feyerabend, 1978). 
If any of these suggestions were proven then the aspect of smoking 
behaviour known as compensation, which was raised in the Third Report of
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behaviour known as compensation, which was raised in the Third Report of
the ISCSH and investigated in the previous study may be significant.
The conclusion from the previous study that smokers who switch to 
lower yield nicotine cigarettes show partial, persistent compensation 
undermines the ISCSH policy of reducing the "lifetime intake of toxic 
substances". Rather than hoping that compensation would decrease with 
time it might be important to endeavour to reduce the amount of 
compensation. If, therefore, the nicotine level in the cigarette, or the amount 
of nicotine that is obtained from the cigarette, is the determining factor in the 
amount of compensation that results from switching to a lower yielding 
product then it may be possible to reduce the compensation by increasing the 
amount of nicotine in the product, or decreasing the tar : nicotine ratio. 
Additionally, previous studies of similar design where the subjects switched to 
cigarettes yielding lower tar and nicotine raised the question of mechanical 
versus nicotine aspects of compensatory smoking behaviour changes. 
Modifying tar : nicotine ratios at constant pressure drop, ventilation and other 
physical parameters may help to resolve the mechanical versus nicotine 
question.
A further study was therefore designed to examine the effects of 
switching to lower tar products but where the nicotine was independently 
varied. As in the previous study habitual smokers of at least 10 manufactured 
cigarettes of a middle or low-to-middle tar brand per day would be recruited. 
Their smoking behaviour while smoking their own brand would be examined 
for an extended period, after which they would be asked to switch to one of 
two experimental products. The experimental products were a conventional 
low tar, low nicotine product (control product) and a low tar product with a 
nicotine content similar to a middle tar brand ('maintained' nicotine product).
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Their smoking behaviour on the experimental product would then be 
examined over a further extended period. The objective was to recruit 50 
smokers into each group.
3.2.2 Subjects
The subjects were recruited initially using posters, local newspapers 
and local radio. Due to a poor response from these sources a local Market 
Research Agency was used to perform initial recruitment and screening of the 
subjects. Potential subjects who smoked a pipe, cigars, hand-rolled 
cigarettes or low tar cigarettes (<1 Omg tar yield) were excluded. The subjects 
were aged between 18 and 65 with at least five years smoking experience. 
No subjects with cardiopulmonary disease were enrolled and any female 
becoming pregnant was excluded from further investigation. Many of the 
subjects who enrolled did not commence the study, many failing to attend for 
their first appointment. Many of the latter were enrolled by the recruitment 
company and there was a delay between the initial contact and first 
appointment, resulting in a loss of interest.
The study protocol was approved by the Ethical Committee of the 
University of Surrey and all subjects gave informed consent in writing before 
beginning. The subjects purchased their own cigarette brand as usual from 
retail outlets for the first phase of the study and were provided with study 
cigarettes at a reduced price, equivalent to the duty and tax component of the 
retail price, for the second phase. The study cigarettes were manufactured 
by a tobacco company specifically for the study.
1 1 0
3.2.3 Plan of Study
The subjects were asked to visit the laboratory in order to monitor their 
smoking behaviour and collect saliva samples. Each subject was asked to 
abstain from smoking before each visit for at least 30 minutes in order to 
minimise the short-term effects of previous cigarettes. Studies were 
performed throughout the working day and early evening, but each subject 
always attended at the same time and day of the week to minimise any 
diurnal variations or any variations in smoking habits between weekdays and 
weekends.
On the first three visits, at six weekly intervals, subjects smoked their 
own brand exclusively, or in exceptional circumstances where that brand 
became unavailable, a closely similar brand (in terms of tar and nicotine 
yield). On the third visit one of the experimental products was allotted to 
them according to a randomised schedule and approximately 30 minutes 
after smoking their own brand cigarette they smoked the first of their new 
cigarettes. The subjects were then asked to smoke the experimental product 
exclusively for the remaining duration of the project. The subjects were 
provided with a supply of cigarettes packed in plain white packs. They then 
attended for a further three visits at eight week intervals, smoking the 
experimental products. On each visit measurements of smoking behaviour, 
ventilation and alveolar carbon monoxide were made and pre- and post­
smoking saliva samples were taken. At the first visit measurements of lung 
function were made and the MRG Questionnaire on Respiratory Symptoms 
(1965) was administered with some supplementary questions on smoking 
habits. At the second and subsequent visits the subject was asked to collect 
the butts of all the cigarettes smoked over the preceeding 24 hours. At the 
second visit only, a post-smoking alveolar carbon monoxide measurement
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made. The interval between visits was a compromise between the desire for 
as many data points as possible from the pre- or post-switching period to 
ensure consistent behaviour had been observed, tending to increase the 
number of measurements, and the necessity to minimise the inconvenience 
to the subject, tending to increase defaulting. The measurements made are 
shown in Table 3.3.
Table 3.3 : Details of experimental protocol
Visit Number 1 2 3 3a 4 5 6
Weeks from start 0 6 12 12 20 28 36
Cigarette brand own own own expt’l expt'l expt'l expt'l
Lung function measurements 
and MRG questionnaire
+
Pre- and post-smoking saliva 
sample collected
+ + + + + +
Previous 24 hours' butts 
collected
+ + + + + '
Study butt collected + + + +
Pre-smoking alveolar 0 0 + + + + + +
Post-smoking alveolar 0 0 +
Pre- and post-smoking O 2  
and OO2
+
Sensory questionnaire + + +
1 1 2
3.2.4 Experimental Procedure
The subjects smoked the cigarettes in a special room within the 
laboratory, in order to provide as relaxed an atmosphere as possible, with all 
the recording instrumentation placed outside the room.
3.2.4.1 Puffing behaviour
This was measured using a conventional 2mm orifice plate cigarette 
holder (Creighton et al, 1978) with the differential pressure across the 
cigarette linearised electronically and integrated to a flow signal (Smoking 
Analyser 4P (SA4P), CGC Instruments). This flow signal and the pressure 
signal across the cigarette, both analogue, were digitised at 20ms intervals 
using a CED 1401 interface (Cambridge Electronic Design Ltd., Cambridge) 
and passed to an Apricot Xi computer (Apricot Computers Ltd., Birmingham) 
for storage and off-line analysis. The computer was also used for storage 
and off-line analysis of measurements of ventilation and alveolar carbon 
monoxide.
The subject took three puffs from the cigarette before lighting it. These 
unlit puffs were used to check that the holder was being used correctly and 
that there were no leaks. The indices of puffing behaviour that were 
measured or derived are :-
(1 ) values derived from the flow signal for each puff
(i) maximum flow rate (mls'^)
(ii) puff volume (ml)
(2) values derived from pressure signal for each puff
(i) maximum pressure (kPa)
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(ii) pressure integral (kPa.s)
(3) time values per puff
(i) puff duration (s)
(ii) inter-puff interval (s)
(4) indices derived from pressure and flow per puff
(i) resistance, P17.5 (kPa)
(ii) work of puffing (mJ)
(5) indices for the smoked cigarette
(i) number of puffs per cigarette
(ii) duration of smoking (s)
(iii) total puff volume (ml)
(iv) tar delivery (mg)
(v) nicotine delivery (mg)
(vi) carbon monoxide delivery (mg)
The tar, nicotine and carbon monoxide deliveries are calculated using 
the ratio of the subject's total puff volume and the machine-smoked total puff 
volume and the machine-smoked tar, nicotine and carbon monoxide yields.
3.2.4.2 Saliva
The subject was asked to rinse the mouth three times with tap water 
over a period of about 30 seconds and then to collect saliva in a small beaker 
until 5ml had been produced. Saliva samples were collected before and after 
smoking and were stored at -20°C before analysis for cotinine content using 
the procedure described in Chapter 2.2.4.
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A similar quality control procedure to that described in Appendix B, for 
the previous study, was employed to monitor the saliva analysis.
3.2.4.3 Sensory questionnaire
This consisted of ten questions relating to sensory attributes and 
'liking' of the cigarette. Immediately after smoking the cigarette on visits 3 
(the last own brand cigarette smoked), 3a (the first study cigarette smoked) 
and 6 (the last study cigarette smoked) the subject was asked to complete 
the questionnaire by assessing the intensity of each attribute relating to the 
cigarette just smoked. The intensity was scored by ringing the number, 0 to 
10, between a minimum and maximum rating, which best reflected the 
subject's opinion. The attributes are shown in Table 3.4.
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Table 3.4 : Attributes determined in Sensory Questionnaire
Attribute Minimum rating 
(0)
Maximum rating 
(10)
Effect on throat none very great effect
Cigarette strength very mild very strong
Taste strength none very strong
Taste liking dislike very much like very much
Snx)othness very smooth very rough
Smoke temperature very cool very hot
Ease of draw very easy very hard
Overall liking dislike very much like very much
Change in taste during 
smoking
no change marked change
Change in cigarette strength 
during smoking
no change marked change
3.2.5 Results
A subset of the complete results is presented, comprising subject 
numbers, details of the study cigarettes, some of the smoking behaviour 
measurements and the saliva cotinine data, together with some derived 
measurements of smoking behaviour and the results of the sensory 
questionnaire. The remaining results were not relevant to the work of this 
thesis.
1 1 6
3.2.5.1 Statistical analysis
As in the previous study the pre-switching data (visits 2 and 3 only 
since visit 1 was treated as a familiarisation visit) were examined for 
variations using the Friedman two-way analysis of variance since the data 
were in many cases not normally distributed. The Wilcoxon matched pairs 
test was used to compare the data from visit 3a (or 4 for saliva cotinine and 
daily cigarette consumption since these were not measured or did not differ 
from visit 3 respectively) with the pre-switching data. The post-switching data 
were examined for variation using the Friedman two-way analysis of variance 
and for trends using the Page L trend test. The differences between the 
three groups were examined using the Friedman two-way analysis of 
variance.
3.2.5.2 Subjects
In total 170 subjects responded to the various means of advertising 
described above, of these, 33 could not be enrolled because they either 
smoked unsuitable products (low tar, hand-rolled or mentholated cigarettes) 
or appointments could not be made. Of the 137 with whom first appointments 
were made, 64 did not attend, generally because of a loss of interest. Of the 
73 remaining subjects 44 dropped out of the study between the first visit and 
the fifth visit; there were no further drop-outs after visit 5. The reasons for 
dropping out during the study are shown in Table 3.5.
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Table 3.5 : Reasons given for dropping-out of study between visits 1 and 5.
No longer interested 12 III health 2
Too busy 8 Disliked saliva sampling 2
Not recorded 6 Moved House 1
Given up smoking 4 Premature switch to low tar 1
Disliked low tar cigarettes 4 Pregnancy 1
Changed smoking habits 3 TOTAL 44
The distribution of the subjects who completed the study between the 
two study cigarettes is shown in Table 3.6.
Table 3.6 : Distribution of subjects who completed the study between study 
cigarettes.
Control cigarette 13
Maintained nicotine 16
cigarette
TOTAL 29
3.2.5.S Own brand and study cigarettes
The deliveries of the subjects' own pre-switching brands and two study 
cigarettes under standard machine-smoking conditions are shown in Table
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3.7. Smoking machines take a 35ml puff, of two seconds duration, at a rate 
of one per minute until a pre-determined butt length has been reached, if the 
required butt length is reached during a puff then the puff is terminated at that 
point. The tar, CO and nicotine yields of the control cigarettes were on 
average 40% lower than the own brand cigarettes smoked by this group. The 
yields of the maintained nicotine cigarettes were 30%, 37% and 7% lower 
respectively than the cigarettes smoked before switching.
Table 3.7 : Tar, nicotine and carbon monoxide deliveries of subjects own 
brand of cigarette and study cigarettes under machine-smoking conditions. 
Data on own brands published by the Laboratory of the Government 
Chemist.
Own brand Study cigarette
Group Tar
(mg)
CO
(mg)
Nicotine
(mg)
Puff
number
Tar
(mg)
CO
(mg)
Nicotine
(mg)
Puff
number
Control 14.17 15.15 1.33 10.4 8.6 8.5 0.81 9.8
Maintained 14.52 15.10 1.32 9.2 10.1 9.5 1.23 8.9
3.2.S.4 Analysis of data v is it by v is it
The statistical analyses are summarised in Table 3.8. Columns 3 and 
4 comprise the mean value for each variable for the pre-switching visits, 2 
and 3, and any differences between the groups (e.g. the mean number of 
puffs in the group smoking the control cigarette for the cigarettes smoked 
on visits 2 and 3, which were not significantly different, was 14.1, which was 
not significantly different from the maintained group, 14.6). For several 
variables there were significant differences between visits 2 and 3 
(Wilcoxon), denoted by *. Columns 5 and 6 comprise the value for visit 3a,
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or 4 for cigarette consumption and saliva cotinine, and the significance of 
any difference between the values for visit 3 and 3a, or 4 as appropriate, 
i.e. on switching, using the Wilcoxon matched pairs test. Columns 7 to 10 
comprise the mean post-switch value and consider any changes during the 
post-switch period, with the significance of the Page trend test and direction 
of trend, the significance of the variation and between the groups (Friedman 
two way analysis of variance). The visit-by-visit data are also presented in 
Figures 3.10 - 3.21.
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In the control group mean puff volume rose 8% on switching (P < 0.05) 
but did not change thereafter; in the maintained nicotine group mean puff 
volume rose slightly but not significantly. The total puff volume in the control 
group did not change significantly as the puff number dropped by 17%. Since 
puff number and mean puff volume did not change in the maintained group 
there was no change in total puff volume. (Figures 3.10 - 3.12).
Figure 3.10 : Mean puff volume data (mean of all puffs on a cigarette 
excluding lighting puff) in two groups of smokers who switched to 
experimental cigarettes at visit 3a. Data are the means for each visit.
60 1
50 -
40 -
Controla=
Maintained20 -
3a 
Visit No.
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Figure 3.11 : Number of puffs per cigarette in two groups of smokers who
switched to experimental cigarettes at visit 3a. Data are the means for each
visit.
18 n
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12 -
Control
■X—  Maintained
3a 
Visit No.
Figure 3.12 : Total puff volume per cigarette in two groups of smokers who 
switched to experimental cigarettes at visit 3a. Data are the means for each 
visit.
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Visit. No
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Cigarette consumption did not alter significantly before or on switching 
in either of the groups, or after switching in the maintained nicotine group. 
There was, however, a significant downward trend in consumption in the 
control group between visits 4 and 6 (Figure 3.13).
Figure 3.13 : Cigarette consumption in two groups of smokers who switched 
to experimental cigarettes at visit 3a. Data are the means for each visit (N.B. 
no value for consumption on visit 3a).
30 1
25 -
Control
Maintained
3a 
Visit No.
Of the 29 subjects who completed the study, pre- and post-smoking 
saliva samples were analysed for cotinine in 18 subjects. These data are 
shown in Figure 3.14. Although post-smoking saliva cotinine was 1.4% 
higher than pre-smoking saliva cotinine, the difference was not significant (P 
> 0.5), therefore the mean of the pre and post values has been used in all 
statistical analyses.
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Figure 3.14 : Comparison between pre- and post-smoking saliva cotinine for
all visits in 18 subjects
600
500 -
400 -
J  300 -
200 -
100 -
500 600400200 300
Pre-smokIng saliva cotinine (ng/ml)
100
The visit by visit data for each of the study groups is shown in Figures 
3.15 and 3.16 and in Figure 3.17 for the two groups together. Since the 
saliva cotinine data were normally distributed (Shapiro-Francia test) the 
means and standard deviations are plotted in Figures 3.15 and 3.16 and 
means only (for clarity) in Figure 3.17.
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Figure 3.15 : Saliva cotinine data for control group. Data are mean ±  1 s.d.
for each visit, (n = 8)
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Figure 3.16 : Saliva cotinine data for maintained group. Data are mean ±  1 
s.d. for each visit, (n = 10)
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Figure 3.17 : Saliva cotinine data in two groups of smokers who switched
to experimental cigarettes at visit 3a. Data are the means for each visit.
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Thus although the nicotine yields of the experimental cigarettes were 
significantly lower (39% (P<0.001) and 7% (P<0.05) for control and 
maintained nicotine cigarettes respectively) there were no significant 
reductions in the saliva cotinine levels. Using the saliva cotinine data 
estimates of compensation were made (calculated as in section 3.1.5 in the 
previous study) and these are shown in Figure 3.18.
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Figure 3.18 : Estimates of compensation based on mean saliva cotinine. 
Data are the means for each post-switch visit for each group.
250 n
200 - Control
Maintained&
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-50 J
Visit No.
Although there appears to be a considerable difference between the 
maintained, nicotine group and the control group, the compensation data were 
so variable (particularly in the maintained nicotine group) that there were no 
significant differences or trends either between visits or groups (Friedman 
and Page tests respectively). The mean compensation figures (based on 
saliva cotinine) for the two groups were control group 70% and maintained 
nicotine group 94%.
The amount of nicotine that the subject obtained from the cigarette that 
was smoked in the laboratory can be calculated from the subjects' total puff 
volume data and the nicotine yields of the cigarettes under standard machine 
smoking conditions. This relies on the assumption that the nicotine delivery is 
linearly proportional to the puff volume. Data for the amount of nicotine 
delivered to the subject are presented in Table 3.8 and Figure 3.19. In both
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groups there was a significant reduction in the amount of nicotine delivered to 
the mouth on switching (P < 0.05) with the larger reduction in the control 
group (P < 0.001). Whilst there was no significant difference between the 
groups pre-switching, the maintained nicotine group value was significantly 
higher than the control group post-switching and remained so for the whole of 
the post-switch period (P < 0.001).
If the subject were to smoke all of the cigarettes consumed on a daily 
basis in the same way as the cigarette in the laboratory then daily intakes of 
tar and nicotine can be estimated. These data are shown in Table 3.8 and 
Figures 3.20 and 3.21. The control group showed reductions in both 
estimated tar and nicotine intake (P < 0.005), but the reduction in estimated 
nicotine intake in the maintained nicotine group, although significant (P < 
0.05), was less than the corresponding reduction in tar intake (P < 0.0001).
Figure 3.19 : Calculated nicotine delivery from cigarettes smoked in the 
laboratory in two groups of smokers who switched at visit 3a to experimental 
cigarettes. Data are the means for each visit.
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Figure 3.20 : Estimated daily tar intake by smokers estimated from cigarettes 
smoked in the laboratory in two groups of smokers who switched at visit 3a to 
experimental cigarettes. Data are the means for each visit.
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Figure 3.21 : Estimated daily nicotine intake by smokers estimated from 
cigarettes smoked in the laboratory in two groups of smokers who switched at 
visit 3a to experimental cigarettes. Data are the means for each visit.
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3.2.5.S Sensory questionnaire
There were no significant changes in responses to the sensory 
questionnaire in the control group (Table 3.9). In the maintained nicotine 
group (Table 3.10) the first of the experimental cigarettes (visit 3a) was 
thought to be less smooth and hotter than the subjects' own brand (P < 0.05), 
an effect which persisted to the sixth visit. Although the maintained nicotine 
cigarettes were liked less the difference was not significant.
Table 3.9 : Responses to sensory questionnaire administered directly after 
smoking on visits 3, 3a and 6 from the control group. Data are mean ±  1 s.d.
Visit 3 Visit 3a Visit 6
Effect on throat 2.00 ± 1.73 1.56±1.13 2.11 ±2.15
Cigarette strength 4.78 ±2.44 4.78 ±2.05 4.22 ±2.28
Change in cigarette 
strength during 
smoking
1.78 ±1.86 2.33 ±3.00 1.78 ±1.86
Taste strength 5.11 ±1.83 5.22 ± 1.99 4.11 ±2.32
Taste liking 7.22±2.17 6.22 ±2.22 6.00 ± 1.87
Change in taste 
during smoking
1.44 ± 1.59 2.22 ±2.82 2.33 ± 2.65
Smoothness 4.33 ±3.24 3.33 ±2.18 4.00 ±2.24
Smoke temperature 4.44 ± 2.24 3.56 ±1.94 4.33 ± 2.29
Ease of draw 2.44 ± 1.51 2.00 ±2.35 3.56 ±3.50
Overall liking &89±226 5.67 ±2.83 6.33 ± 2.69
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Table 3.10 : Responses to sensory questionnaire administered directly 
after smoking on visits 3, 3a and 6 from the maintained group. Data are 
mean ±  1 s.d. * Denotes a significant difference between visits 3 and 3a or 
between visits 3a and 6 (Wilcoxon, P < 0.05)
Visit 3 Visit 3a Visit 6
Effect on throat 2.85 ± 3 .0 5 4.23 ± 3 .4 9 2.73 ± 2 .5 5
Cigarette strength 5.31 ± 0 .8 6 5.62 ± 1 .9 4 5.13 ± 1 .3 0
Change in cigarette 
strength during 
smoking
2.39 ± 2 .9 3 3.00 ± 2 .4 5 3.20 ± 2 .2 7
Taste strength 5.08 ±  1.26 5.77 ± 1 .7 9 5.67 ± 1 .3 5
Taste liking 7.23 ± 2 .1 7 5.69 ±  2.66 6.47 ± 2 .1 0
Change in taste 
during smoking
2.46 ± 2 .9 0 3.31 ± 2 .7 2 3.07 ± 2 .6 9
Smoothness 4.08 ± 2 .1 4 5.23 ± 2 .2 0 * 4.47 ±1 .8 1
Smoke temperature 3.08 ± 1 .7 5 4.23 ±  1.69 * 4.73 ± 1 .4 4
Ease of draw 3.08 ± 2 .6 0 2.77 ± 2 .2 8 3.00 ± 1 .6 0
Overall liking 7.62 ± 1 .7 6 5.77 ±2 .7 1 6.47 ± 2 .0 3
3.2.6 Discussion
Cotinine has a half-life of about 18 hours (Benowitz et a/,1983b) and 
may act as an indicator of exposure to nicotine over the preceeding 48 hours 
although the previous study casts some doubt over this. In each of the study 
groups, compensation, based on the saliva cotinine measurements, was 
observed. In the control group the mean estimates of compensation was 
70% (s.d. ±  27.5%), while that for the maintained group was higher at 94% 
(s.d. ±  315%). The considerable variation in the compensation estimates
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prevented there being any significant differences between the groups; 
however, the control group was relatively consistent thoughout the post­
switch period (Figure 3.20) suggesting a consistent response to the 
experimental cigarettes.
The degree of compensation found in the control group is in 
agreement with that found before, both in the previous study and in previous 
published reports (Benowitz et al, 1983a; Ossip-Klein at al, 1983; Wald et al, 
1984). However, the maintained nicotine group appear to demonstrate 
almost complete compensation, i.e. they changed their smoking behaviour in 
such a way as to maintain their nicotine intake at the same level, in fact, 
because the nicotine delivery of the maintained nicotine cigarettes was only 
7% on average less than their own brands, the subjects barely had to alter 
their smoking behaviour at all, assuming nicotine delivery is the driving force. 
The data from the control group suggests that the change in smoking 
behaviour is immediate, as soon as the first lower yielding product is smoked, 
and continues as long as that cigarette is smoked, however the variability of 
the compensation data for the maintained nicotine group precludes any 
similar deductions.
The mechanism by which the compensation was achieved appears to 
vary between the two groups. In the control group mean puff volume 
increased but puff number decreased resulting in no significant change in 
total puff volume. In accordance with other studies (Stepney, 1981; 
Woodman et al, 1987; Armitage et ai, 1988; Bridges et al, 1990) cigarette 
consumption did not alter significantly on switching to the lower tar products 
but a slight increase in the control group was observed. In the maintained 
group there were no significant changes in smoking behaviour as might be
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expected when the nicotine delivery of the experimental product was only 7% 
lower than the pre-switching brands.
Smoking in a laboratory environment, whatever efforts are made to 
relax the subject and control the conditions, is generally more intense than 
that away from the laboratory (Comer and Creighton, 1978). However, the 
estimates of daily tar and nicotine exposure made here, although based on 
an assumption concerning linearity of yield with puff volume, are of interest 
for purposes of comparison. The changes that occur on switching broadly 
reflect the changes in the deliveries of the three cigarettes. There were no 
differences between the groups pre-switching, but both groups showed a 
significant reduction in both tar and nicotine intake on switching, but the 
reduction in nicotine post-switching was less in the maintained nicotine group 
than in the control group.
Several previous studies have evaluated maintained nicotine cigarettes 
(Stepney, 1981; Woodman et al, 1987; Armitage et al, 1988) in comparison 
with reference cigarettes. The cigarette specifications varied between the 
various studies therefore it is unsurprising that the findings also varied. 
Stepney (1981) found that the mouth-level delivery of nicotine was 
significantly greater with the maintained cigarette than with the control, with 
which the data presented here is in agreement. Calculating compensation 
from the Stepney 24hr urinary cotinine data shows that compensation took 
place, about 40% with a low-tar control (11 mg tar, 0.7mg nicotine) and about 
120% with the maintained nicotine cigarette (lOmg tar, 1.1 mg nicotine). 
Armitage et a / (1988), in a study of randomised balanced design evaluating 
low tar (9.1 mg tar, 0.8mg nicotine) and maintained nicotine cigarettes 
(11.2mg tar, 1.4mg nicotine) compared with middle tar cigarettes (16.9mg tar, 
1.7mg nicotine), found compensation of 62% and 165% respectively
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(calculated from pre-retiring saliva cotinine data). Woodman et al (1987) 
measured inhaled smoke volumes directly using a ®^ Kr radiotracer technique 
and found that with a maintained nicotine cigarette (lOmg tar, 1.4mg nicotine) 
the volume of smoke inhaled was 21% less than that from a cigarette with 
similar tar yield (lOmg) but reduced nicotine yield (I.Omg) (29% reduction in 
nicotine yield). Woodman et al also found that inhaled smoke volume from 
the maintained nicotine cigarette was 23% less than that from a cigarette with 
the same nicotine yield (1.4mg) but higher tar yield (17mg) suggesting that 
the tar to nicotine ratio of a cigarette may be as important as the absolute 
yields of tar and nicotine.
From the data presented it would appear, however, that, in spite of 
significant reductions in the estimates of nicotine intake by the subjects on 
switching this did not result in significant reductions in the amount of cotinine 
present in the saliva of the subjects. There are several possible reasons for 
this discrepancy between estimated nicotine intake and the cotinine 
estimates. Firstly, saliva cotinine may not be a good marker of nicotine 
intake, as suggested by the previous study. Secondly, the amount of smoke 
wasted (allowed to escape from mouth or nose prior to inhalation) may have 
changed between the own brand and the experimental brand. Thirdly, there 
may have been variations in the depth and/or duration of inhalation which 
might affect nicotine absorption; this area will be covered in greater detail in 
Chapter 4. Finally, there may be errors in the method of estimating the 
nicotine intake. The way in which the subjects smoked in the laboratory may 
differ from the normal smoking patterns and lead to an inaccurate estimate of 
'normal' smoking behaviour. The estimates of cigarette consumption by the 
subjects may be erroneous; it is likely that consumption is higher than that 
reported. The error may be contributed to by the assumption of a linear
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relationship between puff volume and nicotine delivery which may not always 
be true since filtration might be expected to increase with the volume of 
smoke that passes through the filter. The same assumption has been made 
concerning the puff volume and tar delivery. Notwithstanding this, there was 
also a significant reduction in the estimated amount of tar taken in by both 
groups, although smaller in the maintained group.
From the sensory data it can be seen that both experimental products 
were liked less than the subjects' existing brand but the differences were not 
significant. It is of interest however that the overall liking score increased in 
both groups suggesting some acclimatisation.
3.2.7 Conclusion
The data from this study provide further evidence that smokers of 
middle tar cigarettes do change aspects of their smoking behaviour when 
switching to lower yielding cigarettes, with the result that their exposure to 
smoke components is reduced less than that expected from the reduction in 
yields. The hypothesis that by maintaining the level of nicotine nearer to that 
of their pre-switching brand switchers would compensate less has not been 
supported but it has resulted in a similar reduction in estimated tar intake. 
The inability to provide support is caused by the poor correlation between 
saliva cotinine levels and smoking behaviour.
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CHAPTER FOUR
STUDIES OF NICOTINE RETENTION FROM AEROSOLS OF 
NICOTINE AND FROM CIGARETTE SMOKE
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4.1 INTRODUCTION
The uptake of nicotine during smoking is very rapid. In an 
anaesthetised cat exposed to cigarette smoke introduced into the trachea, 
blood pressure rose within seconds, a similar effect to that produced by 
injecting nicotine intravenously (Armitage, 1978). It has been suggested that, 
in man, "the vanguard of nicotine molecules obtained from the first puff of a 
cigarette may reach the brain in about seven seconds" (Ashton and Stepney, 
1982).
The study of nicotine uptake from tobacco smoke has a long history 
(Larson, Haag and Silvette, 1961; Larson and Silvette, 1968, 1971, 1975). 
Estimates of the absorption of nicotine from the buccal cavity vary between 
2.5% and 66.7%, while the effect of inhalation and breath holding varies 
according to author. There are many uncertainties about these early studies. 
The analytical techniques were crude or indirect and cigarette smoke was 
normally used. Cigarette smoke is very difficult to standardise (Guerin, 
1980); the composition varies according to cigarette type, from puff to puff, 
with the puffing pattern employed and with storage if it is not used 
immediately (Wiley and Wickham, 1974). Attempts have been made to 
standardise the dose with ten puffs of smoke taken into a syringe and injected 
into the mouth (Pomerleau et al, 1989a) and by asking subjects to take puffs 
of fixed duration and interval (Pomerleau et al, 1989b). In the first study no 
allowances were made for losses of nicotine by adsorption onto the 
equipment, (nicotine is very difficult to handle because its polar 
characteristics allow ready adsorption onto any surface) and in the second 
study the puff volume was not measured. Also the use of cigarette smoke 
does not allow the effects to be ascribed to nicotine without uncertainty since
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tobacco smoke contains over 4,000 compounds in addition to nicotine (Dube 
and Green, 1982). However any other form of nicotine administration, such 
as chewing nicotine gum or intravenous administration or nasal nicotine 
solutions, does not allow for the rapid uptake of nicotine via inhalation which 
is the manner characteristic of smoking. In order to model the uptake of 
nicotine from cigarette smoke it is desirable to administer the nicotine in as 
pure a form as possible and in a physical form that resembles cigarette 
smoke.
Several studies have been performed using aerosols to investigate the 
uptake of nicotine (Perkins et al, 1986; Lux and Frecker, 1988; Burch et al, 
1989). Perkins et al, (1986) used an aerosol of nicotine and anise oil (to 
mask the taste and smell of nicotine) in 0.9% saline which was sprayed into 
the nostrils of smokers. Administration of doses of nicotine of between 0.5 
and 2mg led to plasma nicotine boosts of between 10 and 25ngml'\ Lux 
and Frecker (1988) used an aerosol generator of their own design to deliver 
nicotine containing particles with mass median aerodynamic diameter of 
0.5pm, i.e. very similar to cigarette smoke, and achieved blood 
concentrations of about 7.5ngml'\ Burch et al, (1989) used a solution of 
nicotine in 0.9% saline and a dosimeter to deliver nicotine to smokers. They 
were able to produce plasma nicotine levels comparable with smoking (Figure 
4.1), but side effects such as cough and a burning sensation in the throat 
caused a number of subjects to drop out of the study. The side effects may 
have been caused by the high dose given during the study (5mg) and 
exacerbated by the large size of the particles (mass median particle diameter 
4pm as compared with 0.5pm for cigarette smoke, McCusker et al, 1982) 
causing significant impaction in the throat and upper airways.
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Figure 4.1: Plasma nicotine levels after administration of 5mg of aerosolised 
nicotine, chewing 2mg nicotine gum, or smoking a 17mg tar, 1.4mg nicotine 
cigarette. (Burch ef a/, 1989)
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As can be seen, many workers assess nicotine uptake by measuring 
the "boost" in plasma nicotine levels but this method is invasive, requiring an 
in-dwelling catheter for repeated blood samples, takes several minutes to 
complete, requires nicotine exposure similar to that from a cigarette and may 
influence subject compliance with experimental protocol. The determination 
of plasma nicotine levels can also present problems : plasma nicotine levels 
change rapidly during and after smoking (Figures 1.4 and 1.7), so sampling 
time is ciitical and there is large inter-subject variability; the levels are low 
therefore the analytical procedure must be sensitive and selective.
In none of the above studies (Perkins et al, 1986; Lux and Frecker, 
1988; Burch et ai, 1989) was the mode of administration quite the same as
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that which occurs in cigarette smoking, i.e. two distinct actions : that of taking 
a puff and then inhaling. Perkins ef a/(1986) sprayed aerosols into the nose; 
Lux and Frecker (1988) and Burch et al (1989) asked their subjects to inhale 
the aerosol directly.
In an attempt to overcome some of these problems a technique was 
developed in which subjects took measured puffs of an aerosol of aqueous 
nicotine, inhaled room air and then breathed out into a trap which collected 
any nicotine which was exhaled by the subject. The retention of nicotine by 
the subject could then be calculated from the difference between the dose 
and that exhaled. No blood sampling was needed; it avoided the 
uncertainties of interpreting rapidly changing plasma nicotine measurements; 
it was faster than earlier techniques; permitted a lower nicotine exposure 
since each test required only one or two puffs and many separate 
measurements could be made within a single session. This technique has 
been used to examine a number of factors : the availabilty of nicotine as a 
free base (i.e. the effect of pH on availability), the effects of holding the 
aerosol bolus in the mouth, the effects of inhaling and breath-hold and the 
time interval between puffing and sampling. However, since it is an indirect 
measurement it does not distinguish between particle retention on the 
respiratory mucosae and absorption into the blood.
After the studies using nicotine aerosols were completed, the 
technique was applied to cigarette smoke to investigate any differences 
between that and the data obtained from the nicotine aerosol studies.
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4.2 AEROSOL GENERATION AND TRAPPING 
4.2.1 Aerosol Generator
Tobacco smoke is a condensation aerosol, i.e. materials which have 
been vapourised in the burning and hot zones of the cigarette condense onto 
nuclei, possibly ash particles, to form droplets suspended in the gas phase. 
Although aerosol generators which work on the same principle were 
commercially available they would not have been appropriate because of the 
requirement to use aqueous solutions. The aerosol generator used was an 
'Acorn' nebuliser (Medic Aid, Pag ham, W.Sussex, Figure 4.2). This type of 
nebuliser is very widely used for the administration of therapeutic agents. A 
stream of compressed air is used to atomise a liquid into droplets by the 
Venturi effect. The compressed air is forced past the end of a narrow tube, 
the other end of which is immersed in the liquid to be nebulised and an area 
of reduced pressure is created. The liquid is drawn up the tube and is 
fragmented by the high velocity air. More than 99% of the total droplet mass 
impinges on baffles which surround the nebuliser orifice and is returned to the 
reservoir for re-nebulisation. The size distribution of particles generated is 
shown in Figure 4.3 (Malvern Instruments Mastersizer). Although the 
particle size was larger than tobacco smoke (0.1 - 0.5pm) it was felt 
acceptable since there was no reasonable alternative to answer the questions 
under investigation.
Nicotine and nicotine hydrogen tartrate solutions were made up in 
single distilled water at 'cigarette equivalent' concentrations, i.e. sufficient to 
deliver about 100pg per 50ml 'puff of aerosol, assuming 10 puffs per 
cigarette with 1mg nicotine yield. The pH's of these solutions were 10.2 and
3.1 respectively.
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Figure 4.2 : Cross-section through an 'Acorn' nebuliser
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Figure 4.3 : Particle size distibution of a water aerosol produced by an 
'Acorn' nebuliser; measured using a Malvern Instruments Mastersizer.
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The amount of material delivered by the nebuliser was measured by 
dividing the weight of solution used per unit time by the flow rate at the mouth 
of the nebuliser.
4.2.2 Sensory Evaluation of Different Aerosols
It may be that nicotine is closely involved with the sensory effects of 
cigarette smoke and may contribute to the sensation of 'impact' of cigarette 
smoke on the throat. Impact is a short-lived sensation, of rapid onset, which 
is perceived in the throat during the inhalation of smoke. It is used, in part, by 
the smoker in assessing the strength of a cigarette. Nicotine may also 
contribute to irritation in the mouth and throat. This being the case it was 
decided to investigate the sensory effects of the nicotine aerosols. The 
sensory evaluation was not rigorous and was undertaken by two non- 
smokers and one smoker.
A puff of aerosol was taken into the mouth and either blown out 
immediately or held in the mouth for about 5 seconds. The next stage was 
to take a puff, then inhale and exhale.
The low pH aerosol was found to cause slight mouth irritation, some 
throat and upper airway irritation, all of which died down rapidly. The high 
pH aerosol gave more intense mouth and throat irritation, which was of 
greater duration, but reduced upper airway irritation.
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4.2.3 Aerosol Trapping System
Various devices were constructed to trap nicotine aerosols, both as 
delivered directly from the aerosol generator and on exhalation by subjects. 
It was thought that any device which was capable of trapping the nicotine 
aerosols would also be capable of trapping whole smoke satisfactorily. The 
major requirements of the device were that it should be of low impedance and 
have the capacity for high flow rates (at least 20 Imin* )^ in order that 
exhalation could be as normal as possible. The most effective system is 
shown in Figure 4.4.
Figure 4.4 : Diagram of apparatus used to trap exhaled aerosols (not to 
scale)
92mm Pad supported 
on steel gauze
Mouthpiece Rotameter
Pump
100ml Gas
5 litre 
Smoothing flask
At the flow rate used it was found that, with time, the filter pad was 
gradually deformed and the effective surface area was reduced to that of the 
tube downstream of the pad. In order to prevent this deformation it was 
necessary to support the pad with a coarse steel gauze.
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The flow rate through the system was set at 30 lm in'\ a typical 
expiratory flow rate. In order that any variations in the expiratory flow rate 
could be accomodated by the system, a vertically mounted (i.e. plunger 
hanging downwards) 100ml gas syringe was placed downstream of the pad. 
By setting this to about 50ml, it would serve both as an indicator of expiratory 
flow rate and act as a compensator if the expiratory flow rate deviated from 
30 lm in'\ Due to the reduced pressure within the system when operational, 
it was necessary to weight the plunger so that it would remain stationary at 
50ml. If the rate of exhalation into the system dropped below 30 lm in'\ the 
plunger would rise to compensate, or it would fall if the rate was greater than 
30 lm in'\ Thus, when exhaling into the trap, the subject was able to watch 
the plunger and endeavour to keep it stationary, thereby maintaining his rate 
of exhalation at 30 Imin'^-
4.2.4 Evaluation of Trapping System
The recovery of nicotine from the trapping system was determined 
under a variety of conditions, where the pH of the nicotine solution nebulised, 
the pH of the filter pad and the duration of nébulisation were varied. Each 
condition was repeated twice. All combinations of the following variables 
were investigated: (i) pad treatment: none, acid or alkali; (ii) pH of nebulised 
solution: 3, 8 or 10; (iii) duration of nébulisation: 0, 0.5,1, 2 or 4 minutes.
For this evaluation the nebuliser was attached directly to the trap and 
the gas syringe was omitted (Figure 4.5). The pump for the trap was 
switched on just before the nebuliser pump, which was timed, and switched 
off just after the nebuliser pump was switched off to ensure that all the
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nicotine in the aerosol was collected on the pad in the trap. The whole 
apparatus was contained within a fume cupboard.
Figure 4.5 : Diagram of apparatus for evaluation of aerosol trap (not to scale)
92mm Pad supported 
on steel gauze
Net air flow
Rotameter
Nebuliser in
5 litre 
Smoothing flask
The concentrations of nicotine and nicotine hydrogen tartrate solutions 
used for nébulisation were lower than those used in the sensory evaluation 
(equivalent to about 20|ig per 50ml puff). This was to compensate to some 
degree for the increased durations of the experiment. From the nicotine 
dissociation curve (Figure 1.3) it can be seen that to achieve a situation 
where 50% of the nicotine is present as the ionised form and 50% as the 
unionised form a solution at pH 8 is required. The solution at pH 8 was made 
up by titrating the nicotine solution (pH 10) with the nicotine hydrogen tartrate 
solution (pH 3) in order to maintain the effective concentration of nicotine. 
For each combination of pad treatment and solution the order of the 15 
samples (each duration in triplicate) was determined using the random 
number facility of a Casio FX82c calculator.
147
4.2.5 Pre-treatment of Filter Pads
The 92mm Cambridge filter pads were soaked with 0.5 M sulphuric 
acid or 1 M sodium hydroxide and allowed to air-dry at room temperature. 
They were then stored in air-tight containers until use. The pH of distilled 
water, adjusted to pH 7, was not affected when four 92mm filter pads were 
placed in it. It was therefore assumed that the untreated pads were of neutral 
pH.
4.2.6 Determination of Nicotine Content of Pads
Immediately an experiment was finished the pad was removed from its 
holder, cut into about 10 pieces, placed in a 150ml polypropylene screw-top 
flask. 20ml 5M sodium hydroxide and 3ml n-butyl acetate (BuAc) were 
added, the flask sealed and shaken for 15 minutes in a flat-bed shaker. The 
bottles were allowed to stand for a few minutes then the resulting mixture was 
poured into a centrifuge tube, allowed to stand again while the aqueous and 
organic phases separated and then a portion of the BuAc layer was 
transferred to an autosampler vial for analysis. Each extract was analysed 
five times by gas chromatography and the mean value used to give the 
nicotine content from gravimetric calibration solutions analysed consecutively. 
The gas chromatographic conditions are as described in section 2.2.4.3.
4.2.7 Results
For each condition a maximum recovery was calculated and this is 
presented with the concentration found and as a percentage for comparison 
in Tables 4.1 - 4.3 and Figures 4.6 - 4.8.
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Table 4.1
aerosols
Recovery of nicotine from acidified pads with different pH
Duration
(min)
Nicotine conc. in extract (ngml’ )^ 
(% expected)
Maximum
Conc.
expected
(pgml'i)
pH of nebulised solution
pH 3 pH 8 pH 10
0 0 0 0 0
0.5 375 (80) 298 (64) 335 (72) 467
1 758 (81) 668 (72) 527 (56) 933
2 1858 (99) 1383 (74) 1576 (84) 1866
4 3525 (94) 2765 (74) 3230 (87) 3732
Table 4.2 : Recovery of nicotine from untreated pads with different pH 
aerosols
Duration
(min)
Nicotine conc. in extract (pgml )^ 
(% expected)
Maximum
Conc.
expected 
(pgml 1)
pH of nebulised solution
pH 3 pH 8 pH 10
0 0 0 0 0
0.5 300 (64) 267 (57) 336 (72) 467
1 716 (77) 502 (54) 653 (70) 933
2 1465 (79) 1107 (59) 1288 (69) 1866
4 2560 (69) 2085 (56) 2277 (61) 3732
Table 4.3 : Recovery of nicotine from alkaline pads with different pH aerosols
Duration
(min)
Nicotine conc. in extract (pgml'^) 
(% expected)
Maximum
Conc.
expected
(pgml-i)
pH of nebulised solution
pH 3 pH 8 pH 10
0 0 0 0 0
0.5 351 (75) 215 (46) 226 (48) 467
1 769 (82) 455 (49) 478 (51) 933
2 1427 (66) 856 (46) 672 (36) 1866
4 2474 (66) 1681 (45) 1005 (45) 3732
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Figure 4.6
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Figure 4.7 : Recovery of nicotine from untreated pads with different pH 
aerosols
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Figure 4.8
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Generally, the lower the pH of either the solution for nébulisation, or 
the pad, the higher was the recovery from the trap. The two extreme sets of 
conditions (a) acid pad/pH 3 solution and (b) alkaline pad/pH 10 solution 
showed mean recoveries of nearly 90% and about 45% respectively, with the 
other combinations ranged between.
4.2.8 Discussion
From Figure 1.3 it can be seen that the higher the pH of the nicotine 
solution the greater the proportion of nicotine that will be in the unionised 
form. The greater the amount in the unionised form the greater will be the 
partial pressure of nicotine in the vapour phase, thus the higher the pH of the 
solution the more easily will the nicotine evaporate from the aerosol particles.
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Conversely, there will be little or no nicotine in the vapour phase around the 
particles from the pH 3 solution. The particles will be trapped effectively on 
all pads and therefore from the pH 3 solution the majority of the nicotine will 
be trapped. However, when particles from this aerosol are trapped on the 
alkaline pad their pH will rise, then some of the nicotine will vapourise, be 
stripped off the pad by the air flowing over the pad and the total recovery will 
be reduced. Recovery of nicotine from an untreated pad will reflect the 
proportion of nicotine in the ionised form and hence the particulate phase. 
At pH 10 100% of nicotine is in the unionised form and will vapourise readily 
from the aerosol particles, however, if the pad is acidic it will ionise some of 
the nicotine vapour and retain it.
From the above it can be seen that none of the combinations resulted 
in complete recovery of the nicotine from the aerosol, possibly because 
varying proportions of nicotine vapour had passed through the pad. A further 
experiment was therefore conducted to establish whether the nicotine that 
was not trapped by the pad had passed through the pad. This was achieved 
by placing a further acidified pad behind the first pad and extracting the 
nicotine from it as above. In this way greater than 98% of the nicotine from 
an aerosol of pH 3 nicotine solution was trapped over a range of nébulisation 
times.
4.2.9 Conclusion
From the above validation the aerosol trap worked most effectively 
when two acidified pads were used, when greater than 98% of the nicotine 
was trapped. It was therefore considered suitable for use in experiments to
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investigate the retention of nicotine from nebulised solutions of nicotine by 
human subjects.
4.3 PILOT NICOTINE AEROSOL STUDY
As has already been described, the act of smoking involves smoke 
generation, smoke manipulation and smoke inhalation and it was decided that 
a preliminary investigation would be made of the sensory effects and 
retention of nicotine from the aerosols on inhalation.
4.3.1 Effect of Inhalation
Initial experiments were conducted by taking puffs from the aerosol 
generator, either inhaling or not and blowing out/exhaling into the trap and 
determining the amount of nicotine trapped as before. The retention was 
calculated as the difference between the nicotine concentration in the extracts 
from puff only and puff + inhale manoeuvres (i.e. that due to inhalation) as a 
proportion of that in the puff only manoeuvre (Table 4.4).
Table 4.4 : Nicotine retention in preliminary inhalation experiments
Nicotine concentration in 
extract (pgml'^)
Retention 
due to 
inhalation
(%)Expt Subject pH of soin puff only puff + inhale
1 A 3 101 35 65
2 A 3 108 40 63
3 B 3 178 29 84
4 A 10 43 10 77
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Experiments 1 and 2 showed similar results suggesting fair 
reproducibility by subject A but subject B had a much higher puff only value 
suggesting larger puffs, and a lower puff and inhale value suggesting greater 
inhalation or breath-hold time. At pH 10 the puff only recovery was reduced, 
suggesting that retention in the mouth was higher, but the retention on 
inhalation increased for that subject also.
4.3.2 Puff Volume Measurement
It was realised that without puff volume measurements no true 
comparison could be made between subjects or between conditions. A 
human smoking behaviour analyser (SA4P, CGC Instruments) which uses a 
cigarette holder as a flow meter (Creighton et al, 1978) in the same way as 
the apparatus described in Chapter 3 for the long-term smoking behaviour 
studies was used. It was found, however, that the puff volumes measured 
were very inaccurate or non-existent on comparison with drawing on a 
cigarette. Data collection on the SA4P was triggered by a pressure of 0.3 cm 
water gauge on the mouth side of the orifice plate. With a cigarette in place 
data collection was triggered as soon as a puff commenced, due to the high 
impedance of the cigarette. Without a cigarette in place, and with only the 
very low impedance of the holder, the pressure threshold was very rarely 
exceeded, thus no puff recordings were triggered. Unfortunately, it was not 
possible to trigger data collection from the flow signal (the pressure difference 
across the orifice) due to the high sensitivity of the 'flow' transducer and 
inherent problems with spurious flow signals caused by movement of the 
holder. In order to increase the pressure drop across the orifice in the
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cigarette holder a 30mm length of 3mm i.d. plastic tubing was included 
(Figure 4.9).
Figure 4.9 : Diagram of apparatus for measurement of aerosol puff volume
Nebuliser
Plastic tube
J I
Cigarette holder 
I  Mouthpiece
To pressure  
transducers 
and SA 4P
The initial experiments were then repeated and the measured nicotine 
concentrations were adjusted to a mean puff volume of 50ml/puff for 
purposes of comparison and the retention figures were calculated as before. 
These data are presented in Table 4.5.
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Table 4.5 : Nicotine retention with puff volume measurement
Nicotine concentration in 
extract (pgml’ )^ 
(Adjusted to 50ml puff 
volume)
mean puff p u ff+ Retention
Expt Subject pH of soln volume
(ml)
puff only inhale (%)
5 A 3 50.3 36.6 20.5 44
6 A 3 61.6 38.6 22.8 41
7 B 3 79.1 51.5 13.4 74
8 A 10 54.2 19.2 2.6 86
9 A 10 55.0 20.9 5.5 74
10 B 10 82.3 21.2 2.0 91
Overall, the recoveries of nicotine were reduced when the aerosol was 
inhaled, compared with puff only, indicating retention in some way. At pH 3, 
subject A retained about 40% of that puffed, on inhalation, compared with 
about 80% at pH 10. Subject B showed much greater retention of both 
aerosols, with greater than 90% retention of nicotine from the high pH aerosol 
on inhalation. For both subjects the amount recovered from the puff only at 
pH 10 was about 50% of that pH 3. Subject B, a smoker, consistently took 
larger puffs than subject A, a non-smoker, and may have inhaled deeper, 
thereby achieving greater retention on both aerosols.
These results are consistent with the principle that the higher the pH of 
the nebulised solution the more nicotine is present in the unionised form. In 
the unionised form the nicotine will vapourise from the particles more easily 
and may then be taken up in the lung more readily.
On using the orifice plate cigarette holder and tubing (Figure 4.9) it 
was found that with both pH 3 and 10 aerosols the irritation in mouth and
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throat/upper airways was reduced, with the high pH reduced less than the low 
pH.
Before the orifice plate holder was included the amounts of nicotine 
recovered were substantially larger (Table 4.4). The lower recovery after 
addition of the tube/holder this may have been due to a reduction in the 
number of large particles that passed through the tube/holder, or adsorption 
of nicotine in the plastic tubing, causing a reduction in the total delivery. 
However, since the objective here was to investigate the effect of inhalation, 
the comparison was made between the amounts retained after puffing, with 
and without inhalation, rather than comparing the amount retained by puffing 
alone. It was therefore not necessary to know whether the amount of nicotine 
in the aerosol taken into the mouth was 100% of the dose available.
4.3.3 Conclusions
The aerosol generator, although the particles were larger than 
cigarette smoke, proved satisfactory in this work. The aerosol trapping 
system functioned efficiently and conveniently for use in human experiments. 
The sensory effects of the nicotine aerosols were established, although 
particle size and number may have influenced the magnitude and location of 
the effects. There was retention of nicotine from a low pH aerosol when 
inhaled, compared with a puff taken into the mouth only. This retention 
increased greatly when the aerosol was derived from a solution of high pH. 
However, these experiments were based on two subjects, one smoker and 
one non-smoker and provide only an indication of the situation in the smoking 
population. It was therefore important to investigate further these 
observations in a larger number of subjects. In addition, no assessment of
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retention in the mouth was made, and with the higher pH aerosol it appears 
that there was more retention in the mouth than with the low pH aerosol.
4.4 NICOTINE AEROSOL STUDY
The preliminary experiments with human subjects showed that the 
system used was capable of generating aerosols of nicotine solutions, that 
these aeiosols could be puffed into the mouth or inhaled into the lungs and 
that the amount of nicotine exhaled could be determined. There were, 
however, several shortcomings in the procedure. The actual dose of nicotine 
taken in by the subjects was calculated from the nebuliser output rather than 
measured in a "puffing" type manoeuvre and mouth retention was not 
measured. The volumes of air inhaled after puffing and exhaled after 
puffing/inhaling were not measured and the number of subjects was very 
small. In order to improve on these shortcomings the apparatus was modified 
and extended and a further series of experiments were conducted with a 
larger number of subjects.
4.4.1 Subjects
Eight subjects were studied, none of whom gave a history of 
cardiopulmonary disease. Before beginning, the purpose of the study was 
explained to them and they gave informed consent. The group consisted of 
seven males and one female, anthropometric data are given in Table 4.6. Six 
were current cigarette smokers, one had recently stopped and one had never 
smoked.
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Table 4.6 : Anthropometric data for subjects
Mean Range
Age (yrs) 38.5 2 8 - 5 5
Height (cm) 174 1 65 -1 8 1
Weight (kg) 74.4 5 9 - 8 0
4.4.2 Aerosol Generation
As with the previous v/ork the Acorn nebuliser was used for aerosol 
generation. However, certain modifications to the aerosol administration 
circuit were necessary in order to achieve satisfactory puff volume 
measurement. The puff volume was determined as before with a smoking 
analyser. The length of plastic tubing between the tubing and the orifice plate 
holder (Figure 4.9) was replaced initially with a 20mm length of 1mm i.d. 
glass capillary tubing. This was found to increase the pressure drop to a level 
that was similar to a cigarette but the puff volume measurement using the 
SA4P was unreliable, possibly due to a "jetting" effect of the air leaving the 
capillary tubing impinging on the pressure port of the holder. The glass 
restrictor was therefore modified by adding a larger diameter glass tube 
between it and the holder to act as a mixing chamber (Figure 4.10), which 
appeared to eliminate the problem and permit satisfactory puff volime 
measurement. The holder was calibrated using successive 50ml puffs from a 
glass gas syringe fitted with a stop at 50ml. Periodic checks were made with 
50, 70 and 100ml puffs from further syringes. The complete apparatus for 
aerosol generation and puff volume measurement is shown in Figure 4.11.
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Figure 4.10 : Diagram of glass restrictor used to simulate impedance of
cigarette.
Aerosol Generator 
< --------------------------
7 mm
42 mm
Figure 4.11 : Diagram of aerosol generation and puff volume measurement 
apparatus
Glass restrictor.
Nebuliser
Cigarette holder 
I  Mouthpiece
1■
To pressure 
transducers 
and SA4P
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4.4.3 Inhalation Circuit
The inhalation circuit, Figure 4.12, enabled the subject tc inhale 
approximately one litre of air from the two litre anaesthetic bag through a 
gauze pneumotachograph (Mercury Electronics) attached to a capacitance 
manometer (Furness Controls) to measure the actual volume inhaled. 32mm 
diameter flexible tubing was used between the various elements of the circuit.
Figure 4.12 : Diagram of inhalation circuit (not to scale)
Collapsible 2 litre 
anaesthetic bag
Pneumotachograph
Mouthpiece
Taps
1 litre Syringe
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4.4.4 Aerosol Trap
The aerosol trap was modified to allow the measurement of the volume 
of air exhaled, using a bias flow through the pneumotachograph (Figure 
4.13). The subject breathed out through the mouthpiece and the expired 
volume was recorded with a pneumotachograph attached to a sidearm 
(calibrated and checked as below). Before each test, the flow through the 
main tube was occluded to give a baseline reading for integration, then on 
release, a second level was obtained representing the balance of flow 
between the main tube and the sidearm. The start of exhalation was sensed 
as a disturbance in the second level as the mouth was placed over the tube. 
The subject monitored the expiratory rate by watching a gauge to avoid 
breathing out faster than the pump was drawing air through the filter. 
Acidified 92mm Cambridge filter pads were used in the trap throughout.
Figure 4.13 : Diagram of aerosol trap/exhalation circuit (not to scale)
Pneumotachograph 92mm Pad supported 
on steel gauze
Rotameter
Mouthpiece
Pump
5  litre 
Smoothing flask
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The experimental system was built in three separate sections, rather 
than with a single mouthpiece and a valvebox or with taps, to minimise the 
internal surface area to which nicotine was exposed and thereby minimise 
nicotine adsorption.
The flow signals from the SA4P and the manometers (to which the 
pneumotachographs were connected) were digitised using an analogue to 
digital interface (CED 1401, Cambridge Electronic Design), sampling at 20ms 
intervals, and integrated using a microcomputer (Apricot Xi, Apricot 
Computers), which was also used to control and measure the timing of the 
procedure.
The solutions used in the nebuliser were initially made up as in 
previous work, but it was found that the nicotine delivery from the aerosol was 
lower, probably due to the restrictor further reducing the number of particles 
passing through and excluding the larger particles. To compensate for the 
lower nicotine delivery the concentrations of the solutions were increased to 
112mgmM nicotine and 332mgmM nicotine hydrogen tartrate, the pH 10 and 
pH 3 solutions respectively, and titrated together to produce the pH 8 
solution.
4.4.5 Calibration
This was performed in two stages. A 50ml glass gas syringe was used 
to draw air through the cigarette holder and the integrated signal was 
measured on ten successive strokes; (the circuit is unidirectional and will only 
give a flow signal if suction is applied to the holder). The mean value of the 
integrated signals was displayed on the computer screen together with the
163
coefficient of variation as a check on the consistency of the calibration; the 
calibration was only accepted if the coefficient of variation was below 10%. A 
similar process was used to calibrate the two pneumotachograph heads; they 
were ganged together and five complete strokes of a one litre syringe applied. 
These signals were bidirectional so that ten consecutive integrated values 
were obtained per channel from the five strokes.
Before each separate manoeuvre, in calibration or during the test 
manoeuvres described below, the baseline positions of the three channels 
were measured over two seconds and all integration based on these. This 
procedure was particularly important with the expiratory measurements, since 
the pads in the trap might have had different impedances which might alter 
the steady flow through the trap.
At intervals during each session both the cigarette holder and the 
pneumotachograph heads were checked with further gas syringes, at 50 or 
100ml and one litre respectively.
4.4.6 Procedure
Six manoeuvres were performed :
(1) Syringe : Using a 100ml gas syringe, a 100ml puff of aerosol was taken 
through two acidified pads in the same holder.
(2) Mouth 0 : The subject took a puff of aerosol into the mouth and 
immediately blew it out into the trap and exhaled to residual volume.
(3) Mouth 15 : The subject took a puff of aerosol into the mouth and held it in 
the mouth for 15 seconds before blowing it out into trap and exhaling.
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(4) Breath 0 : The subject took a puff of aerosol, immediately inhaled a litre of 
air from the inhalation circuit and then immediately exhaled into the trap.
(5) Breath 15 : The subject took a puff of aerosol, immediately inhaled a litre 
of air, held that inhalation for 15 seconds and then exhaled into the trap.
(6) Blank : The subject inhaled a litre of air (no puff of aerosol) and then 
exhaled into the trap.
The concentration of the aerosol delivered to the subject was 
measured in manoeuvre 1, while manoeuvre 6 provided a background value 
for the nicotine analysis. Each subject performed the above manoeuvres with 
each pH aerosol, and each manoeuvre was performed twice. The order of 
the manoeuvres and the order of the aerosols was randomised using the 
random number generator of a CASIO fx82c calculator.
4.4.7 Determination of Nicotine Content of Pads
The nicotine was extracted from the pads and analysed as described 
in section 4.2.6.
4.4.8 Results
The amount of nicotine delivered to the subject in 100ml of aerosol 
was determined from the syringe manoeuvre. From that, and the puff volume 
taken by the subject, the amount of nicotine taken in by the subject could be 
calculated. The amount of nicotine retained by the subject was therefore the
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difference between the amount taken in and the amount recovered from the 
pad in the trap.
The mean puff volume for the whole study was 62.4ml ranging 
between subjects from 39.7ml ±  5.8ml to 94.3ml ±  6.7ml. The mean inspired 
volume for manoeuvres involving inhalation was 1045ml (range 936ml to 
1130ml) and the mean exhaled volume for the whole series was 2025ml 
(range 895ml to 4020ml).
The nicotine retention data for all subjects are presented in Table 4.7 
and Figures 4.14 and 4.15. Data on the number of observations (4 studies 
were discarded because the analyses of the extracts of the pads were 
unsatisfactory) and the total durations of the manoeuvres from the start of 
puffing on the cigarette to the end of exhalation are presented in Table 4.8.
From Figure 4.14 it can be seen that mouth retention of nicotine 
increased significantly (P < 0.0001) with pH. It also increased with mouth- 
hold duration (pH 3, P < 0.05; pH 8 and 10, P < 0.01). The mouth-hold data 
were always significantly less than the corresponding breath-hold data (P < 
0.01), except for the pH 10,15 second mouth and breath-hold manoeuvres.
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Figure 4.14 : Proportion of nicotine intake retained by subjects during mouth- 
hold manoeuvres using different pH aerosols. (Mean of duplicate 
measurements in 8 subjects)
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Figure 4.15 : Proportion of nicotine intake retained by subjects during breath- 
hold manoeuvres using different pH aerosols. (Mean of duplicate 
measurements in 8 subjects)
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Table 4.7 : Proportion of nicotine intake retained by subjects during mouth- 
hold and breath-hold manoeuvres using different pH aerosols. (Mean and s.d. 
of duplicate measurements in 8 subjects)
Manoeuvre : %  of dose retained
d H 3 pH 8 pH 10
Mouth 0 37.9 26.0 57.6 16.0 81.3 12.7
Mouth 15 59.6 20.7 74.0 9.0 95.3 3.6
Breath 0 90.7 4.1 94.7 2.4 96.7 3.9
Breath 15 93.3 5.5 95.4 3.2 94.2 7.1
(mean) (s.d.) (mean) (s.d.) (mean) (s .d .).
Table 4.8 : Number of observations and mean duration of manoeuvres (All 
subjects)
Manoeuvre:
pH 3 pH 8 P H 10
No. Duration (s) No. Duration (s) No. Duration (s)
Mouth 0 10 5.6 11 6.1 11 6.2
Mouth 15 11 19.3 11 19.7 10 20.1
Breath 0 11 10.0 11 9.9 11 10.3
Breath 15 11 24.0 10 24.4 10 24.4
Figure 4.15 demonstrates that greater than 90% of the nicotine is 
retained on inhalation largely independent of pH and breath-hold duration. 
The increase in retention with pH at breath-hold 0 is significant (P < 0.001). 
In detail, at pH 3 and pH 8 the same trends are seen as with mouth-hold, but 
are not significant. At pH 10 there is a decrease in retention on increased 
breath-hold. If, however, the data is inspected more closely it can be seen 
that the decrease is contributed by the non-smokers data (Table 4.9), the 
smokers showing a slight increase (Table 4.10). At present there is no
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explanation for this although it may be an artefact due to the small number of 
data points.
Table 4.9 : Nicotine retention data : 2 Non-smokers
Manoeuvre : %  of dose retained
pi- 3 pl- 8 pH 10
Mouth 0 34.4 26.5 52.2 9.7 81.3 5.5
Mouth 15 55.2 38.6 68.5 11.7 91.7 4.7
Breath 0 88.9 6.4 92.3 3.4 98.3 1.1
Breath 15 92.1 6.9 92.6 3.5 87.5 10.6
(mean) (s.d.) (mean) (s.d.) (mean) (s.d.)
Table 4.10 : Nicotine retention data : 6 Smokers
Manoeuvre : %  of dose retained
pl- 3 pl- 8 pH 10
Mouth 0 39.5 27.8 59.6 17.9 81.3 14.8
Mouth 15 61.3 13.1 76.1 7.6 97.3 1.8
Breath 0 91.3 3.2 95.6 1.2 96.0 4.4
Breath 15 93.7 5.4 96.6 2.4 96.7 2.5
(mean) (s.d.) (mean) (s.d.) (mean) (s.d.)
4.5 CIGARETTE SMOKE STUDY
Although the experiments with nicotine aerosols gave a useful 
indication of the behaviour of nicotine in cigarette smoke, the similarity 
between the model system, an aerosol of aqueous nicotine solution, and
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cigarette smoke is limited both in terms of composition and particle size. 
Cigarette smoke is a mixture of at least 4,000 different compounds (Dube and 
Green, 1982) which is continuously changing as the smoke ages. An aerosol 
of an aqueous nicotine solution is, of course, an extreme simplification and it 
is important to be able to compare the model process with that being 
modelled. It was decided therefore to make measurements of nicotine 
retention from cigarette smoke after similar mouth and breath-hold 
manoeuvres.
4.5.1 Subjects
4.5.1.1 Mouth-hold experiments
Four subjects were studied, none of whom gave a history of 
cardiopulmonary disease. Before beginning, the purpose of the study was 
explained to them and they gave informed consent. Three were current 
cigarette smokers and one had never smoked. Three repeated the 
experiments on a second occasion and all had taken part in the nicotine 
aerosol experiments.
4.5.1.2 Breath-hold experiments
Duplicate measurements were made with four subjects, none of whom 
gave a history of cardiopulmonary disease. Before beginning, the purpose of 
the study was explained to them and they gave informed consent. All four 
were current cigarette smokers and had taken part in the nicotine aerosol 
experiments, two had taken part in the mouth-hold experiments.
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4.5.2 Apparatus
The previous experiments had shown that the actual inhaled volume 
(mean 1045ml) did not differ greatly from the nominal volume (1000ml) and 
that the exhaled volume (mean 2025ml) exceeded the sum of the inhaled 
volume and the puff volume (62.4ml). Since the subjects were now familiar 
with the procedures it was felt that it was not necessary to measure inhaled 
and exhaled volumes and the apparatus was simplified accordingly.
4.5.2.1 Smoke generation
Weight and pressure-drop selected cigarettes (UK type, Virginia 
tobacco; yields under machine smoking conditions : tar 10.23mg, nicotine 
0.66mg; weight 918 ±18mg, pressure drop 88.5 ±3.5mm water gauge) were 
smoked using an orifice plate cigarette holder and smoking analyser (SA5, 
CGC Instruments) for measurement of puff volume. The subjects were asked 
to take puffs of smoke from the cigarette that were as near as possible to 
their normal volume.
4.5.2.2 Inhalation circuit
The inhalation circuit was used as before, except that the 
pneumotachograph was omitted since measurement of inhaled volume was 
not required, Figure 4.16.
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Figure 4.16 : Diagram of inhalation circuit (not to scale)
Collapsible 2 litre 
anaesthetic bag
Mouthpiece
Taps
1 litre Syringe
4.5.2.3 Exhalation circuit
The exhaled air trap was returned to its original format and is 
illustrated in Figure 4.17. Acidified 92mm Cambridge filter pads were used in 
the trap as before.
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Figure 4.17 : Diagram of apparatus used to trap exhaled smoke (not to 
scale)
92mm Pad supported 
on steel gauze
Mouthpiece Rotameter
Pump
1G6mi Gas 
syringe
5 litre
Smoothing flask
4.5.3 Procedure
4.5.3.1 Mouth-hold manoeuvres
Mouth-hold time was varied between 0 and 20 seconds. The 'zero' 
(minimum mouth-hold) was estimated to be between one and two seconds 
but was kept as small as possible by the subjects who exhaled into the trap 
as soon as possible after taking a puff on the cigarette. A 50ml lighting puff 
was taken from the cigarette using a gas syringe and discarded and the 
cigarette was presented to the subject who took a puff 60 seconds after the 
cigarette had been lit. The subject was asked to exhale as far as possible 
after taking the puff, and then the cigarette was extinguished. For each 
experiment a fresh cigarette was used so that the amount of nicotine in the
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puff was as uniform as possible, i.e. the second puff on the cigarette was 
used each time. The order of the mouth-hold times was randomised as 
before, and within each set each mouth-hold time was performed twice. A 
blank puff was taken from an unlit cigarette with a clean gas syringe during 
each set and blown into the trap.
4.S.3.2 Breath-hold manoeuvres
The inhaled volume was set at one litre and the breath-hold time after 
inhalation was varied between 0 and 20 seconds. Thus the sequence of 
events was: puff, inhale, breath-hold for 0 - 20 seconds and exhale. Again, 
the 'zero' was minimised by the subjects who moved to the inhalation circuit 
as soon as possible after taking the puff of smoke from the cigarette, and to 
the exhalation circuit as soon as possible after inhaling. Initial measurements 
using single puffs resulted in too little nicotine being exhaled onto the pads for 
reliable analysis, so whole cigarettes were used. The subject was given a 
cigarette, prelit as in the mouth-hold manoeuvres and was asked to take puffs 
at 60 second intervals. Six, seven or eight puffs were used, depending upon 
how far down the cigarette had smoked. As before, a blank, of one litre of air 
inhaled and exhaled onto the pad, repeated six times, was included.
4.5.3.3 Analysis of trapped nicotine
After use each pad was cut into pieces and placed in a 100ml Schott 
bottle containing 20ml 5M NaOH and 20ml ethyl acetate (containing 0.01% 
v/v triethylamine to reduce nicotine adsorption onto glass surfaces and 
2.5pgmM quinoline internal standard) and shaken for 30 minutes on a rotary
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shaker. A sample of the organic layer was analysed by gas chromatography. 
(Hewlett Packard 5880 gas chromatograph with HP 7673A autoinjector; 10m 
0.53mm i.d. CP Sil-5-CB fused silica column; on-column injection; nitrogen 
phosphorus detector). Each extract was analysed in triplicate and the mean 
value used to give the nicotine content from gravimetric calibration solutions 
analysed consecutively.
The solvent used for extraction in these experiments was ethyl acetate 
rather than butyl acetate because it is less susceptible to hydrolysis under 
alkaline conditions.
4.5.4 Results
4.5.4.1 Estimation of nicotine intake
In order to be able to estimate the amount of nicotine that the subject 
received each time a puff was taken, measurements of the puff-by-puff 
nicotine delivery were made using a Borg-Waldt RM20/CS smoking machine 
with a 50ml puff volume. A puff volume of 50ml was chosen as being nearer 
a typical human puff volume than the standard machine puff volume of 35ml. 
With this type of smoking machine cigarettes are held in a carousel which 
rotates around a single Cambridge filter pad holder. A puff of smoke, of pre­
determined size, is drawn from each cigarette in turn onto the pad which traps 
all the particulate matter, including nicotine and water. The total particulate 
matter is measured g ravi metrically before the water and nicotine are 
extracted from the pad and analysed by gas chromatography. By changing 
the pad after each complete rotation of the carousel all of the puffs from that 
rotation can be collected and analysed separately from the previous and
175
subsequent puffs and therefore puff-by-puff deliveries determined. Although 
the cigarettes were smoked to a standard butt length (length of tipping paper 
plus 5mm), which may result in the machine taking part puffs, only the data 
for whole puffs is presented in Table 4.11 and Figure 4.18. The deliveries 
from puffs six and seven would appear to be anomalous, but the low yield 
from puff six and the high yield from puff seven were consistent through each 
of the three replicates that were performed.
From the puff-by-puff nicotine delivery data and the measurement of 
the puff volume taken by the subject it was possible to estimate the amount of 
nicotine taken in by the subject.
Table 4.11 : Puff-by-puff nicotine delivery of cigarettes used (50ml puff 
volume; mean of 15 cigarettes)
Puff no. 1 2 3 4 5 6 7
Nicotine 
delivery (fig)
41.8 78.0 98.0 100.9 103.2 65.8 142.6
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Figure 4.18 : Puff-by-puff nicotine delivery of cigarettes used in nicotine 
retention study (50ml puff volume; mean of 3 determinations of 5 cigarettes)
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4.5.4.2 Nicotine retention
The amount of nicotine retained by the subject was calculated by 
subtracting the amount of nicotine found in the exhaled air trap from the 
estimated nicotine intake. These data are expressed as a proportion of the 
nicotine intake and are presented in Table 4.12 and Figure 4.19.
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Table 4.12 : Proportion of nicotine intake from cigarette smoke retained by 
subjects during mouth-hold and breath-hold manoeuvres. Mean (s.d.)
%  of intake retained
Manoeuvre Duration of manoeuvre
(s)
0 10 20
Mouth-hold 36.2 38.9 46.8
(n = 7) (10.5) (19.1) (18.1)
Breath-hold 98.7 99.0 99.3
(n = 8) (1.0) (0.9) (0.4)
Figure 4.19 : Proportion of nicotine intake from cigarette smoke retained by 
subjects during mouth-hold and breath-hold manoeuvres (Mean of all 
observations)
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The mouth-hold experiments show that about 40% of the nicotine in 
the cigarette smoke is retained with a slight, but not significant, increase in 
retention of nicotine with mouth-hold duration. The breath-hold experiments 
show that greater than 98% of the nicotine generated by the smoker is 
retained on inhalation, irrespective of the duration of breath-hold. This is 
greater than that seen with the nicotine aerosols.
4.6 DISCUSSION
4.6.1 The Behaviour of Inhaled Particles
Although the techniques described in this chapter involved 
considerable subject co-operation, with the use of two or three mouthpieces 
in each manoeuvre, the subjects quickly mastered the techniques. This is 
supported by the various volume measurements and the consistent durations 
of the various manoeuvres in the nicotine aerosol study (Table 4.7). The 
range of puff volumes was slightly larger than those found with cigarette 
smoking through a holder, but this may have been due to the impedance of 
the glass restrictor being slightly less than a cigarette. The inhaled volumes 
were very consistent (the deviation from one litre being contributed, to some 
extent, by the flexibility of the tubing used in the circuit). The expiratory 
volumes were of the expected level for a full exhalation although there was at 
least one occasion when the full inhalation was not exhaled since the lowest 
volume was 895ml, this was in the female subject who was also of the 
smallest stature. It was important that the subject breathed out as far as 
possible to exhale as much un retained nicotine as possible.
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With acidified pads in the trap greater than 96% of any exhaled 
nicotine was trapped on the pad. A maximum of 4% was trapped on a 
second pad placed behind the first in tests to measure any breakthrough; this 
compares with 2% found when the trap was initially evaluated. As can be 
seen from section 4.2.7 there were slight differences in the trapping of the 
different aerosols on the pad, but these are corrected for in the experimental 
design as the human measurements are compared with an in vitro 
measurement (manoeuvre 1 in the nicotine aerosol study) within each block 
of measurements. The rate of exhalation, at 30 lm in'\ is far lower than the 
maximum possible (up to 600 Imin'^) and there were delays while the mouth 
was moved between the mouthpieces, but the minimum exposure time, about 
6 seconds, is similar to that in smoking (Guyatt etal, 1984).
The critical measurement is the nicotine delivery to the mouth which 
requires an accurate estimate of the volume. The volume can be fixed by 
injection from a syringe (Pomerleau et al, 1989a) but these workers did not 
measure the actual nicotine concentration in the smoke or allow for 
adsorption on the internal surfaces of the equipment. The orifice plate holder 
used here, with an added glass restrictor, caused some loss of aerosol, but 
this was again allowed for in the experimental design. Retention 
measurements will also be overestimated if there is no correction for any 
background level of nicotine. However the 'blank' manoeuvre (number 6 in 
the nicotine aerosol study) gave very low or zero levels producing errors of 
1 % or less.
Particles of a diameter greater than about 5pm are normally retained 
by the upper airways; in the extrathoracic airways depositions of 60% have 
been observed with large particles (Stuart, 1973). In the studies described 
here, the average retention in the mouth for the pH 3 aerosol was 37.9% and
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much higher for the other aerosols. At pH 3, the nicotine is completely 
ionised and the retention may have been due to deposition in the buccal 
cavity. The 'Acorn' nebuliser produces particles with diameters as much as 
six times that of cigarette smoke so that effects such as deposition and 
impaction might be more important. There was also an increase in retention 
with time and this may reflect effects such as sedimentation or a change in 
droplet size due to evaporation or condensation of water vapour and 
coalescence of the smaller droplets.
There was, however, a very marked difference with pH and this may 
be due to loss of nicotine from the droplets as a vapour at pH 8 and 10. As a 
free base, nicotine has an appreciable vapour pressure, 221 pgM at 20°C and 
899pgM at 37°C, (B.E.Frost, personal communication) but this disappears if 
the nicotine is in the form of a salt. At the higher pH's nicotine vapour would 
begin to be released during nébulisation and be carried by bulk flow into the 
mouth with the aerosol. Once in the mouth, some of the nicotine vapour 
would dissolve in the saliva, which in adults has an average pH of 6.4 (95% 
range 5.8 to 7.1, Geigy, 1970). The saliva volume would be sufficient to 
buffer the nicotine if it reached the wall as vapour and convert it 
predominantly to the ionised form, but it might not be sufficient to buffer all the 
nicotine contained in the particles as well.
After inhalation, retention was always greater than 90%, due probably 
to considerable deposition in the bronchial tree. Even here it appeared to 
increase with the higher pH aerosols, but few of the differences were 
significant, probably due to the fact that so little nicotine was recovered that 
analytical variability becomes predominant. It must be concluded therefore 
that retention following inhalation is not strongly dependant upon pH.
181
The retention of sub-micronic particles (<1.0|im) has been well 
studied, and when the particles are hydrophobic (sodium stearate being 
commonly used), then if the size of the inspirate is 500ml, so that the alveoli 
are readily attained, then on expiration 98% of the particles are recovered in 
the expirate (Gumming etal, 1967).
Can this information be applied to the nicotine aerosol ? Although the 
size of the aerosol particles as inhaled by the subjects was not known, the 
original aerosol as produced by the nebuliser was characterised and it was 
thought that a large proportion of the larger particles were removed from it by 
the apparatus, since the monitored dose was lower, therefore it may be that a 
large proportion of the particles were now sub-micronic. Since this is an 
aqueous aerosol, knowledge of the behaviour of sub-micronic hydrophilic 
aerosols would be useful, but this area seems to have been little studied. It 
may be that the lack of knowledge is due to technical difficulties which are 
caused by the way in which water and water vapour are handled by the 
airways.
It is a biological requirement that inspired gas is warmed to 37°C and is 
fully saturated with water vapour before it enters the alveoli, quite 
independently of the prevailing atmospheric conditions. Warming and adding 
water is the function of the nasal passages, upper airways and bronchi and is 
done at the expense of their heat content so that their surface is cooled. On 
expiration, moisture from the fully saturated gas condenses on the cooled 
surface and so plays a part in overall fluid balance (Gumming and Warwick, 
1981). It is the flux of water which makes the study of aqueous aerosols so 
difficult, since particulate growth due to the flux is most likely and thus entirely 
changes the conditions for retention.
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If retention occurs on the bronchial wall the aqueous particles will 
coalesce with the fluid lining the wall, which has a pH of 7.4. The lateral 
surface of the bronchi is very large and the buffering capacity of the fluid 
substantial so that the deposition in single puff of a hundred micrograms of 
nicotine (the given dose) would leave the physiological pH unchanged 
through the effect of its own pH.
Consequently, aerosols of aqueous solutions of nicotine of any pH, 
once deposited, would present the same proportion of ionised and unionised 
nicotine to the incoming gas, the inspired air, and any unionised nicotine 
could evaporate from the surface and enter the alveoli as a gas. 
Simultaneously, the equilibrium between ionised and unionised nicotine in the 
lining fluid at physiological pH would ensure that the proportion of unionised 
nicotine was maintained, making more available for evaporation.
This mechanism would explain the observations and suggest that 
retention is initially by impaction and deposition, both in the mouth and in the 
bronchi, but in the mouth the buffering capacity is unable to compensate for 
the added nicotine so that mouth lining pH follows that of the aquasol, as 
does the retention.
Nicotine absorption in small quantities in the mouth and throat may 
play an important role in smoking by giving sensory clues to the smoker. For 
instance, smokers tend to reduce puff volume as the cigarette becomes 
shorter by truncating the puff rather than by altering the flow rates used 
(Guyatt et al, 1984). This suggests that they respond almost immediately to 
some component of the smoke while the puff is still in progress and this could 
be, for example, nicotine dissolving in the lining fluid and acting on a receptor. 
There may also be a slower response as the nicotine reaches the cerebral
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circulation; this is suggested by the experience of seven of the subjects who 
sensed an immediate irritation in the throat after puffing the aerosol with slight 
disequilibrium developing after several minutes. It is also suggested by the 
work of Burch et al (1989) who administered ten puffs of aerosol at pH 10 to 
volunteers at 30 second intervals. They found that 14 out of 16 subjects 
experienced mild to severe cough on inhaling, but the symptom severity did 
not correlate with the plasma nicotine level, the peak of which was only seen 
two minutes after puffing ceased.
4.6.2 Electrostatic Considerations
The generation of an aerosol in a nebuliser of the type used in this 
work causes both a reduction in temperature (Joule-Kelvin effect) and a 
charge to be imparted to the particles. Although the mechanisms by which the 
particles become charged are poorly understood (John, 1980), any aerosol 
produced by high velocity dispersion of liquid or solid material is liable to have 
charged particles (unless a charge neutraliser is used). The charge on the 
nicotine aerosol particles has not been measured, but quite large charges 
may be produced - measured in thousands of elementary charge units per 
particle (John, 1980). These tend to be neutralised fairly rapidly in the 
atmosphere but will affect deposition if inhalation occurs immediately after 
generation.
The effect of electric charge on deposition is believed to result chiefly 
from the formation of image charges in the airway walls rather than from 
electrostatic interaction between particles. On inspiration into a structure with 
a large wetted surface, which because of its electrolyte content is a good
184
conductor, conditions are appropriate for the rapid deposition of a charged 
particle (Agnew, 1984).
4.7 CONCLUSION
The explanation which best fits the experimental evidence is thus as 
follows
The particles in the puff of smoke or aerosol, which precede the 
inspired volume of air on its passage down the airways, undergo physical 
changes due to water flux. The combination of flux and electrical charge 
produces rapid deposition on the bronchial walls and conversion to pH 7.4.
The nicotine-free inspirate then passes across this buffered fluid 
resulting in the evaporation of the unionised component to the gaseous form 
which is carried into the alveoli with subsequent rapid absorption.
The change in the mass action balance in the particles deposited on 
the bronchial walls produces more unionised nicotine which can evaporate 
and then pass down into the alveoli where it can be absorbed. Any remaining 
nicotine will pass gradually, either by diffusion or an active transport 
mechanism, into the bronchial circulation and thence into the systemic 
circulation.
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CHAPTER FIVE
GENERAL DISCUSSION
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At the beginning of the thesis three questions were posed and the 
discussion will be based around these.
Can body-fluid levels of nicotine and cotinine be used as reliable 
measurements of nicotine uptake ?
This question arose from reviews of published work and from work that 
was being undertaken at the Midhurst Medical Research Institute as part of a 
programme of research into human smoking behaviour.
In the first of the two long-term studies the smoking behaviour of a 
group of smokers of middle and low-to-middle tar cigarettes was followed 
over a period of six months on their own brand and for a further nine month 
period on a lower tar brand of their own choice. Generally, a reduction in tar 
yield will result in a reduction in nicotine yield of similar proportion. This study 
was established in response to the Third Report of the Independent Scientific 
Committee on Smoking and Health (ISCSH) (Froggatt, 1983). This report 
encouraged the availability of cigarettes with lower smoke yields and 
encouraged smokers to reduce their exposure to potential harm by changing 
to these cigarettes. The ISCSH acknowledged that this practise might lead to 
changes in the smoking behaviour of the smoker who might not only smoke 
more of the lower yield cigarette, but might take larger puffs, more puffs or 
inhale the smoke more deeply, a phenomenon known as compensation. The 
ISCSH felt that it was important that this phenomenon should be more 
carefully examined since it might lead to a greater exposure to some of the 
hazardous components of smoke than might be predicted from the yields of 
the cigarettes. If the subjects smoking behaviour remained unchanged on the 
lower tar brand, then the levels of smoke components taken in would be
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expected to decrease in line with the reduced delivery from the lower delivery 
cigarettes.
Of the thousands of different chemicals in tobacco smoke there are 
only two whose uptake has been investigated to any extent. Carbon 
monoxide, which is present in the gas phase of cigarette smoke, has been 
investigated because of its essentially irreversible affinity for haemoglobin. 
Nicotine has been the subject of considerable interest because of its 
pharmacological properties, and because it can make up 10% of the 
particulate phase of tobacco smoke it is present at sufficiently high levels, and 
is readily absorbed, for its presence in the body to be measured. Nicotine, 
however, is not strictly representative of the particulate phase since it 
vapourises readily, and to date there has been no description in the literature 
of a component of the involatile fraction of tobacco smoke which is taken up 
by the body and can be measured in the body fluids.
In order to assess the uptake of carbon monoxide and nicotine from 
tobacco smoke it was necessary to make measurements of body fluid levels 
of these materials and this thesis has concentrated on nicotine. Chapter 1 
described, amongst other aspects of nicotine, its metabolism. Nicotine is 
metabolised rapidly, predominantly in the liver, to cotinine and, as was 
discovered while this work was being undertaken, 3'-hydroxycotinine. Since 
nicotine has a half-life in plasma of about 40 minutes and cotinine about 18 
hours, plasma measurements give different information. Plasma nicotine 
levels can give an indication of nicotine uptake from a single cigarette, 
whereas plasma cotinine can give an indication of nicotine uptake over the 
preceeding 24 hours or so. Saliva cotinine should give similar information to 
plasma cotinine, but the samples can be taken non-invasively and without 
any associated traumae.
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In this context it was necessary to establish a reliable means of 
analysing nicotine and cotinine in body fluids and this has been described in 
Chapter 2. This required gaining skills in the operation and use of a gas 
chromatograph and in the application of biphasic extractions from body fluids. 
Although the initial direct application of published methods was a limited 
success, it was possible with experience to modify and adapt the methods 
until a procedure of the required speed and accuracy was achieved. In view 
of the large number of samples to be analysed the procedure had to be both 
reliable and robust. This procedure was used over the duration of the two 
studies described in Chapter 3, nearly five years in total, for both plasma and 
saliva analysis.
In the compensation study the average plasma cotinine level fell by 
18% on switching to the lower delivery cigarettes , as did the pre-smoking 
HbCO and HbCO boost. These reductions are, however, less than would be 
predicted from the reductions in machine-smoked yields of the cigarettes 
which were 33 and 37% for nicotine and CO respectively. Clearly, therefore, 
the subjects had made changes to their smoking behaviour so that their 
intake of nicotine and CO was not reduced as much as the delivery. 
Estimates of compensation, based on plasma cotinine, pre-smoking HbCO 
and HbCO boost all gave similar mean values of about 60% and saliva 
cotinine about 45%.
Of the various measures of smoking behaviour mean puff volume 
changed on switching, rising by 15.9%, caused by increases in puff duration 
and flow rate. The increase in mean puff volume with an initial, but not 
persistent, increase in puff number led to an increase in total puff volume.
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It is apparent therefore that the subjects demonstrated partial 
compensation for the reduced yields of their post-switching cigarette brand. 
They appear to have achieved this by adjusting their puff volume. It is difficult 
to determine whether this was a conscious decision based on reduced 
sensory satisfaction, or a consequence of mechanical factors based on the 
lower draw resistance of the lower tar products. This is one area in which this 
work could be extended. It would be very useful to examine the behaviour of 
smokers when asked to switch to products which had similar deliveries of tar, 
nicotine and carbon monoxide but differed in their pressure drop or draw 
resistance. With this range of products it ought to be possible to distinguish 
between the mechanical factors of smoke generation and the sensory factors.
Based on the results of the first study it was decided to investigate the 
smoking behaviour of similar groups of smokers of middle and low-to-middle 
tar cigarettes when they were asked to switch to low tar cigarettes which 
contained nicotine levels similar to either low tar cigarettes or middle tar 
cigarettes. The subjects were followed on their own brand for a 12 week 
period and then allocated to one of the three experimental products and 
followed for a further 24 weeks.
The results from the second study were less conclusive than those 
from the first. Compensation, based on the measurements of saliva cotinine, 
was again observed but was sufficiently variable that the group means of 
70% and 94% for the control product (low tar, low nicotine) and maintained 
nicotine product (low tar, medium nicotine) respectively were not significantly 
different. It appears that slightly more of the control cigarettes were smoked 
and fewer but larger puffs were taken. There were no changes in smoking 
behaviour with the maintained nicotine cigarettes.
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Importantly, the intake of tar or particulate matter was reduced in both 
groups, but less than would be predicted from the reduction in tar yield, as 
shown by the compensation figures. These figures are, however, based on 
saliva cotinine, which gives an indication of nicotine intake rather than tar 
intake. It is in this respect that a marker for the uptake of tar would be of 
particular benefit so that it could be compared with nicotine, but at present 
this is not available.
There were few changes in the sensory scores on switching to the 
lower tar brands. The maintained nicotine cigarette was perceived as being 
harsher, which may be a reflection of the lower tar to nicotine ratio, and the 
experimental cigarettes were liked less than own brand. It may be that 
smokers use the sensory cues obtained from the taste and irritation of a given 
amount of tar or nicotine as a guide to the amount of nicotine they are 
receiving and that this is a learned response that takes time to 'unlearn'. In 
the control and maintained nicotine groups the liking scores rose over the 24 
week post-switching period suggesting that the 'unlearning' might start during 
this period.
These two studies highlighted several areas in which body fluid 
measurements is an unreliable means of assessing nicotine uptake. Plasma 
levels of nicotine vary very rapidly after smoking due to distribution and 
metabolism and the amount of cotinine present in a smoker's body fluids will 
depend upon the way in which that smoker metabolises nicotine. The 
metabolism might differ from day to day or from week to week depending 
upon how much he or she has been smoking, and there may be a difference 
between the sexes, or his or her exposure to other foreign materials which 
may affect metabolism. Thus the sampling technique, both in terms of the 
method of sample collection and in particular the timing of sampling after
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exposure to nicotine is critical with respect to the levels of nicotine and 
cotinine. In view of this difficulty it was decided to abandon body fluid 
measurements.
It was apparent therefore that a means of assessing nicotine uptake in 
which the three areas, smoking behaviour, metabolism and sampling could 
either be controlled or eliminated as sources of variation would be very 
important and hence the second question arose :
Is there an alternative means of measuring nicotine uptake ?
Of the three areas the only one that can be controlled is the smoking 
behaviour, since the metabolism and sampling occur after the nicotine has 
entered the subject. The ideal therefore would be to measure the part of 
nicotine uptake that takes place before the nicotine enters the circulation i.e. 
before and during inhalation. Since it is not possible, at present, to measure 
nicotine uptake during inhalation per se, a technique was developed in which 
the amount of nicotine retained by the subject was determined. This was 
achieved by measuring the amounts of nicotine taken in and exhaled by the 
subject; then, by subtracting the amount exhaled from the amount taken in, 
the amount retained could be estimated.
At this point it is appropriate to restate the paradox that was introduced 
at the end of Chapter 1. The pharmacological effects of nicotine are 
observed very rapidly, suggesting that uptake has taken place in the alveolar 
region of the lung in order for nicotine to reach the brain sufficiently quickly. 
However, nicotine is in the particulate phase of smoke on generation and it is 
not believed to be possible for the smoke particles to reach the alveolar 
region. The hypothesis was therefore that the nicotine evaporates from the 
particles during inhalation and this then became the third question :
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Does nicotine evaporate from particies during inhaiation ?
If, therefore, during the measurements of retention suggested above, 
the depth of inhalation or the duration of breath-hold were varied it might be 
possible to establish the rate of evaporation. However, initially, to investigate 
the evaporation it became necessary to be able to control the evaporation i.e. 
to have situations where it would be either maximised or minimised or held at 
some point between. The extent to which nicotine evaporates depends upon 
its ionic state. Pure nicotine, in which all the nicotine is unionised, has a very 
high vapour pressure, whereas a pure salt of nicotine, in which all the nicotine 
is ionised, has zero vapour pressure. The most effective way of controlling 
the ionisation state of nicotine is in aqueous solution where the pH can be 
varied and controlled accurately.
The most effective means of administering these aqueous solutions is 
in an aerosol generated in a nebuliser. With the aerosol the smoking process 
can be reproduced. A puff of aerosol can be taken, manipulated if necessary, 
then a volume of air can be inhaled afterwards and the breath held before 
exhalation. If an aqueous solution of high pH is used, the nicotine should 
evaporate readily from the particles and if a low pH solution is used, the 
nicotine should remain associated with the particles and not evaporate.
An aerosol of nicotine also provides a means of measuring retention in 
a model situation. If the output of the generator is known, and the amount of 
aerosol taken in is known, then an accurate estimate of the dose can be 
made. Then, by measuring the amount of nicotine in the exhalate, the 
retention of nicotine can be calculated. Thus whilst the means to measure 
the dose of nicotine were available, there was no means of measuring the 
exhaled nicotine.
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In order to quantify the exhaled nicotine an exhaled air trap was built 
and tested. It was found that with acidified filter pads up to 98% of the 
nicotine from a nebuliser could be trapped successfully. It was also found 
that subjects could take puffs of aerosol from the nebuliser which contained 
similar amounts of nicotine to cigarette smoke, and that the sensory effects of 
the aerosol, whilst not pleasant, were bearable. By using an orifice plate 
cigarette holder of the type used in the earlier smoking studies and a piece of 
glass tubing to simulate the pressure drop of a cigarette it was possible to 
measure the volumes of aerosol taken in by the subjects and thence the dose 
of nicotine.
With this apparatus it was found that 38% of the dose of nicotine in an 
aerosol of pH 3 was retained when the puff was taken into the mouth and 
blown out immediately. It is likely that all the retention observed in this case 
is due to particle deposition and impaction since the vapour pressure of 
nicotine will be zero at pH 3. When an aerosol of pH 8 was used, where 
about 50% of the nicotine was unionised and could vapourise, the retention 
increased to 58%. It is likely therefore that the increase in retention is due to 
vapourisation of the nicotine from the particle. One might then predict that a 
further 20% increase in retention would be observed when the proportion of 
unionised nicotine is increased to 100% as at pH 10. In fact the observed 
retention increased by 24%. On holding the puff of aerosol in the mouth for 
15 seconds retention increased with each aerosol. At low pH the increase 
was greatest, to 60%, an increase of 22%, and must have taken place due to 
impaction onto buccal surfaces or sedimentation. With the higher pH's the 
increases were less, at 16%, to 74% at pH 8, and at 14%, to 95% at pH 10. 
However, if the increases are viewed as a proportion of the maximum 
possible, the greatest proportionate increase was seen at the highest pH
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(14% out of a maximum possible of 19%) as might be predicted from having 
the greatest evaporation potential.
On inhalation, the amount of nicotine retained from all the aerosols 
increased to greater than 90% in all cases and increased further with a 
breath-hold of 15 seconds although this was only significant at pH 3. There 
was a slight decrease with the pH 10 aerosol, but this may be related to 
differences between the results from the smokers and non-smokers in the 
group of subjects. It must be that the aerosol particles were of sufficient size 
to result in significant impaction in the airways during inhalation, hence the 
increased retention, and that only the slight differences between the aerosols 
were due to differences in evaporation of the nicotine. The breath-hold data 
suggest that sedimentation may have had some effect but the differences in 
retention on breath-hold were not significant.
From these experiments it can be concluded that retention of the 
aerosol particles in the airways, on inhalation, is due to droplet deposition 
rather than evaporation, given the great surface area available, coupled with 
the many branchings, which will increase impaction, and the rapid decrease 
in bronchial diameter, which will increase sedimentation.
When similar experiments were conducted with cigarette smoke of pH 
5.98 the results were broadly similar. With the minimum mouth-hold 
manoeuvre 36% of the nicotine was retained, and this increased to 47% with 
a 20 second mouth-hold. This increase was less than that observed with the 
aerosols and may be a reflection of the smaller smoke particles sedimenting 
less over the course of the manoeuvre. On inhalation of the cigarette smoke, 
greater than 98% of the nicotine was retained and this increased further with 
breath-holding although the increase was not significant. This may be due to
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the size of the smoke particles again. Although the doses of nicotine were 
similar in both cases, the smoke particles were considerably smaller than the 
aerosol droplets and consequently the total surface area would be greater. 
The greater surface area would allow the nicotine to evaporate faster 
resulting in greater retention of the nicotine.
As has been suggested, the smaller smoke particles enable more 
evaporation to take place than would take place from the larger aerosol 
particles. Particle size also supports other observations that there must be a 
proportion of smoke particles which are not deposited since when smokers 
exhale there is a considerable number of particles in the exhalate. This 
immediately suggests a possible further study. To allow a closer comparison 
to be made between the retention of nicotine from cigarette smoke and that 
from an aerosol of nicotine, these experiments should be repeated using an 
aerosol generator capable of producing particles of the same size and 
number as in cigarette smoke.
Since it appears that nicotine does evaporate from the smoke particle 
during smoking, this process could be investigated further by identifying an 
involatile component of the particulate phase of smoke which could be used 
to measure the retention of the particulate matter. If the retention of the 
particulate marker was the same as the retention of nicotine then it would 
suggest that the nicotine was remaining associated with the particles. If, 
however, the particulate marker was retained less than the nicotine then it 
would suggest that the nicotine was evaporating from the particles. This 
might then be confirmed by making up an aerosol containing nicotine and the 
particulate marker and investigating their retention.
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CONCLUSION
It is perhaps unsurprising that the mechanism of uptake of nicotine is, 
like smoking itself, a complex process. Any proposed mechanism must 
explain the very rapid pharmacological effects and at the same time deal with 
the behaviour of particulate matter. How then do the observations of 
deposition and evaporation from the particles during inhalation fit with the 
paradox of the rapid effects of smoking ?
During the progress of the work described herein, the initial hypothesis 
that unionised nicotine evaporates from the particle and is subsequently 
absorbed in the pulmonary circulation has undergone modification as 
experimental evidence has required.
The current hypothesis is that uptake is a three phase process. In 
phase one, during inhalation, the unionised proportion of the nicotine, which 
at the pH of cigarette smoke, 6 for example, is less than 5%, evaporates from 
the particle, enters the alveoli and is absorbed. In phase two, a proportion of 
the smoke particles, as yet unquantified, deposit on the airways and perhaps 
the alveoli by impaction and sedimentation where their pH immediately 
becomes 7.4. At pH 7.4 about 30% of the nicotine is unionised and this 
evaporates into the nicotine free inhalation and is carried down into the alveoli 
where it is absorbed to produce the rapid pharmacological effects. As the 
mass action equilibrium of nicotine in the particle is disturbed, further 
unionised nicotine evaporates so that more of the nicotine can be swept down 
into the alveolar region. In phase three, any nicotine that has not evaporated 
from the deposited particle is absorbed more slowly through the bronchial 
walls into the bronchial circulation.
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If, as it appears, greater than 98% of the nicotine in cigarette smoke is 
retained, only a proportion, also as yet unquantified, need be absorbed very 
rapidly to produce the rapid pharmacological effects, the remainder merely 
adding to the general circulating level. It may be that the decline in plasma 
nicotine which follows the end of phase three produces the stimulus which 
calls for the next puff.
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Abstract. On switching to cigarettes with lower tar and nico­
tine yields, most individuals smoke more intensively, but 
it is not clear if  this effect persists over a long period. Smok­
ing behaviour was monitored in 10 male and 18 female 
volunteers at five monthly visits, smoking commercially 
available cigarettes (tar yield >10 mg), then for six more 
visits at 6-week intervals after switching (mean reduction 
of 5.9 mg tar and 0.45 mg nicotine). Puffing behaviour was 
monitored with a flow sensing holder, and measurements 
were made before and after smoking of plasma cotinine, 
carboxyhaemglobin and alveolar carbon monoxide. After 
switching, cotinine levels only fell 40% of that predicted 
from the fall in nicotine yields, and there were no systematic 
trends for the rest of the study. Puff volumes rose (reflecting 
perhaps the reduced draw resistance of the lower yield ciga­
rettes), and remained higher thereafter. The number of puffs 
per cigarette appeared to rise on switching, but then de­
creased again. In conclusion, most effects of switching to 
lower yield cigarettes appeared to persist for at least 36 
weeks, suggesting that the strategy of reducing exposure 
to cigarette smoke by lowering tar and nicotine yields may 
be of limited value.
Key words: Cigarettes -  Cotinine -  Carboxyhaemoglobin 
-  Puffing behaviour -  Compensation -  Long-term trends
In 1983, the Independent Scientific Committee on Smoking 
and Health, (ISCSH), (Froggatt 1983) recommended to the 
British Government that the Tobacco Industry should con­
tinue their attempts to reduce the sales-weighted tar yields 
of cigarettes. This could involve a fall in nicotine yields 
and the ISCSH had concluded after discussion with the 
Industry:
that the level of nicotine in some cigarettes has already 
reached a point where consumers are trying to maintain 
their nicotine intake by methods of "compensation : these 
include increases in puffing, depth of inhalation and ciga­
rette consumption, and changing brands.
This process would compromise attempts to reduce the 
“ lifetime intake of toxic substances in tobacco smoke". 
After reviewing the literature, they concluded that further 
investigations were necessary including:
Offprint requests to: A.R. G uyall
evidence about changes in the manner of smoking which 
may increase the absorption of toxic substances per ciga­
rette; current information is inadequate and the problem 
should be investigated further ... over extended periods 
of smoking (after short-term adaptation) and using larger 
and more appropriate groups.
The present study is a response to this suggestion. Smoking 
behaviour was monitored in a group of volunteers over 
a period of 4 months while smoking their usual cigarettes, 
then for 9 further months, after switching to cigarettes with 
lower tar and nicotine machine yields, to see if  the effects 
of brand changing persisted. Smoking was studied in two 
ways, using markers of natural smoking and measurements 
made in the laboratory.
McMorrow and Foxx (1983, 1985) distinguished be­
tween nicotine regulation and compensation. The first term 
was defined as “ a smoker's maintenance of a characteristic 
level of nicotine in the body” which is “ presumed to occur 
following either increases or decreases in nicotine yield” . 
Compensation was “ generally used to describe changes in 
smoking behavior contingent on and in correspondance 
with an alteration in nicotine delivery” , (defined in the pres­
ent study as “ machine nicotine yield”). The present analysis 
has been influenced by this approach, since evidence for 
nicotine regulation is considered first before dealing with 
other smoke markers and measurements of smoking behav­
iour. However since the term “ regulation” is not in com­
mon use, and implies uncritical acceptance of the nicotine 
hypothesis, “ compensation” has been preferred through­
out.
Materials and methods
Subjects. These were recruited from established smokers 
of cigarettes with machine tar yields above 10 mg, using 
local television, radio and newspapers, promotions in public 
places, a recruitment agency, and word of mouth. The study 
was approved by the Ethical Committee of the Institute 
and all subjects gave informed consent in writing before 
beginning. The subjects purchased all their cigarettes from 
retail outlets, and were only reimbursed for out-of-pocket 
expenses. Commercially available cigarettes were used rath­
er than placed products in order to give a realistic change 
in smoking habits which could be maintained over a long 
period.
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Plan of study. The subjects were asked to refrain from 
smoking for at least half an hour before each study, to 
minimise any effects of previous cigarettes, such as the rise 
in airway resistance described by Nadel and Comroe (1961). 
Although studies were made throughout the working day 
and early evening, each individual was requested to attend 
at the same day of the week and time of day throughout 
to minimise diurnal or weekly variations. On each occasion, 
measurements were made before, during, and after the 
smoking of a single cigarette. The introductory visit was 
used as a practice session without blood sampling, and on 
this occasion the FEV, and F VC were measured (Vitalo- 
graph), and the M RC Questionnaire on respirator}' symp­
toms (1966) was administered, together with extra questions 
on smoking habits.
On the next five visits, at 1-month intervals, subjects 
smoked their original type of cigarette. Very occasionally, 
when brands became unavailable, they were asked to chan­
ge to the cigarettes which most closely matched them for 
the machine yields of tar and nicotine. After the sixth visit, 
they were asked to switch to a cigarette with a machine 
tar yield at least 3 mg lower than their existing brand, cho­
sen from a list of those available locally. Then six more 
visits were made at 6-week intervals smoking the new ciga­
rette. Checks were made between visits by telephone on 
the brands being smoked, and the subjects were encouraged 
to report any problems.
Experimental techniques. The subject sat in a special smok­
ing room listening to music or reading, and venous blood 
and alveolar gas were sampled before and after smoking 
a cigarette. Alveolar gas was sampled after a 20-s breath- 
hold (Jones et al. 1958; Kirkham et al. 1988) and FACO  
was measured by infra red absorption, (ADC Ltd, model 
R Fl 0-100 ppm). The 20 ml blood sample was drawn from 
an antecubital vein and placed in a tube containing ethylen- 
ediaminetetraacetate anticoagulant. HbCO was measured 
by spectrophotometry (Siggaard-Andersen 1977, Radi­
ometer, 0SM 2 Hemoximeter), and after centrifuging, the 
plasma was stored at —20° C before analysis for cotinine, 
(Curvall et al. 1982). The thawed samples were extracted 
into dichloromethane under alkaline conditions, and ana­
lysed by gas chromatography, (Perkin Elmer model 8310 
modified to accept capillary columns). After smoking, the 
cigarette was extinguished in a tube containing dry ice, and 
the butt length was measured between the filter overwrap 
and the line of burning, being taken as the mean of the 
shortest and longest distances.
The cigarette was smoked through a holder incorporat­
ing a 2 mm orifice (Creighton et al. 1978; Guyatt and 
Baldry 1988). The holder was connected via plastic tubing, 
(1.5 m long) to transducers (Validyne MP45 with Hewlett 
Packard 8805b carrier amplifiers) to record the differential 
pressure across the orifice (indicating flow), and the pres­
sure applied to the cigarette (draw pressure). The differen­
tial pressure signal was linearised electronically before anal­
ysis since it was proportional to the square root of flow. 
Both signals were digitized at 20 ms intervals using a micro 
computer (Kontron Psi 80 D) programmed in FORTRAN  
IV.
For each puff, the flow signal was integrated with time 
to give puff volume, and the maximum flow rate and pres­
sure were recorded. The product of the two signals was 
integrated to give an index, “ work of puffing”, with units
of joules (Rawbone 1984) and the pressure signal was inte­
grated with time and divided by puff volume to give the 
draw resistance, being expressed as the pressure drop at 
the standard flow of 17.5 ml s“ L (PI 7.5). The puff duration 
was recorded with the inter-puff interval, and the time taken 
to reach the maximum pressure point, (which is referred 
to here as the “ pressure latency”). This latter index was 
expressed as a percentage of the puff duration (“ latency 
ratio”) and is an expression of the shape of the puff.
The holder assembly was calibrated using air at room 
temperature and no measurements of smoke temperature 
were made. However a separate in vitro study (Guyatt and 
Baldry 1988) suggests that the errors are small, the mean 
puff volume being overestimated by about 2.8%.
Numerical analysis. In this study each subject acted as their 
own control, using the pooled pre-switch data from visits 
2-6, except where there were significant trends over the 
period. In such cases post-switch data were compared with 
data from the sixth visit alone. Non-parametric statistical 
methods (Seigal 1956) are used in this presentation since 
many of the data were not normally distributed. Three prin­
ciple tests have been applied. The Wilcoxon matched pairs 
test was used to compare data on switching between visits 
6 and 7. The Page L  trend test (1963) was used to look 
for changes with time both before and after switching (visits 
2-6 and 7-12), although only the latter data are presented 
in the tables. The Friedman two-way analysis of variance 
was also applied to visits 2-6 and 7-12 to test for significant 
variations between visits. This latter test could detect short 
term effects such as a rise and fall in a measurement which 
would not show as an overall trend over six visits.
The pre- and post-smoking cotinine data were averaged 
before statistical analysis. Preliminary analysis had shown 
that the post-smoking value were only 0.35% greater than 
the pre-smoking (P>0.6). The pre-smoking HbCO and 
FACO data were also analysed and the uptake per cigarette 
estimated from the HbCO “ boost” (that is the post -  pre­
smoking values).
Compensation based on the cotinine values was calcu­
lated using the formula of Sutton et al. (1978).
{0 -E )  X 100/(/-£)
where I  is the initial, pre-switch value, O is the observed 
post-switch value and E  is the expected post-switch value 
based on reduction in machine yields (pooled values for 
all 28 subjects). The formula can be illustrated considering 
someone with a plasma cotinine concentration of 300 ng 
m l'^ while smoking cigarettes with a machine yield of 
1.2 mg nicotine. On changing to a brand with a machine 
yield of 0.6 mg, plasma cotinine will fall to 150 ng m l" ‘ 
if there is no compensation, fall to 225 ng m l'  ^ (ie 50% 
drop) with 50% compensation and stay constant at 300 ng 
ml" * for 100% compensation. Six calculations were made, 
using a common initial value (/) averaged over visits 2-6, 
but with separate observed values {O) for visits 7-12, re­
spectively. The same formula was applied to the HbCO  
and FACO data but referring them to the change in the 
machine yields for carbon monoxide.
The puffing behaviour data were analysed after exclud­
ing the lighting puff and averaging the rest. The total puff 
volume was also calculated as the sum of the individual 
puffs and the duration of smoking as the time interval be­
tween the first and last puffs.
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Table 1. Comparison of anthropometric, lung function and ques­
tionnaire data obtained on visit 1 between study and default group. 
(Only significant difference was for age. f  <0.05)
Study group Default group
Number 28 123
Male 10 54
Female 18 69
Mean Range Mean Range
Age (years) 47.1 21- 70 40.9 18- 73
Height (cm) 167 148-197 169 150-192
Weight (kg) 67.6 42- 94 67.1 45-120
FEV, (% pred) 99.1 83-125 97.3 31-133
FVC (% pred) 97.9 78-129 97.2 50-128
Age started smoking (years) 18.0 11- 30 17.1 5 - 42
Cigarettes/day 25.1 9 - 60 23.6 5 - 51
Fraction o f group who have:
Reduced cigs/day in last year 7/28 34/123
Chronic cough 5/28 34/123
Chronic phlegm 4/28 25/123
History o f bronchitis 8/28 47/123
History o f asthma 2/28 6/123
Regular fume exposure 7/28 18/123
Smoke inhalation question:
None 3 5
Slight 1 7
Moderate 15 66
Deep 9 45
Results
Subjects
The study group consisted of 28 subjects, the characteristics 
of whom are shown in Table 1. This also includes details 
of the default group, a further 123 subjects who attended 
on at least one occasion but either did not complete the 
study or did not fulfil the study criteria. Comparisons in­
cluded the sex distribution of the two groups, anthropo­
metric data, FEV, and F VC (both expressed as a percent­
age of predicted values. Cotes 1979), and questions on respi­
ratory symptoms and smoking history. The differences be­
tween the groups were tested by parametric / test, (anthro­
pometric and lung function data) or Mann-Whitney U. but 
the only significant difference was for age, the study group 
being on average 6.8 years older ( f  <0.05).
Analysis o f data visit by visit
The statistical analyses are summarised in Table 2. Columns 
1-3 consider the changes on switching comprising the mean 
value for visits 2-6, the value at visit 7 and the significance 
of the difference using the Wilcoxon matched pairs test. 
There were three significant trends over the pre-switch peri­
od (falls for pre-smoking FACO, puff volume and PI 7.5): 
in these instances the value for visit 6 is given instead, 
marked by * in Table 2. Columns 4 and 5 consider changes 
over visits 7-12, with the significance of the Page trend 
analysis, (including the trend direction -f or — where sig­
nificant) and the Friedman two-way analysis of variance.
The nicotine machine yield decreased by an average of 
33% on switching, and there was a significant reduction 
in cotinine of approximately 18%, without any significant 
trend over the remaining visits. These data are shown in 
more detail in Fig. 1 with the median values and 95% confi­
dence limits for visits 2-12, (Snedecor and Cochran 1967 t 
The CO machine yields decreased on average by 37%, anc 
there were significant reductions of 18% in both pre-smok­
ing HbCO and HbCO boost, but the only significant trend 
was a fall in the HbCO boost between sessions 7 and 12. 
These data are illustrated in Fig. 2 and again there are no 
large changes after the brand switch.
The compensation estimates for plasma cotinine, pre­
smoking HbCO and pre-smoking FACO showed no trends 
over visits 7-12, and when averaged for these six visits give 
similar values; cotinine 61.0%, (range 45-76% ); HbCO  
55.8%, (34-73%); FACO 59.9%, (33-79%). These values
Table 2, Effects of switching (Wilcoxon), occurrence of trends after switching (Page L test, direction o f trend shown as — or -f ) 
and o f significant variation between visits after switching, (Friedman) two-way analysis o f variance). NS is non-significant (P> 0.05). 
* after number in column 1 indicates a single value for visit 6 only. Average machine yields fell from 1.36 to 0.91 mg (nicotine), 
15.1 mg to 9.3 (tar) and 15.2 mg to 9.6 (CO)
Mean Signif of Visits 7-12
Visits 2-6 Visit 7
difference
Page Friedman
Plasma cotinine (ng m l" ') 378 309 P <  0.005 NS NS
Pre-smoke HbCO (%) 5.16 4.24 P < 0 .05 NS NS
HbCO boost (%) 1.11 0.91 P <  0.005 -P < 0 .0 1 NS
Pre-smoke FACO (ppm) 27.6* 24.5 NS NS , NS
Cigarettes/day 24.9 28.5 NS NS NS
Puff volume (ml) 47.2* 54.7 P<0.001 NS NS
Puff duration (s) 2.10 2.21 NS NS NS
Maximum flow (ml s" *) 40.9 44.9 P<0.001 NS NS
Puffs/cigarette 13.9 15.7 P < 0.05 NS P < 0 .05
Total puff volume (ml) 603 768 P<0.001 NS P<0.01
Inter-pufT interval (s) 34.2 27.7 P<0.001 NS P < 0 .05
Smoking duration (s) 438 399 P<0.01 NS NS
Butt length (mm) 6.64 5.70 NS -f P <  0.005 NS
Work (mJ) 126 137 NS NS NS
PI 7.5 (kPa) 1.42* 1.21 P<0.001 NS NS
Maximum pressure (kPa) 3.33 3.21 NS NS NS
Latency ratio (% ) 31.4 31.2 NS NS NS
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Fig. 1. Plasma cotinine data (top) and machine nicotine yield data 
(bottom) in 28 smokers who switched brands after six visits. Median 
values and 95% confidence limits for visits 2-12
correspond to the “ high nicotine regulation” range of 
McMorrow and Foxx (1983).
Mean puff volume rose 15.9% on switching but showed 
no trends thereafter (Fig. 3). The initial rise in total puff 
volume was greater (27%) due to an associated 13% rise 
in the number of puffs per cigarette. On later visits, the 
number of puffs per cigarette returned to pre-switch levels 
and total puff volume decreased but did not return to pre­
switch levels. The changes over visits 7-12 are also indicated 
by significant Friedman coefficients (Table 2) for puffs per 
cigarette and its corollary inter-puff interval, and for total 
puff volume.
The standard pressure drop (P I7.5) fell significantly on 
switching by nearly 15%, but the “ work of puffing” hardly 
changed (Fig. 4), nor did the peak pressure per puff. Other 
significant changes included a rise in maximum puff flow 
rate of nearly 10% and falls of 9% in the total duration 
of smoking and 19% in the inter-puff interval. The only 
significant trend over visits 7-12 was a rise in butt length, 
but this is of limited importance as it was equivalent to 
a mean increase of just 1.7 mm.
Discussion
The subjects showed an average compensatory response of 
about 60% to the lower tar cigarettes (averaged over visits
8 9 10 11 12
2 3 4  5 6 7 8 9 10 11 12
.«10
10 127 8 9 112 3 4 5 6
Visit Number
Fig. 2. Pre-smoking HbCO (top). HbCO boost on smoking {centre) 
and machine CO yield o f cigarette (bottom) in 28 smokers. Median 
values and 95% confidence limits for visits 2-12
7-12), and maintained this for 36 weeks without any appar­
ent trend in the data. This degree of compensation is similar 
to earlier reports (Benowitz et al. 1983 a: Ossip-Klein et al. 
1983; Wald et al. 1984), and closely similar values were 
observed for cotinine, carboxyhaemoglobin and alveolar 
carbon monoxide despite the contrasting mechanisms of 
delivery and uptake of nicotine and CO.
Cotinine, which has a half-life in plasma of about 18 h 
(Benowitz et al. 1983 b), was used in place of nicotine which
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Fig. 3. Mean puff volume {top), number of puffs per cigarette 
(centre), and total puff volume (bottom), in 28 smokers. Median 
values and 95% confidence limits for visits 2-12
disappears very rapidly (Armitage 1978; Darby et ai. 1984). 
The rate of formation is too slow to show changes produced 
by a single cigarette but it gives a measure of the natural 
smoking in the preceding 24-48 h. Carboxyhaemoglobin 
and alveolar carbon monoxide provide a useful supplement 
to this, since with half-lives of about 3-4 h (Cole 1981), 
they reflect natural smoking over a shorter period than 
cotinine. They are subject to diurnal changes (Rawbone
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Fig. 4. “ W ork of puffing” (top) and pressure drop at 17.5 ml s " ‘ 
(bottom), in 28 smokers. Median values and 95% confidence limits 
for visits 2-12
et al. 1978), but this should have been minimised by tht 
experimental design.
The uptake of CO from a single cigarette can be assessea 
from the HbCO boost. (Although a similar index can be 
derived from the FACO measurements, a preliminary anal­
ysis of these data — Guyatt et al. 1988 -  showed this to 
be underestimated by about 60%, probably due to a transit­
ory effect of smoking on gas exchange in the lung). On 
switching, the pre-smoking and boost HbCO measurements 
decreased by a similar amount (approximately 18%), sug­
gesting that the uptake per cigarette is a major factor in 
determining carboxyhaemoglobin levels in the blood. It  will 
also be affected by changes in cigarette consumption, (here 
shown to be small), and by the tendency of subjects to 
smoke more intensively under laboratory conditions. 
(Comer and Creighton 1978). It should also be noted that 
there was a significant fall in the boost over visits 7-12 
but not with the pre-smoking HbCO.
The main evidence for a mechanism producing compen­
sation was the increase in mean puff volume of 15.9% after 
brand switching. This effect has often been reported (Sur­
geon General 1984), but was shown in this study to persist 
over a 36-week period. By contrast, the number of puffs 
per cigarette rose on switching but then fell back towards 
pre-switching levels, (this also contributed to the changes 
in the total puff volume and inter-puff interval). This was
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the only evidence obtained of a modification in smoking 
after switching, but it was not clear if this also applied 
to natural smoking away from the laboratory.
Since the objective was to look at changes with time, 
it is necessary to consider factors which might produce 
trends. It is important to ensure that the volunteer should 
have a consistent smoking habit and care was taken to 
recruit established smokers. More information was pro­
vided by the replies to the initial questionnaire, and it was 
observed that only one third of the subjects had made any 
major modification to their smoking habit over the preced­
ing year, such as switching brands or changing daily con­
sumption. The subjects were repeatedly asked during the 
study about brands being smoked, and any subject who 
deviated seriously from the protocol was excluded from 
the analysis.
A detailed series of checks was made on the equipment 
at regular intervals (Kirkham et al. 1988; Guyatt et al. 
1988; Guyatt and Baldry 1988). The reproducibility of the 
data was tested on visits 2-6, and in another group of 14 
volunteers who followed the same protocol except for 
smoking one type of cigarette, (less than 10 mg tar) 
throughout. The only significant trends were a fall in mean 
puff volume and pre-smoking FACO over visits 2-6 in both 
subject groups. The fall in puff volume might be due to 
the subject becoming more relaxed as the study progressed, 
and this is interesting in view of the consistent elevation 
seen after brand switching. The fall in FACO suggests a 
reduction in smoking just prior to each visit, perhaps due 
to a lessening of anxiety regarding the tests as the subjects 
became more familiar with the procedure. For some indices, 
where the distribution of data was normal, the trends were 
tested for using linear regression, but this gave very similar 
conclusions to those obtained to the Page L trend test.
The direct measurement of the puffing pattern is com­
promised since the use of a holder may alter the smoking 
pattern (Tobin and Sackner 1982) but without such a device 
much of the present data would be unobtainable. These 
measurements also ignore wastage of smoke from the 
mouth and variations in smoke inhalation (Sinclair 1984). 
More information can be obtained by recording ventilation 
during smoking (Tobin and Sackner 1982; Adams et al. 
1983; McBride et al. 1984), or by measuring the inspired 
smoke volume using a radiotracer technique (Woodman 
et al. 1985), but unless the chemical composition of each 
pufT is known, these methods will not provide quantitative 
data on smoke exposure. With the present objective of look­
ing for long-term trends in large groups of subjects under 
relaxed conditions, these extra measurements seemed inap­
propriate.
The rise in puff volume appears to reflect increases in 
puff duration (5%) and flow rate (approximate 10% rise 
in the maximum rate) but not as the result of changes in 
the shape of the puff profile (the latency ratio did not alter). 
This might be explained by mechanical factors, since most 
low tar cigarettes have a reduced draw resistance due to 
the ventilation holes in the filter and the use of higher poro­
sity cigarette papers. Rawbone (1984) found for most types 
of cigarettes that the work of puffing was independent of 
the draw resistance, implying that smokers generate a con­
stant pressure profile during puffing irrespective of the type 
of cigarette smoked. Accordingly, if the rod impedance is 
reduced, flow rates and puff volumes will increase unless 
the anatomical limits of the buccal cavitv are reached.
The present results are consistent with this; on bra:, 
switching the “ work of puffing” actually increased slight: 
despite the fall in PI 7.5, and while the maximum flow rate 
rose, the maximum pressures hardly changed. Such a mech­
anism would tend to produce larger puff volumes as long 
as the lower impedance cigarettes were smoked. Changes 
in smoke composition would also seem to be very impor­
tant, but it is impractical to resolve these factors on the 
present data since special cigarettes would be needed in 
which draw resistance and tar and nicotine yields were var­
ied independently.
Finally, it is important to see how these results can be 
applied to the population at large. The major problem lies 
in recruiting a suitable group of volunteers: originally 497 
people made enquiries, 214 were recruited, 151 attended 
on at least one occasion but only 28 fulfilled the stud\ 
protocol. The subjects were older on average than the de­
faulters but otherwise there were no significant difference.s 
between the groups. The main reason for defaulting was 
lack of interest or finding the experimental protocol too 
demanding, both of which tended to affect the younger 
rather than the older volunteers. Apart from this difference, 
the summary in Table 1 suggests that the study group was 
representative of the original population as a whole. The 
consistency of the data was striking both among the 28 
subjects and in others who for various reasons did not meet 
the full criteria for analysis, although a formal confirmation 
of this result would require further large scale studies.
The conclusion of this study is that smokers who switch 
to lower nicotine yield cigarettes show evidence of partial 
compensation by the criteria of McMorrow and Foxx 
(1983), and that this effect appears to continue for at least 
36 weeks. From an experimental view point, this is encour­
aging since it implies that short duration studies can still 
supply useful information on the effects of brand switching. 
It also fills an important gap in the literature; in their review 
McMorrow and Foxx (1985) only listed two long duration 
studies, of 12 weeks (Jaffe et al. 1978) and of 20 months 
(Freedman and Fletcher 1976). Although this second study 
was much longer than the present one, it is not strictly 
comparable, since it used very limited techniques with few 
visits. These observations appear to have implications for 
the ISCSH strategy of reducing the “ lifetime intake of toxic 
substances” by lowering the yield of smoke constituents 
(Froggatt 1983), since this improvement would seem to be 
reduced by long-term compensation.
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APPENDIX B - Calibration and Quality Control 
B.1 Calibration
The levels of nicotine and cotinine in the study samples were 
calculated by determining the ratio of their chromatographic peak areas to the 
peak areas of their two internal standards, N-ethyl nornicotine and lidocaine 
respectively and relating that to the peak area ratios determined in a 
calibration routine. The calibration routine consisted of a procedure similar to 
that described in Chapter 2.2.4.4 to validate the extraction procedure, i.e. the 
addition of known amounts of both nicotine and cotinine to blank bovine 
plasma or pooled non-smokers' saliva. These were then taken through the 
extraction procedure and the peak area ratios used to construct a calibration 
curve, examples of which are shown in Figures 8.1 to B.4. From these data, 
regression equations were calculated which were then used to calculate the 
levels of nicotine or cotinine present in the study samples.
Recalibration was necessary at intervals for the following reasons. 
Each time a fresh internal standard solution was made up a new calibration 
curve was prepared since the gravimetric concentrations of the internal 
standard solutions varied slightly. 250 ml of fresh internal standard solution 
was prepared and stored at -20°C in 20 ml aliquots in 25 ml vials. Each week 
an aliquot was thawed and used for analysis during that week. If a new 
chromatography column was installed or the bead assembly in the nitrogen- 
phosphorus detector of the gas chromatograph (a consumable part) was 
replaced a new calibration curve was prepared. If no analysis had been 
performed for two weeks or more, or there had been no other reason to do so 
for two months, a new calibration curve was prepared.
2 2 2
Figure B.1 : Example of calibration curve for plasma nicotine analysis. 
Known amounts of nicotine were added to bovine plasma. Data shown are 
means ±1 s.d. (8 determinations) and a linear regression line through the 
data.
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Figure 8.2 : Example of calibration curve for plasma cotinine analysis. 
Known amounts of cotinine were added to bovine plasma. Data shown are 
means ±1 s.d. (8 determinations) and a linear regression line through the 
data.
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Figure B.3 : Example of calibration curve for saliva nicotine analysis. Known 
amounts of nicotine were added to pooled non-smokers' saliva. Data shown 
are means ±  1 s.d. (8 determinations) and a linear regression line through 
the data.
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Figure B.4 : Example of calibration curve for saliva cotinine analysis. Known 
amounts of cotinine were added to pooled non-smokers' saliva. Data shown 
are means + 1 s.d. (8 determinations) and a linear regression line through the 
data.
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B.2 Quality Control
The Long-Term Compensation Study (Chapter 3.1) was expected to 
take approximately two years to complete and was expected to generate in 
the region of 2000 plasma and 2000 saliva samples. Even with the improved 
nicotine and cotinine analysis this would constitute some 85 days of work 
spread over the two year period. In order to highlight any changes taking 
place in the analytical procedure, such as changes in background nicotine 
level, any deterioration in either chromatography or analytical standards a 
quality control procedure was implemented.
In order to achieve this it was decided to prepare enough quality 
control (QC) samples containing known amounts of nicotine and cotinine that 
could be frozen in advance of the analysis so that one or more QC samples 
could be analysed with each batch of study samples. For the plasma samples 
this was achieved by obtaining a large quantity of bovine blood, 
anticoagulated with 0.1% ethylenediaminetetracetic acid (EDTA), from a local 
abbatoir and separating it by centrifugation into plasma and cells. The pooled 
bovine plasma was divided into four portions and three of the portions were 
spiked with different amounts of nicotine and cotinine. The fourth portion was 
stored in aliquots at -20°C for future use. The likely ranges of nicotine and 
cotinine being between zero and 100 ngmM nicotine and 1000 ngmM 
cotinine, the quality control samples were spiked with nicotine and cotinine at 
three levels within those ranges. These were (i) 10 ngmM nicotine and 100 
ngmM cotinine, (low 00 ); (ii) 30 ngml'^ nicotine and 300 ngmM cotinine, (mid 
0 0 ); and (iii) 70 ngmM nicotine and 700 ngmM cotinine, (high 00). The 0 0  
samples were then stored at -20°0 in 1 ml aliquots in 1.5 ml snap-top plastic 
vials and thawed and analysed as necessary. A similar procedure was not
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possible with saliva since it was not possible to obtain a sufficient quantity of 
a sufficiently similar sample matrix, therefore tap-water was used as the best 
alternative (Feyerabend and Russell, 1980) and QC samples made up as 
above except the concentrations were 150 ngmM nicotine and 100 ngmM 
cotinine (low QC), 750 ngmM nicotine and 500 ngmM cotinine (mid QC) and 
1500 ngmM nicotine and 750 ngml'^ cotinine (high QC) to allow for the higher 
levels of nicotine in saliva (Russell and Feyerabend, 1978).
After these quality control samples had been prepared and frozen a 
number were thawed and analysed in order to determine the levels of the 
analytes within them and therefore an acceptable range of values for the 
analytes during future analysis. These are given in Tables B.1 and 8.2.
Table B.1 : Initial analysis of plasma QC samples
Sample Analyte Nominal
Cone.
(nqml'^)
Actual Cone.
(ngml'^)
( n = 24 )
Recovery
(%)
Mean S.D.
Low QC Nicotine 9 9.5 1.6 105.6
Cotinine 90 87.8 4.4 97.6
Mid 00 Nicotine 30 30.1 4.1 100.3
Cotinine 300 250.9 12.6 83.6
High 00 Nicotine 70 64.2 4.2 91.7
Cotinine 700 546.6 30.4 78.1
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Table B.2 : Initial analysis of saliva QC samples
Sample Analyte Nominal
Cone.
(ngmr^)
Actual Cone.
(ngml'^)
( n = 24 )
Recovery
(%)
Mean S.D.
Low QC Nicotine 150 149.8 8.9 99.9
Cotinine 100 100.1 5.3 100.1
Mid QC Nicotine 750 745.4 15.4 99.4
Cotinine 500 498.1 9.5 99.6
High QC Nicotine 1500 1508.6 33.4 100.6
Cotinine • 750 753.0 16.6 100.4
Although the actual levels in the plasma QC samples were different 
from the nominal levels (mean recovery 92.8%), presumably due to an error 
in calculation or addition, it was decided to use them rather than prepare 
fresh samples. The saliva QC samples were very close to their nominal 
concentrations (mean recovery 100%). Whenever study samples were 
analysed a tap-water blank (Feyerabend and Russell, 1980) and a mid QC 
sample were analysed. Whenever possible, low and high QC samples were 
also analysed. It was decided that if the level of either nicotine or cotinine 
found in any of the QC samples was greater than one standard deviation 
from the mean found above then the samples from that days analysis would 
have to be reanalysed. In practise, as can be seen in Figures B.5 to B.16 and 
Tables B.3 and B.4, this was necessary on only a few occasions.
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Figure B.5 : Nicotine found in Low QC Plasma samples during analysis of
study samples (NB Mean and s.d. are from the initial analysis of GO samples
- Table 1)
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Figure B.6 : Cotinine found in Low QC Plasma samples during analysis of 
study samples (NB Mean and s.d. are from the initial analysis of QC samples 
-Table 1)
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Figure B.7 : Nicotine found in Mid QC Plasma samples during analysis of
study samples (NB Mean and s.d. are from the initial analysis of 0 0  samples
- Table 1)
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Figure 8.8 : Cotinine found in Mid GO Plasma samples during analysis of 
study samples (NB Mean and s.d. are from the initial analysis of QC samples 
- Table 1)
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Figure B.9 : Nicotine found in High QC Plasma samples during analysis of
study samples (NB Mean and s.d. are from the initial analysis of 0 0  samples
- Table 1)
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Figure B.10 : Cotinine found in High QC Plasma samples during analysis of 
study samples (NB Mean and s.d. are from the initial analysis of QC samples 
- Table 1)
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Figure B.11 : Nicotine found in Low QC Saliva samples during analysis of
study samples (NB Mean and s.d. are from the initial analysis of 0 0  samples
- Table 2)
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Figure B.12 : Cotinine found in Low QC Saliva samples during analysis of 
study samples (NB Mean and s.d. are from the initial analysis of QC samples 
- Table 2)
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Figure B.13 : Nicotine found in Mid QC Saliva samples during analysis of
study samples (NB Mean and s.d. are from the initial analysis of GO samples
- Table 2)
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Figure 8.14 : Cotinine found in Mid QC Saliva samples during analysis of 
study samples (NB Mean and s.d. are from the initial analysis of QC samples 
- Table 2)
550
530
1 s.d. 
Mean 
1 s.d.
510
490
470
I  450
430
410
390
370
350
5 15 25 35 400 10 20 30
Day of Analysis
232
Figure B.15 : Nicotine found in High QC Saliva samples during analysis of
study samples (MB Mean and s.d. are from the initial analysis of QC samples
- Table 2)
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Figure 8.16: Cotinine found in High 0 0  Saliva samples during analysis of 
study samples (NB Mean and s.d. are from the initial analysis of 0 0  samples 
- Table 2)
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Table B.3 : Day-by-day analysis of plasma QC samples
Sample Number
of
samples
Analyte Nominal
Cone.
(nqmM)
Actual Cone. 
(ngmM)
Mean S.D.
Low QC 63 Nicotine 9 9.5 1.2
Cotinine 90 87.8 3.4
Mid QC 83 Nicotine 30 30.1 2.8
Cotinine 300 250.8 8.5
High QC 63 Nicotine 70 64.3 3.0
Cotinine 700 549.3 19.1
Table B.4 : Day-by-day analysis of saliva QC samples
Sample Number
of
samples
Analyte Nominal
Cone.
(nqml'^)
Actual Cone, 
(ngml'i)
Mean S.D.
Low QC 35 Nicotine 150 149.0 9.5
Cotinine 100 100.2 5.5
Mid QC 35 Nicotine 750 748.2 12.5
Cotinine 500 497.7 6.1
High QC 35 Nicotine 1500 1511.6 25.6
Cotinine 750 753.4 13.5
In none of the QC samples were the day-by-day means different from 
the means of the initial analyses (unpaired Student's t test). Fewer saliva QC 
samples were analysed because fewer saliva samples from the study were 
analysed. The saliva samples from the study were not analysed until the last 
phase of the study and as a result a large number could be discarded since 
by that time those subjects had either dropped out of the study or it was 
known that they would not satisfy the original study criteria.
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The first approximately 100 human plasma samples were analysed in 
duplicate and the variabilty between the duplicates is shown in Table B.5. 
This being deemed satisfactory, at less than 1%, it was decided that 
subsequently one sample in ten would be duplicated. The samples to be 
duplicated from those to be analysed during a day were determined by using 
the random number facility of a CASIO fx-82c calculator. The variability 
between these duplicates is shown in Table B6.
Table B.5 : Nicotine and Cotinine found in duplicate analyses of 106 
consecutive plasma samples
First Analysis Second Analysis
Analyte Mean Analyte Mean Difference
(nqml'i) (nqml'1)
Nicotine 20.9 Nicotine 20.7 0.2
Cotinine 348.2 Cotinine 346.4 1.8
Table B.6 : Nicotine and Cotinine found in duplicate analyses of 160 
plasma samples, where one in 10 samples were duplicated
First Analysis Second Analysis
Analyte Mean Analyte Mean Difference
(nqml'i) (nqml'i)
Nicotine 27.1 Nicotine 27.0 0.1
Cotinine 342.5 Cotinine 342.1 0.4
235
The schedule of duplicating one sample in ten and analysing four QC 
samples (one tap-water blank and one each of the low, mid and high QC 
samples) fitted conveniently with the maximum number of samples that could 
be analysed in a 24 hour period. The samples, including duplicates and QC 
samples, were extracted in six batches of eight per day and the resulting 48 
extracts could be analysed by the gas chromatograph in just under 24 hours.
